Test Bank for Pharmacology and the Nursing Process, 5th Edition: Linda L. Lilley

Original price was: $35.00.Current price is: $26.50.

Test Bank for Pharmacology and the Nursing Process, 5th Edition: Linda L. Lilley Digital Instant Download

Category:

This is completed downloadable of Fluid Test Bank for Pharmacology and the Nursing Process, 5th Edition: Linda L. Lilley

Product Details:

  • ISBN-10 ‏ : ‎ 0323044867
  • ISBN-13 ‏ : ‎ 978-0323044868
  • Author:  Linda Lilley, Julie S. Snyder

This market-leading text is known for presenting challenging content in a clear and consistent format that engages students. With an eye-catching design, full-color illustrations, and helpful, practical boxed features that highlight need-to-know information, the new edition of this bestseller continues its tradition of making pharmacology easy to learn and understand.

  • A companion CD includes resources such as 450 NCLEX examination-style review questions, 26 state-of-the-art animations, and 9 IV therapy and 5 medication errors checklists.
  • Study Skills Tips include practical advice on time management, note taking, study techniques, and test taking.
  • Drug profiles highlight the pharmacokinetics and unique variations of individual drugs.
  • Case studies and critical thinking activities test students’ knowledge and understanding.
  • Medication Errors: Preventing and Responding chapter discusses specific nursing measures to prevent medication errors, possible consequences of medication errors to nurses, responses to errors, reporting and learning from mistakes, and other ethical issues.
  • Patient teaching tips include key points to convey to patients, their families, and caregivers.
  • Points to Remember boxes summarize major concepts in a bulleted format.
  • NCLEX exam-style review questions provide a pharmacology review and add a new emphasis on prioritization.
  • e-Learning activities boxes list related content and exercises on the companion CD and Evolve website.
  • Key drugs are highlighted with an icon for quick identification.
  • Photo Atlas of Medication Administration depicts steps in drug administration for various routes.
  • Tear-out IV incompatibility chart provides a convenient portable reference.
  • Life Span Considerations boxes highlight important age-related implications for pediatric and elderly patients.
  • A new focus on prioritization identifies key nursing information and helps in preparation for the NCLEX® examination.
  • Preventing Medication Errors boxes reinforce concepts introduced in the medication errors chapter and relate them to specific common errors that occur in clinical practice.
  • Evidence-Based Practice boxes summarize current research relevant to safe and effective drug therapy.
  • Laboratory Values Related to Drug Therapy boxes highlight the therapeutic levels of various drugs.
  • Expanded bioterrorism content now includes chemical agents such as ricin.
  • Increased focus on drug class provides a “big picture” knowledge of how various drugs work in the body.
  • Expanded cultural content covers today’s increasingly diverse patient population.
  • Pharmacokinetic Bridge to the Nursing Process sections apply key pharmacokinetics information to nursing practice.

 

Table of Content:

  1. PART 1 Pharmacology Basics
  2. Pharmacology Basics
  3. STUDY SKILLS TIPS
  4. INTRODUCTION TO STUDY SKILLS CONCEPTS
  5. PURR
  6. Prepare
  7. On-the-Run Action.
  8. Understand
  9. Rehearse
  10. How to Rehearse.
  11. When to Rehearse.
  12. Review
  13. How to Review.
  14. Frequency of Review.
  15. Techniques for Rehearsal and Review.
  16. PHARMACOLOGY BASICS
  17. Prepare
  18. Chapter 1 Objectives
  19. Vocabulary Development
  20. CHAPTER 1 The Nursing Process and Drug Therapy
  21. Objectives
  22. e-Learning Activities
  23. Companion CD
  24. evolve Website (http://evolve.elsevier.com/Lilley/)
  25. Glossary
  26. OVERVIEW OF THE NURSING PROCESS
  27. Box 1-1 Sample Nursing Care Plan Related to Drug Therapy and the Nursing Process
  28. Assessment
  29. Objective Data
  30. Subjective Data
  31. Nursing Diagnoses
  32. Planning: Goals and Outcome Criteria
  33. Implementation
  34. Evaluation
  35. ASSESSMENT
  36. Analysis of Data
  37. NURSING DIAGNOSES
  38. Box 1-2 A Brief Look at NANDA and the Nursing Process
  39. PLANNING
  40. Box 1-3 Selected NANDA-Approved Nursing Diagnoses
  41. Goals and Outcome Criteria
  42. IMPLEMENTATION
  43. Right Drug
  44. Right Dose
  45. Right Time
  46. Preventing Medication Errors
  47. Right Dose?
  48. Table 1-1 Conversion of Standard Time to Military Time
  49. Right Route
  50. Right Patient
  51. System Analysis
  52. Medication Errors
  53. EVALUATION
  54. Legal and Ethical Principles
  55. Charting Don’ts
  56. Points to Remember
  57. NCLEX Examination Review Questions
  58. Critical Thinking Activities
  59. CHAPTER 2 Pharmacologic Principles
  60. Objectives
  61. e-Learning Activities
  62. Companion CD
  63. evolve Website (http://evolve.elsevier.com/Lilley)
  64. Glossary
  65. OVERVIEW
  66. FIGURE 2-1 Chemical structure of the common analgesic ibuprofen and the chemical, generic, and trade names for the drug.
  67. FIGURE 2-2 Phases of drug activity. (From McKenry LM, Tessier E, Hogan M: Mosby’s pharmacology in nursing, ed 22, St Louis, 2006, Mosby.)
  68. PHARMACEUTICS
  69. Table 2-1 Drug Absorption of Various Oral Preparations
  70. Table 2-2 Dosage Forms
  71. PHARMACOKINETICS
  72. Pharmacokinetic Profiles
  73. Absorption
  74. Overview of Pharmacokinetics: Oral Administration
  75. Drug Movement Through the Body
  76. Preventing Medication Errors
  77. Does IV = PO?
  78. Enteral
  79. FIGURE 2-3 First-pass effect is the metabolism of a drug by the liver before its systemic availability.
  80. Impact of Surface Area
  81. Sublingual and Buccal
  82. Table 2-3 Routes of Administration and Related Nursing Considerations
  83. Box 2-1 Drugs to Be Taken on an Empty Stomach and Drugs to Be Taken with Food
  84. Parenteral
  85. Subcutaneous, Intradermal, and Intramuscular
  86. Topical
  87. Box 2-2 Drug Routes and First-Pass Effects
  88. First-Pass Routes
  89. Non–First-Pass Routes
  90. Transdermal
  91. Inhaled
  92. Distribution
  93. FIGURE 2-4 Drug transport in the body. GI, Gastrointestinal. (From McKenry LM, Salerno E: Mosby’s pharmacology in nursing, ed 19, St Louis, 1995, Mosby.)
  94. Distribution of Fat-Soluble vs. Water-Soluble Drugs
  95. Metabolism
  96. Table 2-4 Mechanisms of Biotransformation
  97. Table 2-5 Common Liver Cytochrome P-450 Enzymes and Corresponding Drug Substrates
  98. Cytochrome P-450 Drug Metabolism
  99. Table 2-6 Examples of Conditions and Drugs That Affect Drug Metabolism
  100. Excretion
  101. FIGURE 2-5 Renal drug excretion. The primary processes involved in drug excretion and the approximate location where these processes take place in the kidney are illustrated. GFR, Glomerular filtration rate.
  102. Half-Life
  103. Time to Steady State
  104. Time to Steady State: Starting and Stopping Drug
  105. Table 2-7 Example of Drug Half-Life Viewed from Different Perspectives
  106. FIGURE 2-6 Characteristics of drug effect and relationship to the therapeutic window. (From McKenry LM, Tessier E, Hogan M: Mosby’s pharmacology in nursing, ed 22, St Louis, 2006, Mosby.)
  107. Onset, Peak, and Duration
  108. PHARMACODYNAMICS
  109. FIGURE 2-7 A, Drugs act by forming a chemical bond with specific receptor sites, similar to a key and lock. B, The better the “fit,” the better the response. Drugs with complete attachment and response are called agonists. C, Drugs that attach but do not elicit a response are called antagonists. D, Drugs that attach, elicit some response, and also block other responses are called partial agonists or agonist-antagonists. (From Clayton BD, Stock YN: Basic pharmacology for nurses, ed 13, St Louis, 2004, Mosby.)
  110. Table 2-8 Drug-Receptor Interactions
  111. Agonists/Antagonists
  112. Mechanism of Action
  113. Receptor Interactions
  114. Receptor Interaction
  115. Enzyme Interactions
  116. Nonselective Interactions
  117. PHARMACOTHERAPEUTICS
  118. Acute Therapy
  119. Maintenance Therapy
  120. Supplemental Therapy
  121. Palliative Therapy
  122. Supportive Therapy
  123. Prophylactic Therapy and Empiric Therapy
  124. Monitoring
  125. Therapeutic Index
  126. Drug Concentration
  127. Patient’s Condition
  128. Tolerance and Dependence
  129. Interactions
  130. Table 2-9 Examples of Drug Interactions and Their Effects on Pharmacokinetics
  131. Adverse Drug Events
  132. Other Drug Effects
  133. Box 2-3 Drugs to Avoid in Patients with Glucose-6-Phosphate Dehydrogenase Deficiency
  134. Cultural Implications
  135. Glucose-6-Phosphate Dehydrogenase Deficiency
  136. Box 2-4 Exogenous Causes of Cancer
  137. PHARMACOGNOSY
  138. TOXICOLOGY
  139. CASE STUDY
  140. Pharmacokinetics
  141. Table 2-10 Common Causes of Poisoning and Antidotes
  142. CONCLUSION
  143. Nursing, Medical, and Pharmacology Domains
  144. Points to Remember
  145. NCLEX Examination Review Questions
  146. Critical Thinking Activities
  147. CHAPTER 3 Life Span Considerations
  148. Objectives
  149. e-Learning Activities
  150. Companion CD
  151. evolve Website (http://evolve.elsevier.com/Lilley)
  152. Glossary
  153. DRUG THERAPY DURING PREGNANCY
  154. Table 3-1 Pregnancy Safety Categories
  155. Passive Diffusion
  156. DRUG THERAPY DURING BREAST-FEEDING
  157. CONSIDERATIONS FOR NEONATAL AND PEDIATRIC PATIENTS
  158. Physiology and Pharmacokinetics
  159. Pharmacodynamics
  160. Dosage Calculations for Pediatric Patients
  161. Table 3-2 Classification of Young Patients
  162. Life Span Considerations: The Pediatric Patient
  163. Pharmacokinetic Changes in the Neonate and Pediatric Patient
  164. Absorption
  165. Distribution
  166. Metabolism
  167. Excretion
  168. FIGURE 3-1 West nomogram for infants and children. S.A., Surface area. (Modified from data by E. Boyd and C. D. West. In Behrman RE, Kliegman RM, Jensen HB: Nelson textbook of pediatrics, ed 17, Philadelphia, 2004, Saunders.)
  169. CONSIDERATIONS FOR ELDERLY PATIENTS
  170. Lifespan Considerations: The Elderly Patient
  171. Percentage of Population over 65 Years of Age
  172. Polypharmacy and Drug Use
  173. Life Span Considerations: The Elderly Patient
  174. Alzheimer’s Disease
  175. Physiologic Changes
  176. Table 3-3 Physiologic Changes in the Elderly Patient
  177. Pharmacokinetics
  178. Absorption
  179. Life Span Considerations: The Elderly Patient
  180. Pharmacokinetic Changes
  181. Absorption
  182. Distribution
  183. Metabolism
  184. Excretion
  185. Distribution
  186. Metabolism
  187. Excretion
  188. Problematic Medications for the Elderly
  189. Table 3-4 Problematic Medications and Conditions to Consider for the Elderly Patient
  190. ♦ NURSING PROCESS
  191. ♦ ASSESSMENT
  192. EVIDENCE-BASED PRACTICE
  193. The Beers Criteria for Drug Use in the Elderly
  194. Review
  195. Type of Evidence
  196. Results of Study
  197. Link of Evidence to Nursing Practice
  198. ♦ NURSING DIAGNOSES
  199. ♦ PLANNING
  200. Goals
  201. Outcome Criteria
  202. ♦ IMPLEMENTATION
  203. ♦ EVALUATION
  204. Life Span Considerations: The Pediatric Patient
  205. Age-Related Considerations for Medication Administration from Infancy to Adolescence
  206. General Interventions
  207. Infants
  208. Toddlers
  209. Preschoolers
  210. School-Aged Children
  211. Adolescents
  212. Points to Remember
  213. NCLEX Examination Review Questions
  214. Critical Thinking Activities
  215. CHAPTER 4 Cultural, Legal, and Ethical Considerations
  216. Objectives
  217. e-Learning Activities
  218. Companion CD
  219. evolve Website (http://evolve.elsevier.com/Lilley)
  220. Glossary
  221. Table 4-1 Summary of Major U.S. Drug Legislation
  222. Table 4-2 Controlled Substances: Schedule Categories
  223. U.S. DRUG LEGISLATION
  224. Table 4-3 Controlled Substances: Categories, Dispensing Restrictions, and Examples
  225. NEW DRUG DEVELOPMENT
  226. Investigational New Drug Application
  227. Informed Consent
  228. U.S. Food and Drug Administration Drug Approval Process
  229. Preclinical Investigational Drug Studies
  230. Four Clinical Phases of Investigational Drug Studies
  231. Phase I
  232. Phase II
  233. Phase III
  234. Phase IV
  235. LEGAL AND ETHICAL PRINCIPLES
  236. Use of Placebos
  237. Expedited Drug Approval
  238. LEGAL ISSUES AND NURSING IMPLICATIONS
  239. LEGAL AND ETHICAL PRINCIPLES
  240. Ethical Terms Related to Nursing Practice
  241. Box 4-1 American Nurses Association Code of Ethics for Nurses
  242. Provisions of the Code
  243. Ethical Practice
  244. Box 4-2 Legal-Ethical Considerations in Nursing Practice: The ICN Code of Ethics for Nurses
  245. CULTURAL CONSIDERATIONS
  246. Influence of Ethnicity and Genetics
  247. CULTURAL IMPLICATIONS
  248. Cultural Terms Related to Nursing Practice
  249. CULTURAL IMPLICATIONS
  250. Common Practices of Selected Cultural Groups
  251. Table 4-4 Examples of Varying Drug Responses in Different Racial or Ethnic Groups
  252. ♦ NURSING PROCESS
  253. ♦ ASSESSMENT
  254. Maintaining Health
  255. Protecting Health
  256. Restoring Health
  257. ♦ NURSING DIAGNOSES
  258. ♦ PLANNING
  259. Goals
  260. Outcome Criteria
  261. ♦ IMPLEMENTATION
  262. ♦ EVALUATION
  263. Points to Remember
  264. NCLEX Examination Review Questions
  265. Critical Thinking Activities
  266. CHAPTER 5 Medication Errors: Preventing and Responding
  267. Objectives
  268. e-Learning Activities
  269. Companion CD
  270. evolve Website (http://evolve.elsevier.com/Lilley)
  271. Glossary
  272. INTRODUCTION
  273. General Impact of Errors on Patients
  274. Medication Errors
  275. FIGURE 5-1 Diagram illustrating the various classes and subclasses of adverse drug events. ADRs, Adverse drug reactions; ARs, allergic reactions; IRs, idiosyncratic reactions; SEs, side effects.
  276. Box 5-1 Common Classes of Medications Involved in Serious Errors
  277. PSYCHOSOCIAL ISSUES THAT CONTRIBUTE TO ERRORS
  278. Organizational Issues
  279. PREVENTING MEDICATION ERRORS
  280. Selected Examples of Commonly Confused Drug Names
  281. Educational System Issues and Their Potential Impact on Medication Errors
  282. Medication Errors and Related Sociologic Factors
  283. PREVENTING AND RESPONDING TO ERRORS
  284. Reporting and Responding to Medication Errors
  285. Medication Reconciliation
  286. OTHER ETHICAL ISSUES
  287. Notification of Patients Regarding Errors
  288. Whistle-Blowing
  289. NURSING MEASURES TO PREVENT MEDICATION ERRORS
  290. LEGAL AND ETHICAL PRINCIPLES
  291. Use of Abbreviations
  292. Possible Consequences of Medication Errors for Nurses
  293. Life Span Considerations: The Elderly Patient
  294. Medication Errors
  295. Life Span Considerations: The Pediatric Patient
  296. Medication Errors
  297. POLITICAL ACTION
  298. An Ounce of Prevention: Nurse Advocacy for Safer Health Care Organizations
  299. CASE STUDY
  300. Medication Errors
  301. SUMMARY
  302. Points to Remember
  303. NCLEX Examination Review Questions
  304. Critical Thinking Activities
  305. CHAPTER 6 Patient Education and Drug Therapy
  306. Objectives
  307. e-Learning Activities
  308. Companion CD
  309. evolve Website (http://evolve.elsevier.com/Lilley)
  310. ASSESSMENT OF LEARNING NEEDS RELATED TO DRUG THERAPY
  311. Box 6-1 Erikson’s Stages of Development
  312. CULTURAL IMPLICATIONS
  313. Patient Education
  314. NURSING DIAGNOSES RELATED TO LEARNING NEEDS AND DRUG THERAPY
  315. Patient Noncompliance
  316. PLANNING RELATED TO LEARNING NEEDS AND DRUG THERAPY
  317. Table 6-1 Educational Strategies to Address Common Changes Related to Aging That May Influence Learning
  318. IMPLEMENTATION RELATED TO PATIENT EDUCATION AND DRUG THERAPY
  319. EVIDENCE-BASED PRACTICE
  320. The Impact of Better Education of Nurses on Patient Outcomes
  321. Type of Evidence
  322. Results of Study
  323. Link of Evidence to Nursing Practice
  324. Box 6-2 General Teaching and Learning Principles
  325. LEGAL AND ETHICAL PRINCIPLES
  326. Discharge Teaching
  327. EVALUATION OF PATIENT LEARNING RELATED TO DRUG THERAPY
  328. SUMMARY
  329. Patient Teaching Tips
  330. Points to Remember
  331. NCLEX Examination Review Questions
  332. Critical Thinking Activities
  333. CHAPTER 7 Over-the-Counter Drugs and Herbal and Dietary Supplements
  334. Objectives
  335. e-Learning Activities
  336. Companion CD
  337. evolve Website (http://evolve.elsevier.com/Lilley)
  338. Glossary
  339. OVER-THE-COUNTER DRUGS
  340. Box 7-1 Timetable of Major Legal Events Affecting U.S. Drug Use
  341. Box 7-2 Criteria for Over-the-Counter Status
  342. Indication for Use
  343. Safety Profile
  344. Practicality for Over-the-Counter Use
  345. Box 7-3 Reclassified Over-the-Counter Products
  346. Analgesics
  347. Histamine Blockers
  348. H1 Receptors
  349. H2 Receptors
  350. Mast Cell Stabilizers
  351. Smoking Deterrents
  352. Topical Medications
  353. FIGURE 7-1 Example of an over-the-counter drug label.
  354. Table 7-1 Common Over-the-Counter (OTC) Drugs
  355. HERBALS AND DIETARY SUPPLEMENTS
  356. History
  357. Table 7-2 Conventional Medicines Derived from Plants
  358. Consumer Use of Dietary Supplements
  359. Safety
  360. HERBAL THERAPIES AND DIETARY SUPPLEMENTS
  361. Selected Herbs and Dietary Supplements and Their Possible Drug Interactions
  362. Epidemiology
  363. ♦ NURSING PROCESS
  364. ♦ ASSESSMENT
  365. Over-the-Counter Drugs
  366. Herbal Products and Dietary Supplements
  367. ♦ NURSING DIAGNOSES
  368. ♦ PLANNING
  369. Goals
  370. Outcome Criteria
  371. ♦ IMPLEMENTATION
  372. CULTURAL IMPLICATIONS
  373. Drug Responses and Cultural Factors
  374. ♦ EVALUATION
  375. Patient Teaching Tips
  376. Points to Remember
  377. NCLEX Examination Review Questions
  378. Critical Thinking Activities
  379. CHAPTER 8 Substance Abuse
  380. Objectives
  381. e-Learning Activities
  382. Companion CD
  383. evolve Website (http://evolve.elsevier.com/Lilley)
  384. Glossary
  385. Box 8-1 Categories of Abused Substances
  386. Major Categories
  387. Individual Drugs
  388. OPIOIDS
  389. Mechanism of Action and Drug Effects
  390. Indications
  391. Contraindications
  392. Adverse Effects
  393. Management of Withdrawal, Toxicity, and Overdose
  394. Box 8-2 Signs and Symptoms of Opioid Withdrawal
  395. Peak Period
  396. Duration
  397. Signs
  398. Symptoms
  399. Box 8-3 Medications for Treatment of Opioid Withdrawal
  400. Clonidine (Catapres) Substitution
  401. Methadone Substitution
  402. STIMULANTS
  403. Table 8-1 Various Forms of Amphetamine and Cocaine with Street Names
  404. Life Span Considerations: The Pediatric Patient
  405. Substance Abuse
  406. Mechanism of Action and Drug Effects
  407. Indications
  408. Contraindications
  409. Adverse Effects
  410. Management of Withdrawal, Toxicity, and Overdose
  411. Box 8-4 Signs and Symptoms of Stimulant Withdrawal
  412. Peak Period
  413. Duration
  414. Signs
  415. Symptoms
  416. DEPRESSANTS
  417. Mechanism of Action and Drug Effects
  418. Indications
  419. Contraindications
  420. Adverse Effects
  421. Management of Withdrawal, Toxicity, and Overdose
  422. Box 8-5 Signs, Symptoms, and Treatment of Depressant Withdrawal
  423. Peak Period
  424. Duration
  425. Signs
  426. Symptoms
  427. Treatment of Benzodiazepine Withdrawal
  428. Treatment of Barbiturate Withdrawal
  429. Table 8-2 Barbiturate Equivalencies
  430. ALCOHOL
  431. Mechanism of Action and Drug Effects
  432. Indications
  433. Adverse Effects
  434. Management of Withdrawal, Toxicity, and Overdose
  435. Box 8-6 Signs, Symptoms, and Treatment of Ethanol Withdrawal
  436. Mild Withdrawal
  437. Signs and Symptoms
  438. Treatment
  439. Moderate Withdrawal
  440. Signs and Symptoms
  441. Treatment
  442. Severe Withdrawal (Delirium Tremens)*
  443. Signs and Symptoms
  444. Treatment
  445. Table 8-3 Acetaldehyde Syndrome
  446. NICOTINE
  447. Mechanism of Action and Drug Effects
  448. Indications
  449. Adverse Effects
  450. Management of Withdrawal, Toxicity, and Overdose
  451. ♦ NURSING PROCESS
  452. ♦ ASSESSMENT
  453. Table 8-4 Nicotine Withdrawal Therapies
  454. ♦ NURSING DIAGNOSES
  455. ♦ PLANNING
  456. Goals
  457. Outcome Criteria
  458. ♦ IMPLEMENTATION
  459. ♦ EVALUATION
  460. Life Span Considerations: The Elderly Patient
  461. Substance Abuse
  462. Patient Teaching Tips
  463. Points to Remember
  464. NCLEX Examination Review Questions
  465. Critical Thinking Activities
  466. CHAPTER 9 Photo Atlas of Drug Administration
  467. PREPARING FOR DRUG ADMINISTRATION
  468. ENTERAL DRUGS
  469. Administering Oral Drugs
  470. Oral Medications
  471. FIGURE 9-1 Using a computer-dispensing system to remove unit-dose medication.
  472. FIGURE 9-2 Checking the medication against the order on the medication administration record.
  473. FIGURE 9-3 Always check the patient’s identification and allergies before giving medications.
  474. Box 9-1 Standard Precautions
  475. Sublingual and Buccal Medications
  476. FIGURE 9-4 Some medications require special assessment before giving, such as taking an apical pulse.
  477. FIGURE 9-5 Crushing tablets with a mortar and pestle.
  478. FIGURE 9-6 Enteric-coated tablets and long-acting medications should not be crushed.
  479. FIGURE 9-7 Giving oral medications.
  480. FIGURE 9-8 Proper placement of a sublingual tablet.
  481. FIGURE 9-9 Example of a medication administration record (MAR).
  482. Liquid Medications
  483. FIGURE 9-10 Liquid medication in a unit-dose package. B, Liquid measured into a medicine cup from a multidose container. C, Liquid medicine in an oral-dosing syringe.
  484. Oral Medications and Infants
  485. FIGURE 9-11 Measuring liquid medication.
  486. FIGURE 9-12 Administering oral liquid medication to an infant.
  487. Administering Drugs Through a Nasogastric or Gastrostomy Tube
  488. FIGURE 9-13 Elevate the head of the bed before administering medications through a nasogastric tube.
  489. FIGURE 9-14 Medications given through gastric tubes should be administered separately. Dilute crushed pills in 15 to 30 mL of water before administration.
  490. FIGURE 9-15 Pour liquid medication into the syringe, then unclamp the tubing and allow it to flow in by gravity.
  491. Administering Rectal Drugs
  492. FIGURE 9-16 Lubricate the suppository with a water-soluble lubricant.
  493. FIGURE 9-17 Inserting a rectal suppository.
  494. PARENTERAL DRUGS
  495. Preparing for Parenteral Drug Administration
  496. FIGURE 9-18 NEVER RECAP A USED NEEDLE! Always dispose of uncapped needles in the appropriate sharps container. Refer to Box 9-1 for Standard Precautions.
  497. FIGURE 9-19 An UNUSED needle may need to be recapped before the medication is given to the patient. The “scoop method” is one way to recap an unused needle safely. Be sure not to touch the needle to the countertop or to the outside of the needle cap.
  498. FIGURES 9-20 AND 9-21 There are several types of needlestick prevention syringes. This example (Figure 9-20) has a guard over the unused syringe. After the injection, the nurse pulls the guard up over the needle until it locks into place (Figure 9-20).
  499. FIGURE 9-22 The parts of a syringe and hypodermic needle.
  500. FIGURE 9-23 Close-up view of the bevel of a needle.
  501. FIGURE 9-24 Be sure to choose the correct size and type of syringe for the drug ordered.
  502. FIGURE 9-25 Needles come in various gauges and lengths. The larger the gauge, the smaller the needle. Be sure to choose the correct needle—gauge and length—for the type of injection ordered.
  503. FIGURES 9-26 AND 9-27 Some medications come in a prefilled, sterile medication cartridge. Figures 9-26 and 9-27 show the Carpuject prefilled cartridge and syringe system. Follow the manufacturer’s instructions for assembling prefilled syringes. After use, the syringe is disposed of in a sharps container; the cartridge is reusable.
  504. Inserting a Pre-Filled Cartridge with Needle into the Carpuject Syringe
  505. FIGURE 9-28 Ampules containing medications come in various sizes. The ampules must be broken carefully to withdraw the medication.
  506. FIGURE 9-29 A filter needle should be used when withdrawing medication from an ampule. Filter needles help to remove tiny glass particles that may result from the ampule breakage. DO NOT USE A FILTER NEEDLE for injection into a patient! Some facilities may require the use of a filter needle to withdraw medications from a vial.
  507. Removing Medications from Ampules
  508. Drawing up Medication from an Ampule
  509. FIGURE 9-30 Tapping an ampule to move the fluid below the neck.
  510. FIGURES 9-31 AND 9-32 Breaking an ampule.
  511. FIGURE 9-33 Using a filter needle to withdraw medication from an ampule.
  512. Removing Medications from Vials
  513. Withdrawing Medication from a Vial
  514. Mixing Two Medications in One Syringe from Two Vials
  515. Mixing Two Medications in One Syringe from One Vial and One Ampule
  516. Mixing Two Medications in One Pre-Filled Cartridge and a Vial
  517. Mix-O-Vials
  518. FIGURE 9-34 Insert air into a vial before withdrawing medication (needleless system shown).
  519. FIGURE 9-35 Withdrawing medication from a vial (needleless system shown).
  520. FIGURE 9-36 Using a needle and syringe to remove medication from a vial.
  521. Injections Overview
  522. Needle Insertion Angles for Intramuscular, Subcutaneous, and Intradermal Injections
  523. FIGURE 9-37 Various needle angles.
  524. Z-Track Method
  525. FIGURES 9-38 AND 9-39 The Z-track method for intramuscular injections.
  526. Air-Lock Technique
  527. FIGURE 9-40 Air-lock technique for intramuscular injections.
  528. Intradermal Injection
  529. FIGURES 9-41 AND 9-42 Intradermal injection.
  530. Subcutaneous Injections
  531. FIGURE 9-43 Potential sites for subcutaneous injections.
  532. Insulin Syringes
  533. FIGURE 9-44 Before giving an injection, cleanse the skin with an alcohol or antiseptic swab.
  534. FIGURE 9-45 Giving a subcutaneous injection at a 90-degree angle.
  535. FIGURE 9-46 When giving a subcutaneous injection in the abdomen, be sure to choose a site at least 2 inches away from the umbilicus.
  536. FIGURE 9-47 Insulin syringes are available in 100-unit and 50-unit calibrations.
  537. FIGURE 9-48 A variety of devices are available for insulin injections.
  538. FIGURE 9-49 Mixing two types of insulin in the same syringe.
  539. Intramuscular Injections
  540. FIGURE 9-50 Finding landmarks for a ventrogluteal injection.
  541. Ventrogluteal Site
  542. FIGURES 9-51 AND 9-52 Ventrogluteal intramuscular injection.
  543. Vastus Lateralis Site
  544. FIGURE 9-53 Vastus lateralis intramuscular injection in an infant.
  545. FIGURES 9-54, 9-55, AND 9-56 Vastus lateralis intramuscular injection.
  546. Dorsogluteal Site
  547. FIGURES 9-57, 9-58, AND 9-59 Dorsogluteal intramuscular injection.
  548. Deltoid Site
  549. FIGURES 9-60, 9-61, AND 9-62 Deltoid intramuscular injection.
  550. Preparing Intravenous Medications
  551. FIGURE 9-63 Two types of intravenous piggyback (IVPB) medication delivery systems. These IVPB medications must be activated before administration to the patient.
  552. FIGURE 9-64 Activating an intravenous piggyback infusion bag (step 1).
  553. FIGURE 9-65 Activating an intravenous piggyback infusion bag (step 2).
  554. FIGURE 9-66 Activating an intravenous piggyback infusion bag (step 3).
  555. FIGURES 9-67, 9-68, AND 9-69 Adding a medication to an intravenous infusion bag with a needle and syringe.
  556. FIGURE 9-70 Mix the medication thoroughly before infusing.
  557. FIGURE 9-71 Label the intravenous infusion bag when medication has been added.
  558. Infusions of Intravenous Piggyback Medications
  559. FIGURE 9-72 Infusing an intravenous piggyback medication with a gravity primary intravenous infusion.
  560. FIGURE 9-73 Infusing an intravenous piggyback medication with the primary intravenous infusion on an electronic infusion pump.
  561. FIGURE 9-74 Adding a medication to a volume-controlled administration set.
  562. FIGURE 9-75 Instructing the patient on the use of a patient-controlled analgesia pump.
  563. Intravenous Push Medications
  564. Intravenous Push Medications Through an Intravenous Lock
  565. Intravenous Push Medications Through an Existing Infusion
  566. After Injection of an Intravenous Push Medication
  567. FIGURE 9-76 Cleanse the port before attaching the syringe.
  568. FIGURE 9-77 Attaching the syringe to the intravenous lock.
  569. FIGURE 9-78 Slowly inject the intravenous push medication through the intravenous lock; use a watch to time the injection.
  570. FIGURE 9-79 When giving an intravenous push medication through an intravenous line, pinch the tubing just above the injection port.
  571. TOPICAL DRUGS
  572. Administering Eye Medications
  573. Eyedrops
  574. FIGURE 9-80 Cleanse the eye, washing from the inner to outer canthus, before giving eye medications.
  575. Eye Ointment
  576. After Instillation of Eye Medications
  577. FIGURE 9-81 Insert the eyedrop into the lower conjunctival sac.
  578. FIGURE 9-82 Applying eye ointment.
  579. FIGURE 9-83 Applying gentle pressure against the nasolacrimal duct after giving eye medications.
  580. Administering Eardrops
  581. FIGURE 9-84 For adults, pull the pinna up and back.
  582. FIGURE 9-85 For infants and children younger than 3 years of age, pull the pinna down and back.
  583. Administering Nasal Medications
  584. Nasal Drops
  585. FIGURE 9-86 Nasal medications may come in various delivery forms.
  586. FIGURE 9-87 Administering nose drops.
  587. Nasal Spray
  588. After Administration of Nasal Medicines
  589. FIGURE 9-88 Before self-administering the nasal spray, the patient should occlude the other nostril.
  590. Administering Inhaled Drugs
  591. Metered-Dose Inhalers
  592. FIGURE 9-89 A, Metered-dose inhaler (MDI). B, Automated, or breath-activated, MDI. C, Dry powder inhaler that delivers powdered medication.
  593. FIGURE 9-90 Using a metered-dose inhaler without a spacer.
  594. FIGURE 9-91 Instructing the patient on how to use a spacer device.
  595. FIGURE 9-92 Using a spacer device with a metered-dose inhaler.
  596. Small-Volume Nebulizers
  597. FIGURE 9-93 Adding medication to the nebulizer cup.
  598. FIGURE 9-94 Administering a small-volume nebulizer treatment.
  599. Administering Medications to the Skin
  600. Lotions, Creams, Ointments, and Powders
  601. FIGURE 9-95 Use gloves to apply topical skin preparations.
  602. Transdermal Patches
  603. After Administration of Topical Skin Preparations
  604. FIGURE 9-96 Spread the lotion on the skin with long, smooth, gentle strokes.
  605. FIGURE 9-97 Measure nitroglycerin ointment carefully before application.
  606. FIGURE 9-98 Opening a transdermal patch medication.
  607. FIGURE 9-99 Ensure that the edges of the transdermal patch are secure after applying.
  608. Administering Vaginal Medications
  609. Creams, Foams, or Gels Applied with an Applicator
  610. FIGURE 9-100 Vaginal suppositories (right) are larger and more oval than rectal suppositories (left).
  611. FIGURE 9-101 Vaginal cream and suppository, with applicators.
  612. Suppositories
  613. FIGURE 9-102 Administering vaginal cream with an applicator.
  614. FIGURE 9-103 Administering a vaginal suppository.
  615. ILLUSTRATION CREDITS
  616. PART 2 Drugs Affecting the Central Nervous System
  617. Drugs Affecting the Central Nervous System
  618. STUDY SKILLS TIPS
  619. VOCABULARY
  620. TEXT NOTATION
  621. LANGUAGE CONVENTIONS
  622. CHAPTER 10 Analgesic Drugs
  623. Objectives
  624. e-Learning Activities
  625. Companion CD
  626. evolve Website (http://evolve.elsevier.com/Lilley)
  627. Drug Profiles
  628. Glossary
  629. PHYSIOLOGY AND PSYCHOLOGY OF PAIN
  630. CULTURAL IMPLICATIONS
  631. The Patient Experiencing Pain
  632. Table 10-1 Conditions That Alter Pain Threshold
  633. Table 10-2 Acute Versus Chronic Pain
  634. Table 10-3 A and C Nerve Fibers
  635. FIGURE 10-1 Gate theory of pain transmission. CNS, Central nervous system.
  636. Treatment of Pain in Special Situations
  637. Box 10-1 Potential Opioid Adverse Effects and Their Management
  638. Constipation
  639. Nausea and Vomiting
  640. Sedation and Mental Clouding
  641. Respiratory Depression
  642. Subacute Overdose
  643. Other Opioid Adverse Effects
  644. OPIOID DRUGS
  645. Chemical Structure
  646. Mechanism of Action and Drug Effects
  647. Indications
  648. Table 10-4 Chemical Classification of Opioids
  649. Table 10-5 Opioid Receptors and Their Characteristics
  650. CASE STUDY
  651. Opioid Administration
  652. PREVENTING MEDICATION ERRORS
  653. Fentanyl Transdermal Patches
  654. Contraindications
  655. Adverse Effects
  656. Table 10-6 Opioid-Induced Adverse Effects by Body System
  657. LEGAL AND ETHICAL PRINCIPLES
  658. The Impact of Nursing Assessment on Medication Administration–Related Errors
  659. Table 10-7 Opioid Antagonists (Reversal Drugs)
  660. Toxicity and Management of Overdose
  661. Interactions
  662. Laboratory Test Interactions
  663. Dosages
  664. Drug Profiles
  665. ▸ morphine sulfate
  666. DOSAGES
  667. Selected Analgesic Drugs and Related Drugs
  668. Pharmacokinetics
  669. ▸ codeine sulfate
  670. Pharmacokinetics
  671. ▸ fentanyl
  672. Table 10-8 Equianalgesic Opioid Potencies (Based on Morphine 10 mg Intramuscularly and 30 mg Orally)
  673. Table 10-9 Transdermal Fentanyl Dosages
  674. Pharmacokinetics
  675. ▸ meperidine hydrochloride
  676. Pharmacokinetics
  677. ▸ methadone hydrochloride
  678. Pharmacokinetics
  679. ▸ oxycodone hydrochloride
  680. Pharmacokinetics (Immediate Release)
  681. Opioids and Agonists-Antagonists
  682. Partial Opioid Agonists
  683. Opioid Antagonists
  684. ▸ naloxone hydrochloride
  685. Pharmacokinetics
  686. ▸ naltrexone hydrochloride
  687. Pharmacokinetics
  688. NONOPIOID ANALGESICS
  689. Mechanism of Action and Drug Effects
  690. Indications
  691. Contraindications
  692. Adverse Effects
  693. Toxicity and Management of Overdose
  694. Interactions
  695. Drug Profiles
  696. Nonopioid Analgesics
  697. ▸ acetaminophen
  698. Pharmacokinetics
  699. tramadol hydrochloride
  700. Pharmacokinetics
  701. ♦ NURSING PROCESS
  702. ♦ ASSESSMENT
  703. Box 10-2 Assessment of Pain
  704. EVIDENCE-BASED PRACTICE
  705. Strategies of Pain Assessment Used by Nurses on Surgical Units
  706. Review
  707. Type of Evidence
  708. Results of Study
  709. Link of Evidence to Nursing Practice
  710. Life Span Considerations: The Pediatric Patient
  711. Opioid Use
  712. Life Span Considerations: The Elderly Patient
  713. Opioid Use
  714. ♦ NURSING DIAGNOSES
  715. ♦ PLANNING
  716. Goals
  717. Outcome Criteria
  718. ♦ IMPLEMENTATION
  719. Box 10-3 Nonpharmacologic Treatment Options for Pain
  720. HERBAL THERAPIES AND DIETARY SUPPLEMENTS
  721. Feverfew (Chrysanthemum parthenium)
  722. Overview
  723. Common Uses
  724. Adverse Effects
  725. Potential Drug Interactions
  726. Contraindications
  727. Table 10-10 Opioid Administration Guidelines
  728. Table 10-11 Drugs Not Recommended for Treatment of Cancer Pain
  729. CASE STUDY
  730. Pain Management in Terminal Illness
  731. ♦ EVALUATION
  732. Patient Teaching Tips
  733. Points to Remember
  734. NCLEX Examination Review Questions
  735. Critical Thinking Activities
  736. CHAPTER 11 General and Local Anesthetics
  737. Objectives
  738. e-Learning Activities
  739. Companion CD
  740. evolve Website (http://evolve.elsevier.com/Lilley)
  741. Drug Profiles
  742. Glossary
  743. GENERAL ANESTHETICS
  744. Box 11-1 General Anesthesia: A Historical Perspective
  745. Table 11-1 Inhaled General Anesthetics
  746. Mechanism of Action and Drug Effects
  747. Table 11-2 General Anesthetic Drugs
  748. Table 11-3 Adjunctive Anesthetic Drugs
  749. Life Span Considerations: The Elderly Patient
  750. Anesthesia
  751. Indications
  752. Contraindications
  753. Adverse Effects
  754. Table 11-4 Effects of Inhaled and Intravenous General Anesthetics
  755. Toxicity and Management of Overdose
  756. Interactions
  757. Dosages
  758. Drug Profiles
  759. enflurane
  760. DOSAGES
  761. Selected General Anesthetic Drugs
  762. Life Span Considerations: The Pediatric Patient
  763. Anesthesia
  764. halothane
  765. isoflurane
  766. methoxyflurane
  767. nitrous oxide
  768. ▸ propofol
  769. sevoflurane
  770. LOCAL ANESTHETICS
  771. Table 11-5 Topical Anesthetics
  772. Box 11-2 Types of Local Anesthesia
  773. Central
  774. Peripheral
  775. Mechanism of Action and Drug Effects
  776. Table 11-6 Selected Parenteral Anesthetic Drugs*
  777. Indications
  778. Contraindications
  779. Adverse Effects
  780. Box 11-3 Chemical Groups of Local Anesthetics
  781. Ester Type
  782. Amide Type
  783. Toxicity and Management of Overdose
  784. Interactions
  785. Dosages
  786. DOSAGES
  787. Local Anesthetic Drug
  788. Drug Profiles
  789. ▸ lidocaine
  790. NEUROMUSCULAR BLOCKING DRUGS
  791. Mechanism of Action and Drug Effects
  792. Indications
  793. Table 11-7 Effects of Ganglionic Blockade by Neuromuscular Blocking Drugs
  794. Contraindications
  795. Adverse Effects
  796. Toxicity and Management of Overdose
  797. PREVENTING MEDICATION ERRORS
  798. Neuromuscular Blocking Drugs
  799. Box 11-4 Conditions That Predispose Patients to Toxic Effects from Neuromuscular Blocking Drugs
  800. Box 11-5 Conditions That Oppose the Effects of Neuromuscular Blocking Drugs
  801. Box 11-6 Drugs That Interact with Neuromuscular Blocking Drugs
  802. Additive Effects
  803. Opposing Effects
  804. Interactions
  805. Dosages
  806. Drug Profiles
  807. Depolarizing Neuromuscular Blocking Drugs
  808. ▸ succinylcholine
  809. Pharmacokinetics
  810. Nondepolarizing Neuromuscular Blocking Drugs
  811. pancuronium
  812. DOSAGES
  813. Selected Neuromuscular Blocking Drugs
  814. Table 11-8 Classification of Neuromuscular Blocking Drugs
  815. Pharmacokinetics
  816. ▸ vecuronium
  817. Pharmacokinetics
  818. MODERATE SEDATION
  819. PHARMACOKINETIC BRIDGE to Nursing Practice
  820. Life Span Considerations: The Pediatric Patient
  821. Moderate or Conscious Anesthesia
  822. ♦ NURSING PROCESS
  823. ♦ ASSESSMENT
  824. HERBAL THERAPIES AND DIETARY SUPPLEMENTS
  825. Possible Effects of Popular Herbal Products When Combined with Anesthetics
  826. ♦ NURSING DIAGNOSES
  827. ♦ PLANNING
  828. Goals
  829. Outcome Criteria
  830. ♦ IMPLEMENTATION
  831. Box 11-7 Moderate or Conscious Sedation: What to Expect
  832. ♦ EVALUATION
  833. Patient Teaching Tips
  834. General Anesthesia
  835. Local Anesthesia
  836. Miscellaneous
  837. NCLEX Examination Review Questions
  838. Critical Thinking Activities
  839. CHAPTER 12 Central Nervous System Depressants and Muscle Relaxants
  840. Objectives
  841. e-Learning Activities
  842. Companion CD
  843. evolve Website (http://evolve.elsevier.com/Lilley)
  844. Drug Profiles
  845. Glossary
  846. SLEEP
  847. Table 12-1 Sedative-Hypnotic Drugs: Points of Interest
  848. BARBITURATES
  849. Mechanism of Action and Drug Effects
  850. Table 12-2 Stages of Sleep
  851. Table 12-3 Barbiturates: Onset and Duration
  852. CULTURAL IMPLICATIONS
  853. Sedatives-Hypnotics
  854. Indications
  855. Contraindications
  856. Adverse Effects
  857. Table 12-4 Barbiturates: Adverse Effects
  858. Toxicity and Management of Overdose
  859. Interactions
  860. Laboratory Test Interactions
  861. Dosages
  862. Drug Profiles
  863. DOSAGES
  864. Selected Barbiturates
  865. Table 12-5 Barbiturates: Controlled Substance Schedule
  866. pentobarbital
  867. Pharmacokinetics
  868. phenobarbital
  869. Pharmacokinetics
  870. secobarbital
  871. Pharmacokinetics
  872. BENZODIAZEPINES
  873. Mechanism of Action and Drug Effects
  874. Table 12-6 Sedative-Hypnotic Benzodiazepines
  875. Indications
  876. Contraindications
  877. Adverse Effects
  878. Toxicity and Management of Overdose
  879. Table 12-7 Flumazenil Treatment Regimen
  880. Table 12-8 Benzodiazepines: Drug Interactions
  881. Interactions
  882. Laboratory Test Interactions
  883. Dosages
  884. Drug Profiles
  885. estazolam
  886. DOSAGES
  887. Benzodiazepines: Selected Hypnotic Drugs
  888. Pharmacokinetics
  889. flurazepam
  890. Pharmacokinetics
  891. quazepam
  892. Pharmacokinetics
  893. ▸ temazepam
  894. Pharmacokinetics
  895. triazolam
  896. Pharmacokinetics
  897. ▸ zaleplon
  898. Pharmacokinetics
  899. ▸ zolpidem
  900. Pharmacokinetics
  901. MUSCLE RELAXANTS
  902. Mechanism of Action and Drug Effects
  903. Indications
  904. Contraindications
  905. Adverse Effects
  906. Toxicity and Management of Overdose
  907. Interactions
  908. Laboratory Test Interactions
  909. Dosages
  910. Drug Profiles
  911. ▸ baclofen
  912. Pharmacokinetics
  913. ▸ cyclobenzaprine
  914. Pharmacokinetics
  915. dantrolene
  916. DOSAGES
  917. Selected Muscle Relaxants
  918. Pharmacokinetics
  919. MISCELLANEOUS DRUGS
  920. ♦ NURSING PROCESS
  921. ♦ ASSESSMENT
  922. ♦ NURSING DIAGNOSES
  923. ♦ PLANNING
  924. Goals
  925. Outcome Criteria
  926. ♦ IMPLEMENTATION
  927. HERBAL THERAPIES AND DIETARY SUPPLEMENTS
  928. Kava (Piper methysticum)
  929. Overview
  930. Common Uses
  931. Adverse Effects
  932. Potential Drug Interactions
  933. Contraindications
  934. HERBAL THERAPIES AND DIETARY SUPPLEMENTS
  935. Valerian (Valeriana officinalis)
  936. Overview
  937. Common Uses
  938. Adverse Effects
  939. Potential Drug Interactions
  940. Contraindications
  941. ♦ EVALUATION
  942. Patient Teaching Tips
  943. Box 12-1 Sleep Diaries and Non-Pharmacologic Treatment of Sleep Disorders
  944. Information for a Sleep Diary
  945. Nonpharmacologic Sleep Interventions
  946. Points to Remember
  947. NCLEX Examination Review Questions
  948. Critical Thinking Activities
  949. CHAPTER 13 Antiepileptic Drugs
  950. Objectives
  951. e-Learning Activities
  952. Companion CD
  953. Evolve Website (http://evolve.elsevier.com/Lilley)
  954. Drug Profiles
  955. Glossary
  956. EPILEPSY
  957. Box 13-1 International Classification of Seizures
  958. Partial Seizures
  959. Description
  960. Simple Seizures
  961. Complex Seizures
  962. Generalized Seizures
  963. Description
  964. ANTIEPILEPTIC DRUGS
  965. Mechanism of Action and Drug Effects
  966. Indications
  967. Table 13-1 Antiepileptic Drugs of Choice
  968. Table 13-2 Antiepileptic Drugs Used for Treatment of Status Epilepticus
  969. Contraindications
  970. Adverse Effects
  971. Interactions
  972. Dosages
  973. Drug Profiles
  974. Table 13-3 Adverse Effects of Selected Antiepileptic Drugs
  975. Barbiturates
  976. ▸ phenobarbital
  977. Table 13-4 Drug Interactions of Selected Antiepileptic Drugs
  978. Table 13-5 Therapeutic Plasma Levels of NTI Antiepileptic Drugs
  979. Table 13-6 Antiepileptic Drugs: FDA Pregnancy Risk Classification
  980. Pharmacokinetics
  981. DOSAGES
  982. Selected Antiepileptic Drugs
  983. Life Span Considerations: The Pediatric Patient
  984. AEDs
  985. Hydantoins
  986. ▸ phenytoin
  987. Table 13-7 Phenytoin Sodium Versus Fosphenytoin Sodium
  988. Pharmacokinetics
  989. ▸ valproic acid
  990. Pharmacokinetics
  991. Iminostilbenes
  992. ▸ carbamazepine
  993. Pharmacokinetics
  994. oxcarbazepine
  995. Pharmacokinetics
  996. Miscellaneous Drugs
  997. ▸ gabapentin
  998. Pharmacokinetics
  999. lamotrigine
  1000. Pharmacokinetics
  1001. levetiracetam
  1002. Pharmacokinetics
  1003. tiagabine
  1004. Pharmacokinetics
  1005. topiramate
  1006. Pharmacokinetics
  1007. zonisamide
  1008. Pharmacokinetics
  1009. pregabalin
  1010. ♦ NURSING PROCESS
  1011. ♦ ASSESSMENT
  1012. ♦ NURSING DIAGNOSES
  1013. ♦ PLANNING
  1014. Goals
  1015. Outcome Criteria
  1016. Implementation
  1017. ♦ EVALUATION
  1018. Patient Teaching Tips
  1019. Points to Remember
  1020. NCLEX Examination Review Questions
  1021. Critical Thinking Activities
  1022. CHAPTER 14 Antiparkinsonian Drugs
  1023. Objectives
  1024. e-Learning Activities
  1025. Companion CD
  1026. Evolve Website (http://evolve.elsevier.com/Lilley)
  1027. Drug Profiles
  1028. Glossary
  1029. PARKINSON’S DISEASE
  1030. FIGURE 14-1 The neurotransmitter abnormality of Parkinson’s disease.
  1031. Table 14-1 Classic Parkinsonian Symptom
  1032. Table 14-2 Antiparkinsonian Drugs
  1033. SELECTIVE MONOAMINE OXIDASE INHIBITOR THERAPY
  1034. Mechanism of Action and Drug Effects
  1035. Table 14-3 Selegiline: Adverse Effects
  1036. Indications
  1037. Contraindications
  1038. Adverse Effects
  1039. Interactions
  1040. PREVENTING MEDICATION ERRORS
  1041. Look-Alike Drugs: Selegiline and Salagen
  1042. Dosage
  1043. Drug Profiles
  1044. ▸ selegiline
  1045. Pharmacokinetics
  1046. DOPAMINERGIC THERAPY
  1047. Mechanism of Action and Drug Effects
  1048. Indications
  1049. Contraindications
  1050. Adverse Effects
  1051. Interactions
  1052. Table 14-4 Dopaminergic Drugs: Adverse Effects
  1053. Dosages
  1054. Drug Profiles
  1055. levodopa
  1056. Pharmacokinetics
  1057. ▸ levodopa-carbidopa
  1058. Pharmacokinetics
  1059. amantadine
  1060. Pharmacokinetics
  1061. Dopamine Agonists
  1062. Dosages
  1063. Selegiline and Selected Dopaminergic Drugs
  1064. bromocriptine and pergolide
  1065. Pharmacokinetics (bromocriptine)
  1066. Pharmacokinetics (pergolide)
  1067. ▸ ropinirole
  1068. Pharmacokinetics
  1069. COMT Inhibitors
  1070. entacapone
  1071. Pharmacokinetics
  1072. ANTICHOLINERGIC THERAPY
  1073. Mechanism of Action and Drug Effects
  1074. Indications
  1075. Contraindications
  1076. Adverse Effects
  1077. Interactions
  1078. Table 14-5 Anticholinergic Drugs: Adverse Effects
  1079. Dosages
  1080. Drug Profiles
  1081. ▸ benztropine mesylate
  1082. Pharmacokinetics
  1083. Dosages
  1084. Selected Anticholinergic Drugs
  1085. ♦ NURSING PROCESS
  1086. ♦ ASSESSMENT
  1087. Life Span Considerations: The Elderly Patient
  1088. Antiparkinsonian Drugs
  1089. ♦ NURSING DIAGNOSES
  1090. ♦ PLANNING
  1091. Goals
  1092. Outcome Criteria
  1093. ♦ IMPLEMENTATION
  1094. ♦ EVALUATION
  1095. Patient Teaching Tips
  1096. Points to Remember
  1097. NCLEX Examination Review Questions
  1098. Critical Thinking Activities
  1099. CHAPTER 15 Psychotherapeutic Drugs
  1100. Objectives
  1101. e-Learning Activities
  1102. Companion CD
  1103. evolve Website (http://evolve.elsevier.com/Lilley)
  1104. Drug Profiles
  1105. Glossary
  1106. CULTURAL IMPLICATIONS
  1107. Psychotherapeutic Drugs
  1108. OVERVIEW OF MENTAL ILLNESS
  1109. ANTIANXIETY DRUGS
  1110. Mechanism of Action and Drug Effects
  1111. Table 15-1 Various Anxiety Disorders: Drugs of Choice
  1112. Indications
  1113. Table 15-2 Benzodiazepines: Approved Indications
  1114. Contraindications
  1115. Adverse Effects
  1116. Table 15-3 Benzodiazepines: Common Adverse Effects
  1117. Toxicity and Management of Overdose
  1118. Box 15-1 Flumazenil Treatment Regimen
  1119. Recommended Regimen
  1120. Duration of Action
  1121. Interactions
  1122. Dosages
  1123. Drug Profiles
  1124. Benzodiazepines
  1125. ▸ alprazolam
  1126. Pharmacokinetics
  1127. ▸ chlordiazepoxide
  1128. Pharmacokinetics
  1129. ▸ diazepam
  1130. Pharmacokinetics
  1131. ▸ lorazepam
  1132. Pharmacokinetics
  1133. Miscellaneous Drugs
  1134. DOSAGES
  1135. Selected Antianxiety Drugs
  1136. hydroxyzine
  1137. Pharmacokinetics
  1138. buspirone
  1139. Pharmacokinetics
  1140. DRUGS USED TO TREAT AFFECTIVE DISORDERS
  1141. PREVENTING MEDICATION ERRORS
  1142. Look-Alike Drugs: Bupropion and Buspirone
  1143. ANTIMANIC DRUGS
  1144. Drug Profiles
  1145. ▸ lithium
  1146. Pharmacokinetics
  1147. valproic acid
  1148. Pharmacokinetics
  1149. ANTIDEPRESSANT DRUGS
  1150. DOSAGES
  1151. Selected Antimanic Drugs
  1152. FIGURE 15-1 Biologic amine hypothesis. NE, Norepinephrine.
  1153. FIGURE 15-2 Permissive hypothesis. NE, Norepinephrine; 5-HT, serotonin.
  1154. SELECTIVE SEROTONIN REUPTAKE INHIBITORS AND SECOND- AND THIRD-GENERATION ANTIDEPRESSANTS
  1155. Mechanism of Action and Drug Effects
  1156. Indications
  1157. Contraindications
  1158. Adverse Effects
  1159. Interactions
  1160. Box 15-2 Common Symptoms of Serotonin Syndrome
  1161. Table 15-4 Newer Generation Antidepressants: Adverse Effects
  1162. Table 15-5 Newer Generation Antidepressants: Drug Interactions
  1163. DOSAGES
  1164. Selected NGAs
  1165. Drug Profiles
  1166. trazodone
  1167. Pharmacokinetics
  1168. ▸ bupropion
  1169. Pharmacokinetics
  1170. ▸ fluoxetine
  1171. Pharmacokinetics
  1172. venlafaxine
  1173. Pharmacokinetics
  1174. ▸ mirtazapine
  1175. Pharmacokinetics
  1176. TRICYCLIC ANTIDEPRESSANTS
  1177. Mechanism of Action and Drug Effects
  1178. Table 15-6 Tricyclic Antidepressants: Therapeutic and Undesirable Drug Effects by Receptor Site
  1179. Indications
  1180. Contraindications
  1181. Adverse Effects
  1182. Table 15-7 Tricyclic Antidepressants: Adverse Effects
  1183. Toxicity and Management of Overdose
  1184. Interactions
  1185. Dosages
  1186. DOSAGES
  1187. Selected Tricyclic Antidepressants
  1188. Box 15-3 Cyclic Antidepressant Categories
  1189. Tertiary Amine TCAs
  1190. Secondary Amine TCAs
  1191. Tetracyclic Antidepressants
  1192. Drug Profiles
  1193. ▸ amitriptyline
  1194. Pharmacokinetics
  1195. MONOAMINE OXIDASE INHIBITORS
  1196. HERBAL THERAPIES AND DIETARY SUPPLEMENTS
  1197. St. John’s Wort (Hypericum perforatum)
  1198. Overview
  1199. Common Uses
  1200. Adverse Effects
  1201. Potential Drug Interactions
  1202. Contraindications
  1203. Table 15-8 MAOIs: Adverse Effects
  1204. Toxicity and Management of Overdose
  1205. Table 15-9 Food and Drink to Avoid When Taking MAOIs
  1206. DOSAGES
  1207. Selected MAOIs
  1208. Interactions
  1209. Dosages
  1210. ANTIPSYCHOTIC DRUGS
  1211. Mechanism of Action and Drug Effects
  1212. Table 15-10 Major Dopamine Systems in the Brain
  1213. Indications
  1214. Contraindications
  1215. Adverse Effects
  1216. Table 15-11 Antipsychotics: Receptor-Related Adverse Effects
  1217. Table 15-12 Antipsychotics: Adverse Effects
  1218. Interactions
  1219. Dosages
  1220. Drug Profiles
  1221. Phenothiazines
  1222. fluphenazine
  1223. DOSAGES
  1224. Selected First-Generation Antipsychotic Drugs
  1225. Table 15-13 Compatibility of Selected Liquid Antipsychotic Dosage Forms with Beverages for Dosing Purposes*
  1226. Pharmacokinetics
  1227. Butyrophenones
  1228. haloperidol
  1229. Pharmacokinetics
  1230. Atypical Antipsychotics
  1231. DOSAGES
  1232. Selected Atypical Antipsychotic Drugs
  1233. clozapine
  1234. Pharmacokinetics
  1235. ▸ risperidone
  1236. Pharmacokinetics
  1237. ▸ olanzapine
  1238. Pharmacokinetics
  1239. quetiapine
  1240. Pharmacokinetics
  1241. ziprasidone
  1242. Pharmacokinetics
  1243. Antipsychotic Drugs Summary
  1244. ♦ NURSING PROCESS
  1245. ♦ ASSESSMENT
  1246. Antianxiety Drugs
  1247. Lifespan Considerations: The Pediatric Patient
  1248. Psychotherapeutic Drugs
  1249. Lifespan Considerations: The Elderly Patient
  1250. Psychotherapeutic Drugs
  1251. Antimanic Drugs
  1252. Antidepressants
  1253. HERBAL THERAPIES AND DIETARY SUPPLEMENTS
  1254. Ginseng
  1255. Overview
  1256. Common Uses
  1257. Adverse Effects
  1258. Potential Drug Interactions
  1259. Contraindications
  1260. Antipsychotics
  1261. ♦ NURSING DIAGNOSES
  1262. ♦ PLANNING
  1263. Goals
  1264. Outcome Criteria
  1265. ♦ IMPLEMENTATION
  1266. Antianxiety Drugs
  1267. Antimanic Drugs
  1268. Antidepressants
  1269. Antipsychotics
  1270. ♦ EVALUATION
  1271. Patient Teaching Tips
  1272. Antianxiety Drugs
  1273. Antimanic Drugs
  1274. Antidepressant Drugs
  1275. MAOIs and TCAs
  1276. Haloperidol
  1277. Points to Remember
  1278. NCLEX Examination Review Questions
  1279. Critical Thinking Activities
  1280. CHAPTER 16 Central Nervous System Stimulants and Related Drugs
  1281. Objectives
  1282. e-Learning Activities
  1283. Companion CD
  1284. evolve Website (http://evolve.elsevier.com/Lilley)
  1285. Drug Profiles
  1286. Glossary
  1287. CENTRAL NERVOUS SYSTEM STIMULANTS
  1288. Table 16-1 Structurally Related CNS Stimulants
  1289. Table 16-2 CNS Stimulants: Site of Action
  1290. Table 16-3 CNS Stimulants and Related Drugs: Therapeutic Categories
  1291. OVERVIEW OF PATHOPHYSIOLOGY
  1292. ATTENTION DEFICIT HYPERACTIVITY DISORDER
  1293. NARCOLEPSY
  1294. DRUGS FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER AND NARCOLEPSY
  1295. Mechanism of Action and Drug Effects
  1296. Indications
  1297. Contraindications
  1298. Adverse Effects
  1299. Interactions
  1300. Drug Profiles
  1301. Amphetamines and Related Stimulants
  1302. ▸ amphetamines
  1303. Table 16-4 CNS Stimulants: Common Drug Interactions
  1304. Pharmacokinetics (dextroamphetamine)
  1305. ▸ methylphenidate
  1306. Pharmacokinetics (Immediate Release)
  1307. atomoxetine
  1308. Pharmacokinetics
  1309. modafinil
  1310. Pharmacokinetics
  1311. Miscellaneous Narcolepsy Drugs
  1312. sodium oxybate
  1313. Pharmacokinetics
  1314. OBESITY
  1315. DOSAGES
  1316. Selected CNS Stimulants and Related Drugs
  1317. LEGAL AND ETHICAL PRINCIPLES
  1318. Handling of Prescription Drugs
  1319. ANOREXIANTS
  1320. Mechanism of Action and Drug Effects
  1321. EVIDENCE-BASED PRACTICE
  1322. An Applied Evidence-Based Review of the Diagnosis and Treatment of Obesity in Adults
  1323. Review
  1324. Type of Evidence
  1325. Results of Study
  1326. Link of Evidence to Nursing Practice
  1327. Indications
  1328. Contraindications
  1329. Adverse Effects
  1330. Interactions
  1331. Drug Profiles
  1332. Anorexiants
  1333. ▸ phentermine
  1334. ▸ sibutramine
  1335. Pharmacokinetics
  1336. orlistat
  1337. Pharmacokinetics
  1338. MIGRAINE
  1339. ANTIMIGRAINE DRUGS (SEROTONIN AGONISTS)
  1340. Mechanism of Action and Drug Effects
  1341. Indications
  1342. Contraindications
  1343. Adverse Effects
  1344. Interactions
  1345. Drug Profiles
  1346. Serotonin Agonists
  1347. ▸ sumatriptan
  1348. Pharmacokinetics
  1349. ANALEPTIC-RESPONSIVE RESPIRATORY DEPRESSION SYNDROMES
  1350. ANALEPTICS
  1351. Mechanism of Action and Drug Effects
  1352. Indications
  1353. Contraindications
  1354. Adverse Effects
  1355. Interactions
  1356. Drug Profiles
  1357. ▸ caffeine
  1358. Pharmacokinetics
  1359. doxapram
  1360. Table 16-5 Caffeine-Containing Beverages and Drugs
  1361. Pharmacokinetics
  1362. ♦ NURSING PROCESS
  1363. ♦ ASSESSMENT
  1364. HERBAL THERAPIES AND DIETARY SUPPLEMENTS
  1365. Selected Herbal Compounds Used for Nervous System Stimulation*
  1366. ♦ NURSING DIAGNOSES
  1367. ♦ PLANNING
  1368. Goals
  1369. Outcome Criteria
  1370. ♦ IMPLEMENTATION
  1371. ♦ EVALUATION
  1372. Patient Teaching Tips
  1373. CNS Stimulants in General
  1374. Anorexiants
  1375. Drugs Used to Treat ADHD
  1376. Antimigraine Drugs
  1377. Points to Remember
  1378. NCLEX Examination Review Questions
  1379. Critical Thinking Activities
  1380. PART 3 Drugs Affecting the Autonomic Nervous System
  1381. Drugs Affecting the Autonomic Nervous System
  1382. STUDY SKILLS TIPS
  1383. PURR APPLICATION
  1384. Planning for the Part
  1385. Part Title
  1386. Part Chapters
  1387. Chapters 19 and 20
  1388. Active Questioning
  1389. Study Groups
  1390. CHAPTER 17 Adrenergic Drugs
  1391. Objectives
  1392. e-Learning Activities
  1393. Companion CD
  1394. evolve Website (http://evolve.elsevier.com/Lilley)
  1395. Drug Profiles
  1396. Glossary
  1397. SYMPATHETIC NERVOUS SYSTEM
  1398. FIGURE 17-1 The sympathetic nervous system in relation to the entire nervous system. ACh, Acetylcholine; NE, norepinephrine.
  1399. Table 17-1 Adrenergic Receptor Responses to Stimulation
  1400. FIGURE 17-2 The mechanism by which stimulation of a nerve fiber results in a physiologic process; adrenergic drugs mimic this same process. COMT, Catechol ortho-methyltransferase; MAO, monoamine oxidase; NE, norepinephrine.
  1401. ADRENERGIC DRUGS
  1402. FIGURE 17-3 Mechanism of physiologic response to direct-acting sympathomimetics. D, Drug; NE, norepinephrine.
  1403. Table 17-2 Catecholamines and Their Dose-Response Relationship
  1404. FIGURE 17-4 Mechanism of physiologic response to indirect-acting sympathomimetics. D, Drug; NE, norepinephrine.
  1405. FIGURE 17-5 Mechanism of physiologic response to mixed-acting sympathomimetics. D, Drug; NE, norepinephrine.
  1406. Mechanism of Action and Drug Effects
  1407. Indications
  1408. Respiratory Indications
  1409. Indications for Topical Nasal Decongestants
  1410. Ophthalmic Indications
  1411. Cardiovascular Indications
  1412. Epinephrine for Cardiac Arrest
  1413. Contraindications
  1414. Adverse Effects
  1415. Life Span Considerations: The Elderly Patient
  1416. Use of β-Adrenergic Agonists
  1417. Toxicity and Management of Overdose
  1418. Interactions
  1419. Laboratory Test Interactions
  1420. Dosages
  1421. Drug Profiles
  1422. Bronchodilators
  1423. DOSAGES
  1424. Selected Bronchodilators
  1425. ▸ albuterol sulfate
  1426. Pharmacokinetics
  1427. ▸ epinephrine
  1428. Pharmacokinetics
  1429. ▸ salmeterol
  1430. Pharmacokinetics
  1431. Nasal Decongestants
  1432. ▸ pseudoephedrine
  1433. Pharmacokinetics
  1434. Ophthalmic Decongestants
  1435. tetrahydrozoline
  1436. DOSAGES
  1437. Selected Nasal and Ophthalmic Decongestant Adrenergics
  1438. Pharmacokinetics
  1439. Vasoactive Adrenergics
  1440. ▸ dobutamine
  1441. Pharmacokinetics
  1442. ▸ dopamine
  1443. Pharmacokinetics
  1444. DOSAGES
  1445. Selected Vasoactive Adrenergics
  1446. ▸ epinephrine
  1447. Pharmacokinetics
  1448. fenoldopam
  1449. Pharmacokinetics
  1450. midodrine
  1451. Pharmacokinetics
  1452. ▸ norepinephrine
  1453. Pharmacokinetics
  1454. phenylephrine
  1455. Pharmacokinetics
  1456. ♦ NURSING PROCESS
  1457. ♦ ASSESSMENT
  1458. ♦ NURSING DIAGNOSES
  1459. ♦ PLANNING
  1460. Goals
  1461. Outcome Criteria
  1462. ♦ IMPLEMENTATION
  1463. LEGAL AND ETHICAL PRINCIPLES
  1464. Infiltrating Intravenous (IV) Infusions
  1465. Situation
  1466. ♦ EVALUATION
  1467. Patient Teaching Tips
  1468. Points to Remember
  1469. NCLEX Examination Review Questions
  1470. Critical Thinking Activities
  1471. CHAPTER 18 Adrenergic-Blocking Drugs
  1472. Objectives
  1473. e-Learning Activities
  1474. Companion CD
  1475. evolve Website (http://evolve.elsevier.com/Lilley)
  1476. Drug Profiles
  1477. Glossary
  1478. α-BLOCKERS
  1479. Mechanism of Action and Drug Effects
  1480. Indications
  1481. FIGURE 18-1 Mechanisms for αadrenergic competitive and noncompetitive blockade by α-blockers. A, α-blocker; NE, norepinephrine.
  1482. CASE STUDY
  1483. Alternative Therapies for Migraine Headaches
  1484. Contraindications
  1485. Adverse Effects
  1486. Toxicity and Management of Overdose
  1487. Table 18-1 α-Blockers: Adverse Effects
  1488. Table 18-2 α-Blockers: Common Drug Interactions
  1489. Interactions
  1490. Dosages
  1491. Drug Profiles
  1492. ergotamine tartrate
  1493. Pharmacokinetics
  1494. phenoxybenzamine hydrochloride
  1495. Pharmacokinetics
  1496. ▸ phentolamine
  1497. Pharmacokinetics
  1498. DOSAGES
  1499. Selected α-Adrenergic-Blocking Drugs
  1500. ▸ prazosin
  1501. Pharmacokinetics
  1502. tolazoline
  1503. Pharmacokinetics
  1504. β-BLOCKERS
  1505. Mechanism of Action and Drug Effects
  1506. Box 18-1 Currently Available β-blockers
  1507. Nonselective β-blockers
  1508. Cardioselective β-blockers
  1509. Indications
  1510. Contraindications
  1511. Adverse Effects
  1512. Toxicity and Management of Overdose
  1513. Interactions
  1514. Table 18-3 β-Blockers: Common Adverse Effects
  1515. Table 18-4 β-Blockers: Drug Interactions
  1516. Dosages
  1517. Drug Profiles
  1518. acebutolol
  1519. Pharmacokinetics
  1520. ▸ atenolol
  1521. Pharmacokinetics
  1522. carvedilol
  1523. DOSAGES
  1524. Selected β-Adrenergic-Blocking Drugs
  1525. Pharmacokinetics
  1526. ▸ esmolol
  1527. Pharmacokinetics
  1528. labetalol
  1529. Pharmacokinetics
  1530. ▸ metoprolol
  1531. Pharmacokinetics
  1532. propranolol
  1533. Pharmacokinetics
  1534. sotalol
  1535. Pharmacokinetics
  1536. PREVENTING MEDICATION ERRORS
  1537. Look-Alike Drugs: Toprol-XL, Topamax, and Tegretol
  1538. ♦ NURSING PROCESS
  1539. ♦ ASSESSMENT
  1540. ♦ NURSING DIAGNOSES
  1541. ♦ PLANNING
  1542. Goals
  1543. Outcome Criteria
  1544. EVIDENCE-BASED PRACTICE
  1545. β-blockers
  1546. Review
  1547. Type of Evidence
  1548. Results of Study
  1549. Link of Evidence to Nursing Practice
  1550. ♦ IMPLEMENTATION
  1551. ♦ EVALUATION
  1552. Patient Teaching Tips
  1553. Points to Remember
  1554. NCLEX Examination Review Questions
  1555. Critical Thinking Activities
  1556. CHAPTER 19 Cholinergic Drugs
  1557. Objectives
  1558. e-Learning Activities
  1559. Companion CD
  1560. evolve Website (http://evolve.elsevier.com/Lilley)
  1561. Drug Profiles
  1562. Glossary
  1563. PARASYMPATHETIC NERVOUS SYSTEM
  1564. FIGURE 19-1 The parasympathetic and sympathetic nervous systems and their relationship to one another. ACh, Acetylcholine; NE, norepinephrine.
  1565. FIGURE 19-2 The sympathetic, parasympathetic, and somatic nervous systems. Note the location of the nicotinic and muscarinic receptors in the parasympathetic nervous system.
  1566. CHOLINERGIC DRUGS
  1567. Mechanism of Action and Drug Effects
  1568. Box 19-1 Cholinergic Drugs
  1569. Direct-Acting Drugs
  1570. Indirect-Acting Drugs
  1571. Indications
  1572. Table 19-1 Cholinergic Agonists: Drug Effects
  1573. Contraindications
  1574. Adverse Effects
  1575. Table 19-2 Cholinergic Drugs: Adverse Effects
  1576. Interactions
  1577. Toxicity and Management of Overdose
  1578. Dosages
  1579. Drug Profiles
  1580. ▸ bethanechol
  1581. EVIDENCE-BASED PRACTICE
  1582. Alzheimer’s Disease and Razadyne ER
  1583. Review
  1584. Type of Evidence
  1585. Results of Study
  1586. Link of Evidence to Nursing Practice
  1587. Pharmacokinetics
  1588. cevimeline
  1589. Pharmacokinetics
  1590. ▸ physostigmine
  1591. Pharmacokinetics
  1592. ▸ pyridostigmine
  1593. DOSAGES
  1594. Selected Cholinergic Agonist Drugs
  1595. Pharmacokinetics
  1596. Cholinergic Agonists Used Specifically for Alzheimer’s Disease
  1597. ▸ donepezil
  1598. Pharmacokinetics
  1599. galantamine
  1600. Pharmacokinetics
  1601. rivastigmine
  1602. Pharmacokinetics
  1603. Miscellaneous Alzheimer’s Disease Medications
  1604. memantine
  1605. ♦ NURSING PROCESS
  1606. ♦ ASSESSMENT
  1607. HERBAL THERAPIES AND DIETARY SUPPLEMENTS
  1608. Ginkgo (Ginkgo biloba)
  1609. Overview
  1610. Common Uses
  1611. Adverse Effects
  1612. Potential Drug Interactions
  1613. Contraindications
  1614. ♦ NURSING DIAGNOSES
  1615. ♦ PLANNING
  1616. Goals
  1617. Outcome Criteria
  1618. ♦ IMPLEMENTATION
  1619. ♦ EVALUATION
  1620. Patient Teaching Tips
  1621. Points to Remember
  1622. NCLEX Examination Review Questions
  1623. Critical Thinking Activities
  1624. CHAPTER 20 Cholinergic-Blocking Drugs
  1625. Objectives
  1626. e-Learning Activities
  1627. Companion CD
  1628. evolve Website (http://evolve.elsevier.com/Lilley)
  1629. Drug Profiles
  1630. Glossary
  1631. CHOLINERGIC-BLOCKING DRUGS
  1632. Mechanism of Action and Drug Effects
  1633. FIGURE 20-1 Site of action of cholinergic blockers in the parasympathetic nervous system. ACh, Acetylcholine.
  1634. Box 20-1 Cholinergic Blockers Grouped According to Chemical Class
  1635. Natural Drugs
  1636. Synthetic and Semisynthetic Drugs
  1637. Indications
  1638. Table 20-1 Cholinergic Blockers: Drug Effects
  1639. Contraindications
  1640. Adverse Effects
  1641. Interactions
  1642. Table 20-2 Cholinergic Blockers: Adverse Effects
  1643. Toxicity and Management of Overdose
  1644. Dosages
  1645. Drug Profiles
  1646. DOSAGES
  1647. Selected Cholinergic Antagonist (Anticholinergic) Drugs
  1648. ▸ atropine
  1649. Atropine for Sinus Bradycardia
  1650. Pharmacokinetics
  1651. ▸ benztropine mesylate
  1652. ▸ dicyclomine
  1653. Pharmacokinetics
  1654. glycopyrrolate
  1655. Pharmacokinetics
  1656. scopolamine
  1657. Pharmacokinetics
  1658. ▸ tolterodine
  1659. Pharmacokinetics
  1660. ♦ NURSING PROCESS
  1661. ♦ ASSESSMENT
  1662. ♦ NURSING DIAGNOSES
  1663. ♦ PLANNING
  1664. Goals
  1665. Outcome Criteria
  1666. ♦ IMPLEMENTATION
  1667. Life Span Considerations: The Elderly Patient
  1668. Overactive Bladder
  1669. EVALUATION
  1670. Patient Teaching Tips
  1671. Points to Remember
  1672. NCLEX Examination Review Questions
  1673. Critical Thinking Activities
  1674. PART 4 Drugs Affecting the Cardiovascular and Renal Systems
  1675. Drugs Affecting the Cardiovascular and Renal Systems
  1676. STUDY SKILLS TIPS
  1677. LINKING LEARNING
  1678. Chapter Structure
  1679. Chapter Objectives
  1680. Example Based on Chapter 21 Objectives
  1681. Chapter Headings
  1682. Glossary
  1683. Glossary and Text Relationship
  1684. TEXT NOTATION
  1685. Text Notation Application
  1686. Chapter 26, Paragraphs One and Two
  1687. Discussion
  1688. Chapter 26, Paragraph Three
  1689. Discussion
  1690. CHAPTER 21 Positive Inotropic Drugs
  1691. Objectives
  1692. e-Learning Activities
  1693. Companion CD
  1694. evolve Website (http://evolve.elsevier.com/Lilley)
  1695. Drug Profiles
  1696. Glossary
  1697. HEART FAILURE AND CARDIAC DYSRHYTHMIAS
  1698. Box 21-1 Myocardial Deficiency and Increased Workload: Common Causes
  1699. Myocardial Deficiency
  1700. Inadequate Contractility
  1701. Inadequate Filling
  1702. Increased Workload
  1703. Pressure Overload
  1704. Volume Overload
  1705. FIGURE 21-1 Conduction system of the heart. AV, Atrioventricular; LA, left atrium; LV, left ventricle; RA, right atrium; RV, right ventricle; SA, sinoatrial. (Modified from Kinney M et al: Comprehensive cardiac care, ed 8, St Louis, 1996, Mosby; Lewis SM, Heitkemper MM, Dirksen SR: Medical-surgical nursing: assessment and management of clinical problems, ed 6, St Louis, 2004, Mosby.)
  1706. CARDIAC GLYCOSIDES
  1707. Mechanism of Action and Drug Effects
  1708. Indications
  1709. Contraindications
  1710. Adverse Effects
  1711. Toxicity and Management of Overdose
  1712. Table 21-1 Cardiac Glycosides: Common Adverse Effects
  1713. Table 21-2 Digoxin Toxicity: Step-by-Step Management
  1714. Life Span Considerations: The Pediatric Patient
  1715. Heart Failure and Cardiac Glycosides
  1716. Interactions
  1717. PREVENTING MEDICATION ERRORS
  1718. The Importance of Decimal Points
  1719. Dosages
  1720. Drug Profiles
  1721. ▸ digoxin
  1722. Pharmacokinetics
  1723. Table 21-3 Cardiac Glycosides: Drug Interactions
  1724. DOSAGES
  1725. Selected Cholinergic Antagonist (Anticholinergic) Drugs
  1726. digoxin immune Fab
  1727. Pharmacokinetics
  1728. PHOSPHODIESTERASE INHIBITORS
  1729. Mechanism of Action and Drug Effects
  1730. Indications
  1731. Contraindications
  1732. Adverse Effects
  1733. Toxicity and Management of Overdose
  1734. Interactions
  1735. Dosages
  1736. Drug Profiles
  1737. milrinone
  1738. Pharmacokinetics
  1739. MISCELLANEOUS HEART FAILURE DRUGS
  1740. ♦ NURSING PROCESS
  1741. ♦ ASSESSMENT
  1742. Table 21-4 Conditions Predisposing to Digitalis Toxicity
  1743. ♦ NURSING DIAGNOSES
  1744. ♦ PLANNING
  1745. Goals
  1746. Outcome Criteria
  1747. ♦ IMPLEMENTATION
  1748. ♦ EVALUATION
  1749. Patient Teaching Tips
  1750. Points to Remember
  1751. NCLEX Examination Review Questions
  1752. Critical Thinking Activities
  1753. CHAPTER 22 Antidysrhythmic Drugs
  1754. Objectives
  1755. e-Learning Activities
  1756. Companion CD
  1757. evolve Website (http://evolve.elsevier.com/Lilley)
  1758. Drug Profiles
  1759. Glossary
  1760. DYSRHYTHMIAS AND NORMAL CARDIAC ELECTROPHYSIOLOGY
  1761. Normal Electrophysiology
  1762. FIGURE 22-1 Resting membrane potential of a cardiac cell. ATPase, Adenosine triphosphatase.
  1763. FIGURE 22-2 Action potentials. RMP, Resting membrane potential; SA, sinoatrial; TP, threshold potential.
  1764. FIGURE 22-3 Purkinje fiber action potential.
  1765. FIGURE 22-4 Aspects of an action potential. APD, Action potential duration; ERP, effective refractory period; RRP, relative refractory period.
  1766. Table 22-1 Comparison of Action Potentials in Different Cardiac Tissue
  1767. Electrocardiography
  1768. FIGURE 22-5 The waves and intervals of a normal electrocardiogram. (From Goldberger AL: Clinical electrocardiography: a simplified approach, ed 6, St Louis, 1999, Mosby.)
  1769. Common Dysrhythmias
  1770. Table 22-2 Common Dysrhythmias
  1771. Table 22-3 Vaughan Williams Classification of Antidysrhythmic Drugs
  1772. ANTIDYSRHYTHMIC DRUGS
  1773. Mechanism of Action and Drug Effects
  1774. Table 22-4 Antidysrhythmic Drugs: Mechanisms of Action
  1775. Box 22-1 Effects of Antidysrhythmic Drugs
  1776. Class I (moricizine)
  1777. Class Ia (disopyramide, procainamide, quinidine)
  1778. Class Ib (lidocaine, mexiletine, phenytoin)
  1779. Class Ic (flecainide, propafenone)
  1780. Class II (β-blockers [e.g., atenolol, esmolol, metoprolol])
  1781. Class III (amiodarone, sotalol*, ibutilide, dofetilide)
  1782. Class IV (diltiazem, verapamil)
  1783. Indications
  1784. Contraindications
  1785. Adverse Effects
  1786. Toxicity and Management of Overdose
  1787. Interactions
  1788. Table 22-5 Antidysrhythmic Drugs: Indication
  1789. Drug Profiles
  1790. Class Ia Drugs
  1791. Table 22-6 Common Adverse Effects of Various Antidysrhythmic Drugs
  1792. procainamide
  1793. Table 22-7 Common Electrocardiographic Effects of Various Antidysrhythmic Drugs
  1794. Table 22-8 Selected Antidysrhythmic Drugs: Management of Overdose
  1795. Pharmacokinetics
  1796. quinidine
  1797. Table 22-9 Common Drug Interactions for Selected Antidysrhythmic Drugs
  1798. Pharmacokinetics
  1799. Class Ib Drugs
  1800. ▸ lidocaine
  1801. DOSAGES
  1802. Selected Antiepileptic Drugs
  1803. Pharmacokinetics
  1804. mexiletine
  1805. Pharmacokinetics
  1806. Class Ic Drugs
  1807. flecainide
  1808. Pharmacokinetics
  1809. propafenone
  1810. Pharmacokinetics
  1811. Class II Drugs
  1812. ▸ atenolol
  1813. Pharmacokinetics
  1814. esmolol
  1815. Pharmacokinetics
  1816. ▸ metoprolol
  1817. Pharmacokinetics
  1818. ▸ propranolol
  1819. Pharmacokinetics
  1820. ▸ sotalol
  1821. Pharmacokinetics
  1822. Class III Drugs
  1823. Amiodarone for Ventricular Tachycardia
  1824. Amiodarone for Ventricular Fibrillation
  1825. ▸ amiodarone
  1826. Table 22-10 Recommendations for Oral Dosage after IV Infusion of Amiodarone
  1827. Pharmacokinetics
  1828. ibutilide
  1829. Pharmacokinetics
  1830. Class IV Drugs
  1831. ▸ diltiazem
  1832. Cardiac Effects of Diltiazem Injection
  1833. Pharmacokinetics
  1834. ▸ verapamil
  1835. Pharmacokinetics
  1836. Unclassified Antidysrhythmics
  1837. adenosine
  1838. Cardiac Effects of Adenosine
  1839. Pharmacokinetics
  1840. PHARMACOKINETIC BRIDGE to Nursing Practice
  1841. ♦ NURSING PROCESS
  1842. ♦ ASSESSMENT
  1843. ♦ NURSING DIAGNOSES
  1844. ♦ PLANNING
  1845. Goals
  1846. EVIDENCE-BASED PRACTICE
  1847. Antidysrhythmics and the Elderly Patient
  1848. Review
  1849. Type of Evidence
  1850. Results of Study
  1851. Link of Evidence to Nursing Practice
  1852. Outcome Criteria
  1853. ♦ IMPLEMENTATION
  1854. ♦ EVALUATION
  1855. Patient Teaching Tips
  1856. Points to Remember
  1857. NCLEX Examination Review Questions
  1858. Critical Thinking Activities
  1859. CHAPTER 23 Antianginal Drugs
  1860. Objectives
  1861. e-Learning Activities
  1862. Companion CD
  1863. evolve Website (http://evolve.elsevier.com/Lilley)
  1864. Drug Profiles
  1865. Glossary
  1866. ANGINA AND CORONARY ARTERY DISEASE
  1867. Acute Myocardial Infarction
  1868. Table 23-1 Antianginal Drugs: Therapeutic Effects
  1869. ANTIANGINAL DRUGS
  1870. FIGURE 23-1 Benefit of drug therapy for angina through increasing oxygen supply and decreasing oxygen demands.
  1871. NITRATES AND NITRITES
  1872. Mechanism of Action and Drug Effects
  1873. Indications
  1874. Contraindications
  1875. Adverse Effects
  1876. Interactions
  1877. Dosages
  1878. Drug Profiles
  1879. ▸ isosorbide dinitrate
  1880. Pharmacokinetics
  1881. ▸ isosorbide mononitrate
  1882. Pharmacokinetics
  1883. ▸ nitroglycerin
  1884. DOSAGES
  1885. Selected Antianginal Nitrate Coronary Vasodilators
  1886. PREVENTING MEDICATION ERRORS
  1887. Rate vs. Dose
  1888. Pharmacokinetics
  1889. β-BLOCKERS
  1890. Mechanism of Action and Drug Effects
  1891. Indications
  1892. Contraindications
  1893. Table 23-2 β-Blockers: Adverse Effects
  1894. Table 23-3 β-Blockers: Common Drug Interactions
  1895. Adverse Effects
  1896. Interactions
  1897. Dosages
  1898. Drug Profiles
  1899. DOSAGES
  1900. Selected β-Adrenergic-Blocking Drugs
  1901. ▸ atenolol
  1902. Pharmacokinetics
  1903. ▸ metoprolol
  1904. Pharmacokinetics
  1905. CALCIUM CHANNEL BLOCKERS
  1906. Table 23-4 Classification of Calcium Channel Blockers
  1907. Mechanism of Action and Drug Effects
  1908. Indications
  1909. Contraindications
  1910. Adverse Effects
  1911. Interactions
  1912. Dosages
  1913. Table 23-5 Calcium Channel Blockers: Adverse Effects
  1914. Table 23-6 Calcium Channel Blockers: Common Drug Interactions
  1915. Drug Profiles
  1916. ▸ diltiazem
  1917. Pharmacokinetics
  1918. amlodipine
  1919. Pharmacokinetics
  1920. MISCELLANEOUS ANTIANGINAL DRUGS
  1921. Drug Profiles
  1922. ranolazine
  1923. DOSAGES
  1924. Selected Calcium Channel-Blocking Drugs
  1925. SUMMARY OF ANTIANGINAL PHARMACOLOGY
  1926. PHARMACOKINETIC BRIDGE To Nursing Practice
  1927. ♦ NURSING PROCESS
  1928. ♦ ASSESSMENT
  1929. ♦ NURSING DIAGNOSES
  1930. ♦ PLANNING
  1931. Goals
  1932. Outcome Criteria
  1933. ♦ IMPLEMENTATION
  1934. ♦ EVALUATION
  1935. Patient Teaching Tips
  1936. Nitroglycerin
  1937. Isosorbide Dinitrate or Isosorbide Mononitrate
  1938. Points to Remember
  1939. NCLEX Examination Review Questions
  1940. Critical Thinking Activities
  1941. CHAPTER 24 Antihypertensive Drugs
  1942. Objectives
  1943. e-Learning Activities
  1944. Companion CD
  1945. evolve Website (http://evolve.elsevier.com/Lilley)
  1946. Drug Profiles
  1947. Glossary
  1948. Box 24-1 New Hypertension Guidelines—The Seventh Report
  1949. HYPERTENSION
  1950. Evidence-Based Practice
  1951. Effects of Exercise on Blood Pressure in Those 55 Years of Age and Older
  1952. Review
  1953. Type of Evidence
  1954. Results of Study
  1955. Link of Evidence to Nursing Practice
  1956. Table 24-1 Classification and Management of Blood Pressure
  1957. FIGURE 24-1 Normal regulation of blood pressure and corresponding medications. ACE, Angiotensin-converting enzyme; CNS, central nervous system.
  1958. ANTIHYPERTENSIVE DRUGS
  1959. Box 24-2 Categories and Subcategories of Antihypertensive Drugs
  1960. Adrenergic Drugs
  1961. Angiotensin-Converting Enzyme Inhibitors
  1962. Angiotensin II Receptor Blockers
  1963. Calcium Channel Blockers
  1964. Diuretics
  1965. Vasodilators
  1966. FIGURE 24-2 Location of the nicotinic receptors in the parasympathetic and sympathetic nervous systems. ACh, Acetylcholine; NE, norepinephrine.
  1967. REVIEW OF AUTONOMIC NEUROTRANSMISSION
  1968. CULTURAL IMPLICATIONS
  1969. Antihypertensive Drug Therapy
  1970. ADRENERGIC DRUGS
  1971. Mechanism of Action and Drug Effects
  1972. Renin-Angiotensin in Control of Blood Pressure
  1973. FIGURE 24-3 Site and mechanism of action of the various antihypertensive drugs. (From U.S. Department of Health and Human Services: The seventh report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7), Washington, DC, 2003, National Institutes of Health. In Lewis SM, Heitkemper MM, Dirksen SR: Medical-surgical nursing: assessment and management of clinical problems, ed 6, St Louis, 2003, Mosby.)
  1974. Indications
  1975. Contraindications
  1976. Adverse Effects
  1977. Table 24-2 Adrenergic Drugs: Drug Interactions
  1978. Interactions
  1979. Dosages
  1980. Drug Profiles
  1981. α2-Adrenergic Receptor Stimulators (Agonists)
  1982. ▸ clonidine
  1983. DOSAGES
  1984. Selected Antihypertensive Drugs: Adrenergic Agonist and Antagonists
  1985. Pharmacokinetics
  1986. α1-Blockers
  1987. prazosin
  1988. Pharmacokinetics
  1989. Dual-Action α1 and β Receptor Blockers
  1990. carvedilol
  1991. Pharmacokinetics
  1992. ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
  1993. Table 24-3 ACE Inhibitors: Distinguishing Characteristics
  1994. Mechanism of Action and Drug Effects
  1995. Indications
  1996. Contraindications
  1997. Table 24-4 ACE Inhibitors: Therapeutic Effects
  1998. DOSAGES
  1999. Selected Antihypertensive Drugs: ACE Inhibitors and Angiotensin II Receptor Blockers
  2000. Adverse Effects
  2001. Toxicity and Management of Overdose
  2002. Interactions
  2003. Dosages
  2004. Drug Profiles
  2005. ▸ captopril
  2006. Pharmacokinetics
  2007. enalapril
  2008. Pharmacokinetics
  2009. ANGIOTENSIN II RECEPTOR BLOCKERS
  2010. Mechanism of Action and Drug Effects
  2011. Indications
  2012. Contraindications
  2013. Adverse Effects
  2014. Toxicity and Management of Overdose
  2015. Interactions
  2016. Table 24-5 Angiotensin II Receptor Blockers (ARBs): Drug Interactions
  2017. Dosages
  2018. Drug Profile
  2019. ▸ losartan
  2020. Pharmacokinetics
  2021. CALCIUM CHANNEL BLOCKERS
  2022. DIURETICS
  2023. VASODILATORS
  2024. Mechanism of Action and Drug Effects
  2025. Indications
  2026. Contraindications
  2027. Adverse Effects
  2028. Toxicity and Management of Overdose
  2029. Interactions
  2030. Dosages
  2031. Table 24-6 Direct-Acting Vasodilators: Drug Interactions
  2032. Drug Profiles
  2033. ▸ hydralazine hydrochloride
  2034. Pharmacokinetics
  2035. DOSAGES
  2036. Selected Antihypertensive Drugs: Vasodilators
  2037. sodium nitroprusside
  2038. Pharmacokinetics
  2039. MISCELLANEOUS ANTIHYPERTENSIVE DRUGS
  2040. Drug Profiles
  2041. eplerenone
  2042. bosentan
  2043. treprostinil
  2044. DOSAGES
  2045. Miscellaneous Antihypertensive Drugs
  2046. LABORATORY VALUES RELATED TO DRUG THERAPY
  2047. Sodium Nitroprusside
  2048. ♦ NURSING PROCESS
  2049. ♦ ASSESSMENT
  2050. ♦ NURSING DIAGNOSES
  2051. ♦ PLANNING
  2052. Goals
  2053. Outcome Criteria
  2054. CASE STUDY
  2055. Hypertension
  2056. ♦ IMPLEMENTATION
  2057. ♦ EVALUATION
  2058. Patient Teaching Tips
  2059. Antihypertensives in General
  2060. α-Adrenergic Agonists
  2061. β-Blockers
  2062. Points to Remember
  2063. NCLEX Examination Review Questions
  2064. Critical Thinking Activities
  2065. CHAPTER 25 Diuretic Drugs
  2066. Objectives
  2067. e-Learning Activities
  2068. Companion CD
  2069. evolve Website (http://evolve.elsevier.com/Lilley)
  2070. Drug Profiles
  2071. Glossary
  2072. OVERVIEW OF RENAL PHYSIOLOGY
  2073. DIURETIC DRUGS
  2074. FIGURE 25-1 The nephron and diuretic sites of action. ADH, Antidiuretic hormone.
  2075. Table 25-1 Classification of Diuretics
  2076. CARBONIC ANHYDRASE INHIBITORS
  2077. Mechanism of Action and Drug Effects
  2078. Indications
  2079. Contraindications
  2080. Adverse Effects
  2081. Interactions
  2082. Dosages
  2083. Drug Profiles
  2084. acetazolamide
  2085. Pharmacokinetics
  2086. LOOP DIURETICS
  2087. Mechanism of Action and Drug Effects
  2088. Summary of Major Drug Effects of Loop Diuretics
  2089. Indications
  2090. Contraindications
  2091. Table 25-2 Loop Diuretics: Common Adverse Effects
  2092. Table 25-3 Loop Diuretics: Common Drug Interactions
  2093. Adverse Effects
  2094. Toxicity and Management of Overdose
  2095. Interactions
  2096. Dosages
  2097. Drug Profiles
  2098. Pharmacokinetics
  2099. ▸ furosemide
  2100. DOSAGES
  2101. Selected Loop Diuretics and Osmotic Diuretics
  2102. Pharmacokinetics
  2103. OSMOTIC DIURETICS
  2104. Mechanism of Action and Drug Effects
  2105. Indications
  2106. Contraindications
  2107. Adverse Effects
  2108. Interactions
  2109. Dosages
  2110. Drug Profiles
  2111. ▸ mannitol
  2112. Pharmacokinetics
  2113. POTASSIUM-SPARING DIURETICS
  2114. Mechanism of Action and Drug Effects
  2115. Life Span Considerations: The Pediatric Patient
  2116. Diuretics
  2117. Indications
  2118. Contraindications
  2119. Adverse Effects
  2120. Interactions
  2121. Table 25-4 Potassium-Sparing Diuretics: Common Adverse Effects
  2122. Dosages
  2123. Drug Profiles
  2124. amiloride
  2125. Pharmacokinetics
  2126. ▸ spironolactone
  2127. Pharmacokinetics
  2128. triamterene
  2129. Pharmacokinetics
  2130. DOSAGES
  2131. Selected Potassium-Sparing Diuretic Drugs
  2132. THIAZIDES AND THIAZIDE-LIKE DIURETICS
  2133. Mechanism of Action and Drug Effects
  2134. Indications
  2135. Table 25-5 Thiazide and Thiazide-Like Diuretics: Potential Adverse Effects
  2136. Contraindications
  2137. Adverse Effects
  2138. Table 25-6 Thiazide and Thiazide-Like Diuretics: Common Drug Interactions
  2139. DOSAGES
  2140. Thiazide and Selected Thiazide-Like Diuretic Drugs
  2141. Toxicity and Management of Overdose
  2142. Interactions
  2143. Dosages
  2144. Drug Profiles
  2145. ▸ hydrochlorothiazide
  2146. Pharmacokinetics
  2147. metolazone
  2148. Pharmacokinetics
  2149. ♦ NURSING PROCESS
  2150. ♦ ASSESSMENT
  2151. ♦ NURSING DIAGNOSES
  2152. ♦ PLANNING
  2153. Goals
  2154. Outcome Criteria
  2155. ♦ IMPLEMENTATION
  2156. CASE STUDY
  2157. Diuretic Therapy
  2158. Life Span Considerations: The Elderly Patient
  2159. Diuretic Therapy
  2160. ♦ EVALUATION
  2161. Patient Teaching Tips
  2162. Points to Remember
  2163. NCLEX Examination Review Questions
  2164. Critical Thinking Activities
  2165. CHAPTER 26 Fluids and Electrolytes
  2166. Objectives
  2167. e-Learning Activities
  2168. Companion CD
  2169. evolve Website (http://evolve.elsevier.com/Lilley)
  2170. Drug Profiles
  2171. Glossary
  2172. PHYSIOLOGY OF FLUID BALANCE
  2173. FIGURE 26-1 Distribution of total body water (TBW). ECF, Extracellular fluid; ICF, intracellular fluid; ISF, interstitial fluid; PV, plasma volume.
  2174. Table 26-1 Fluid Location: Descriptive Terms and Actual Volumes
  2175. FIGURE 26-2 Colloid osmotic pressure (oncotic pressure). As shown, the colloids inside the blood vessel are too large to pass through the vessel wall. The resulting oncotic pressure exerted by the colloids draws fluid from the surrounding tissues and other extravascular spaces into the blood vessels and also keeps fluid inside the blood vessel.
  2176. Table 26-2 Types of Dehydration
  2177. Table 26-3 Conditions Leading to Fluid Loss or Dehydration and Associated Corresponding Symptoms*
  2178. CRYSTALLOIDS
  2179. Mechanism of Action and Drug Effects
  2180. Table 26-4 Crystalloids
  2181. Indications
  2182. Contraindications
  2183. Adverse Effects
  2184. Table 26-5 Crystalloids and Colloids: Dosing Guidelines
  2185. Interactions
  2186. Dosages
  2187. Drug Profiles
  2188. sodium chloride
  2189. Pharmacokinetics
  2190. COLLOIDS
  2191. Table 26-6 Commonly Used Colloids
  2192. Mechanism of Action and Drug Effects
  2193. Indications
  2194. Contraindications
  2195. Adverse Effects
  2196. Interactions
  2197. Dosages
  2198. Drug Profiles
  2199. albumin
  2200. Pharmacokinetics
  2201. dextran
  2202. Pharmacokinetics
  2203. BLOOD PRODUCTS
  2204. Mechanism of Action and Drug Effects
  2205. Table 26-7 Blood Products
  2206. Table 26-8 Blood Products: Indications
  2207. Indications
  2208. Contraindications
  2209. Adverse Effects
  2210. Table 26-9 Suggested Guidelines for Blood Products: Management of Bleeding
  2211. Interactions
  2212. Dosages
  2213. Drug Profiles
  2214. Packed Red Blood Cells
  2215. Fresh Frozen Plasma
  2216. PHYSIOLOGY OF ELECTROLYTE BALANCE
  2217. POTASSIUM
  2218. Box 26-1 Symptoms of Hypokalemia
  2219. Early
  2220. Late
  2221. Mechanism of Action and Drug Effects
  2222. Indications
  2223. Contraindications
  2224. Adverse Effects
  2225. Toxicity and Management of Overdose
  2226. Interactions
  2227. Dosages
  2228. Drug Profiles
  2229. Pharmacokinetics
  2230. Table 26-10 Potassium: Various Salt Forms
  2231. sodium polystyrene sulfonate (potassium exchange resin)
  2232. SODIUM
  2233. Mechanism of Action and Drug Effects
  2234. Indications
  2235. Contraindications
  2236. Adverse Effects
  2237. Toxicity and Management of Overdose
  2238. Interactions
  2239. Dosages
  2240. Drug Profiles
  2241. sodium chloride
  2242. Pharmacokinetics
  2243. ♦ NURSING PROCESS
  2244. ♦ ASSESSMENT
  2245. LABORATORY VALUES RELATED TO DRUG THERAPY
  2246. Calcium
  2247. ♦ NURSING DIAGNOSES
  2248. ♦ PLANNING
  2249. Goals
  2250. Outcome Criteria
  2251. ♦ IMPLEMENTATION
  2252. ♦ EVALUATION
  2253. Patient Teaching Tips
  2254. Points to Remember
  2255. NCLEX Examination Review Questions
  2256. Critical Thinking Activities
  2257. CHAPTER 27 Coagulation Modifier Drugs
  2258. Objectives
  2259. e-Learning Activities
  2260. Companion CD
  2261. evolve Website (http://evolve.elsevier.com/Lilley)
  2262. Drug Profiles
  2263. Glossary
  2264. FIGURE 27-1 Coagulation pathway and factors: extrinsic pathway. Plt, Platelets.
  2265. COAGULATION AND HEMOSTASIS
  2266. FIGURE 27-2 Coagulation pathway and factors: intrinsic pathway. HMW-K, High-molecular weight kininogen; Plt, platelets.
  2267. COAGULATION-MODIFYING DRUGS
  2268. FIGURE 27-3 The fibrinolytic system.
  2269. Table 27-1 Coagulation Modifiers: Comparison of Drug Subclasses
  2270. ANTICOAGULANTS
  2271. Case Study
  2272. Heparin Therapy
  2273. Mechanism of Action and Drug Effects
  2274. Heparin for Acute Coronary Syndrome
  2275. Indications
  2276. Heparin for Atrial Fibrillation
  2277. Contraindications
  2278. Adverse Effects
  2279. Interactions
  2280. Table 27-2 Anticoagulants: Common Adverse Effects
  2281. Toxicity and Management of Overdose
  2282. Table 27-3 Anticoagulants: Drug Interactions
  2283. Dosages
  2284. Drug Profiles
  2285. ▸ warfarin
  2286. Pharmacokinetics
  2287. ▸ enoxaparin
  2288. DOSAGES
  2289. Selected Anticoagulant Drugs
  2290. Pharmacokinetics
  2291. ▸ heparin
  2292. Pharmacokinetics
  2293. lepirudin
  2294. Pharmacokinetics
  2295. argatroban
  2296. Pharmacokinetics
  2297. PLATELET PHYSIOLOGY
  2298. FIGURE 27-4 Relationship between platelets and clotting cascade. ADP, Adenosine diphosphate; 5-HT, serotonin; PF4, platelet factor 4; TXA2, thromboxane A2.
  2299. ANTIPLATELET DRUGS
  2300. Mechanism of Action and Drug Effects
  2301. FIGURE 27-5 Cyclooxygenase pathway. PG, Prostaglandin; TXA2, thromboxane A2.
  2302. Indications
  2303. Contraindications
  2304. Adverse Effects
  2305. Table 27-4 Selected Antiplatelet Drugs: Adverse Effects
  2306. Interactions
  2307. Drug Profiles
  2308. Dosages
  2309. ▸ aspirin
  2310. DOSAGES
  2311. Selected Antiplatelet Drugs
  2312. Pharmacokinetics
  2313. ▸ clopidogrel
  2314. Pharmacokinetics
  2315. ▸ eptifibatide
  2316. Pharmacokinetics
  2317. ANTIFIBRINOLYTIC DRUGS
  2318. Mechanism of Action and Drug Effects
  2319. Indications
  2320. Contraindications
  2321. Adverse Effects
  2322. Table 27-5 Antifibrinolytics: Mechanisms of Action
  2323. Interactions
  2324. Dosages
  2325. Drug Profiles
  2326. aminocaproic acid
  2327. Pharmacokinetics
  2328. desmopressin
  2329. Table 27-6 Antifibrinolytics: Adverse Effects
  2330. DOSAGES
  2331. Selected Antifibrinolytic Drugs
  2332. Pharmacokinetics
  2333. THROMBOLYTIC DRUGS
  2334. Thrombolytic Drugs
  2335. Mechanism of Action and Drug Effects
  2336. Indications
  2337. Contraindications
  2338. Adverse Effects
  2339. Toxicity and Management of Overdose
  2340. Interactions
  2341. Dosages
  2342. Drug Profiles
  2343. ▸ alteplase
  2344. Pharmacokinetics
  2345. ▸ streptokinase
  2346. DOSAGES
  2347. Selected Thrombolytic Drugs
  2348. Pharmacokinetics
  2349. ♦ NURSING PROCESS
  2350. ♦ ASSESSMENT
  2351. LABORATORY VALUES RELATED TO DRUG THERAPY
  2352. Anticoagulants
  2353. ♦ NURSING DIAGNOSES
  2354. ♦ PLANNING
  2355. Goals
  2356. Outcome Criteria
  2357. ♦ IMPLEMENTATION
  2358. Box 27-1 Anticoagulation Therapy and Related Nursing Considerations
  2359. Subcutaneous Heparin Injections
  2360. Intravenous Heparin Administration
  2361. Oral Anticoagulant Administration
  2362. ♦ EVALUATION
  2363. Patient Teaching Tips
  2364. Points to Remember
  2365. NCLEX Examination Review Questions
  2366. Critical Thinking Activities
  2367. CHAPTER 28 Antilipemic Drugs
  2368. Objectives
  2369. e-Learning Activities
  2370. Companion CD
  2371. evolve Website (http://evolve.elsevier.com/Lilley)
  2372. Drug Profiles
  2373. Glossary
  2374. HERBAL THERAPIES AND DIETARY SUPPLEMENTS
  2375. Garlic (allium sativum)
  2376. Overview
  2377. Common Uses
  2378. Adverse Effects
  2379. Potential Drug Interactions
  2380. Contraindications
  2381. HERBAL THERAPIES AND DIETARY SUPPLEMENTS
  2382. Flax
  2383. Overview
  2384. Common Uses
  2385. Adverse Effects
  2386. Potential Drug Interactions
  2387. Contraindications
  2388. LIPIDS AND LIPID ABNORMALITIES
  2389. PRIMARY FORMS OF LIPIDS
  2390. Table 28-1 Lipoprotein Classification
  2391. CHOLESTEROL HOMEOSTASIS
  2392. FIGURE 28-1 Cholesterol homeostasis. CE, Cholesterol ester; HDL, high-density lipoprotein; HMG-CoA, hydroxymethylglutaryl-coenzyme A; IDL, intermediate-density lipoprotein; LCAT, lecithin cholesterol acetyltransferase; LDL, low-density lipoprotein; TG, triglyceride; VLDL, very-low-density lipoprotein.
  2393. ATHEROSCLEROTIC PLAQUE FORMATION
  2394. LINK BETWEEN CHOLESTEROL AND CORONARY HEART DISEASE
  2395. Evidence-Based Practice
  2396. Statins and Stroke Reduction in Patients With and Without Coronary Heart Disease
  2397. Review
  2398. Type of Evidence and Type of Research
  2399. Results of Study
  2400. Link of Evidence to Nursing Practice
  2401. HYPERLIPIDEMIAS AND TREATMENT GUIDELINES
  2402. Box 28-1 Coronary Heart Disease: Risk Factors
  2403. Positive Risk Factors
  2404. Negative Risk Factors
  2405. Table 28-2 Types of Hyperlipidemias
  2406. Table 28-3 Treatment Decisions Based on LDL Cholesterol Level
  2407. Box 28-2 Identifying Features of the Metabolic Syndrome
  2408. HMG–CoA Reductase Inhibitors
  2409. Mechanism of Action and Drug Effects
  2410. Indications
  2411. Contraindications
  2412. Adverse Effects
  2413. Table 28-4 HMG—CoA Reductase Inhibitors: Potential Adverse Effects
  2414. Toxicity and Management of Overdose
  2415. Interactions
  2416. Laboratory Test Interactions
  2417. Dosages
  2418. Drug Profiles
  2419. ▸ atorvastatin
  2420. Pharmacokinetics
  2421. OTHER ANTILIPEMIC DRUGS
  2422. BILE ACID SEQUESTRANTS
  2423. Mechanism of Action and Drug Effects
  2424. Table 28-5 Bile Acid Sequestrants: Adverse Effects
  2425. Indications
  2426. Contraindications
  2427. Adverse Effects
  2428. Toxicity and Management of Overdose
  2429. Interactions
  2430. Dosages
  2431. Drug Profiles
  2432. ▸ cholestyramine
  2433. NIACIN
  2434. Mechanism of Action and Drug Effects
  2435. Indications
  2436. DOSAGES
  2437. Selected Antilipemic Drugs
  2438. Table 28-6 Nicotinic Acid: Potential Adverse Effects
  2439. Contraindications
  2440. Adverse Effects
  2441. Interactions
  2442. Dosages
  2443. Drug Profiles
  2444. ▸ niacin
  2445. Pharmacokinetics
  2446. FIBRIC ACID DERIVATIVES
  2447. Mechanism of Action and Drug Effects
  2448. Indications
  2449. Contraindications
  2450. Adverse Effects
  2451. Table 28-7 Fibric Acid Derivatives: Potential Adverse Effects
  2452. Toxicity and Management of Overdose
  2453. Interactions
  2454. Dosages
  2455. Drug Profiles
  2456. Fibric Acid Derivatives (Fibrates)
  2457. gemfibrozil
  2458. Pharmacokinetics
  2459. Cholesterol Absorption Inhibitors
  2460. ezetimibe
  2461. Pharmacokinetics
  2462. ♦ NURSING PROCESS
  2463. ♦ ASSESSMENT
  2464. ♦ NURSING DIAGNOSES
  2465. ♦ PLANNING
  2466. Goals
  2467. Outcome Criteria
  2468. ♦ IMPLEMENTATION
  2469. LABORATORY VALUES RELATED TO DRUG THERAPY
  2470. Coronary Heart Disease
  2471. ♦ EVALUATION
  2472. Patient Teaching Tips
  2473. Points To Remember
  2474. NCLEX Examination Review Questions
  2475. Critical Thinking Activities
  2476. PART 5 Drugs Affecting the Endocrine System
  2477. Drugs Affecting the Endocrine System
  2478. STUDY SKILLS TIPS
  2479. QUESTIONING STRATEGY
  2480. Part Title
  2481. Chapter Titles
  2482. Chapter Objectives
  2483. Chapter Headings
  2484. Type 1 Diabetes Mellitus
  2485. Mechanism of Action and Drug Effects
  2486. Print Conventions Within the Body of the Chapter
  2487. Chapter Tables
  2488. CHAPTER 29 Pituitary Drugs
  2489. Objectives
  2490. e-Learning Activities
  2491. Companion CD
  2492. evolve Website (http://evolve.elsevier.com/Lilley)
  2493. Drug Profiles
  2494. Glossary
  2495. ENDOCRINE SYSTEM
  2496. Box 29-1 Hormones of the Anterior and Posterior Pituitary
  2497. Anterior Pituitary Adenohypophysis
  2498. Posterior Pituitary (Neurohypophysis)
  2499. FIGURE 29-1 Pituitary hormones. (From McKenry LM, Tessier E, Hogan MA: Mosby’s pharmacology in nursing,ed 22, St Louis, 2006, Mosby.)
  2500. PITUITARY DRUGS
  2501. Mechanism of Action and Drug Effects
  2502. Table 29-1 Anterior and Posterior Pituitary Hormones and Drugs
  2503. Indications
  2504. Table 29-2 Corticotropin: Common Adverse Effects
  2505. Table 29-3 Desmopressin and Vasopressin: Common Adverse Effects
  2506. Table 29-4 Growth Hormone Analogs: Common Adverse Effects
  2507. Table 29-5 Selected Drug Interactions Involving Pituitary Drugs
  2508. Contraindications
  2509. Adverse Effects
  2510. Interactions
  2511. Dosages
  2512. Drug Profiles
  2513. ▸ corticotropin
  2514. Pharmacokinetics
  2515. DOSAGES
  2516. Selected Pituitary Drugs
  2517. Selected Pituitary Drugs
  2518. ♦ NURSING PROCESS
  2519. ♦ ASSESSMENT
  2520. Box 29-2 Pituitary Drugs: Assessment Data
  2521. ♦ NURSING DIAGNOSES
  2522. ♦ PLANNING
  2523. Goals
  2524. Outcome Criteria
  2525. ♦ IMPLEMENTATION
  2526. ♦ EVALUATION
  2527. Patient Teaching Tips
  2528. Points to Remember
  2529. NCLEX Examination Review Questions
  2530. Critical Thinking Activities
  2531. CHAPTER 30 Thyroid and Antithyroid Drugs
  2532. Objectives
  2533. e-Learning Activities
  2534. Companion CD
  2535. evolve Website (http://evolve.elsevier.com/Lilley)
  2536. Drug Profiles
  2537. Glossary
  2538. THYROID FUNCTION
  2539. HYPOTHYROIDISM
  2540. THYROID AUGMENTATION DRUGS
  2541. Mechanism of Action and Drug Effects
  2542. Indications
  2543. Contraindications
  2544. Adverse Effects
  2545. Table 30-1 Thyroid Drugs: Clinically Equivalent Doses
  2546. Interactions
  2547. Dosages
  2548. Table 30-2 Thyroid Drugs: Common Adverse Effects
  2549. Drug Profiles
  2550. ▸ levothyroxine
  2551. Pharmacokinetics
  2552. DOSAGES
  2553. Selected Thyroid Drugs
  2554. HYPERTHYROIDISM
  2555. ANTITHYROID DRUGS
  2556. Mechanism of Action and Drug Effects
  2557. Indications
  2558. Table 30-3 Antithyroid Drugs: Common Adverse Effects
  2559. Contraindications
  2560. Adverse Effects
  2561. Interactions
  2562. Dosages
  2563. Drug Profiles
  2564. ▸ propylthiouracil
  2565. DOSAGES
  2566. Selected Antithyroid Drugs
  2567. Pharmacokinetics
  2568. PHARMACOKINETIC BRIDGE TO NURSING PRACTICE
  2569. ♦ NURSING PROCESS
  2570. ♦ ASSESSMENT
  2571. Life Span Considerations: The Elderly Patient
  2572. Thyroid Hormones
  2573. ♦ NURSING DIAGNOSES
  2574. ♦ PLANNING
  2575. Goals
  2576. Outcome Criteria
  2577. ♦ IMPLEMENTATION
  2578. ♦ EVALUATION
  2579. Patient Teaching Tips
  2580. Points to Remember
  2581. NCLEX Examination Review Questions
  2582. Critical Thinking Activities
  2583. CHAPTER 31 Antidiabetic Drugs
  2584. Objectives
  2585. e-Learning Activities
  2586. Companion CD
  2587. evolve Website (http://evolve.elsevier.com/Lilley)
  2588. Drug Profiles
  2589. Glossary
  2590. PANCREAS
  2591. DIABETES MELLITUS
  2592. Box 31-1 Criteria for Diagnosis of Diabetes
  2593. Box 31-2 Major Long-Term Consequences of Diabetes (Type 1 and Type 2)
  2594. Table 31-1 Type 1 and Type 2 Diabetes: Characteristics
  2595. Type 1 Diabetes Mellitus
  2596. Acute Diabetic Complications: Diabetic Ketoacidosis and Hyperosmolar Nonketotic Syndrome
  2597. Type 2 Diabetes Mellitus
  2598. FIGURE 31-1 Islet of Langerhans. (From Boron WF, Boulapaep EL:Medical physiology, Philadelphia, 2003, Saunders.)
  2599. Table 31-2 Comparison of Some Salient Features of Diabetic Ketoacidosis and Hyperosmolar Nonketotic Syndrome
  2600. Gestational Diabetes
  2601. Prevention and Screening
  2602. Nonpharmacologic Treatment Interventions
  2603. ANTIDIABETIC DRUGS
  2604. INSULINS
  2605. Table 31-3 Human Insulins and Analogues: Comparison of Pharmacokinetic Properties
  2606. Table 31-4 Insulin Mixing Compatibilities
  2607. Mechanism of Action and Drug Effects
  2608. Indications
  2609. Contraindications
  2610. Adverse Effects
  2611. Box 31-3 Intensive Insulin Therapy and Tight Glucose Control
  2612. Table 31-5 Insulin: Common Adverse Effects
  2613. Interactions
  2614. Dosages
  2615. Drug Profiles
  2616. Insulins
  2617. DOSAGES
  2618. Human-Based Insulin Products
  2619. Rapid-Acting Insulins
  2620. ▸ insulin lispro and insulin aspart
  2621. Table 31-6 Sources of Available Insulin Products
  2622. Table 31-7 Considerations for the Use of Antidiabetic Drugs and Insulin
  2623. Short-Acting Insulin
  2624. ▸ regular insulin
  2625. Intermediate-Acting Insulins
  2626. ▸ insulin zinc suspension (Lente) and insulin isophane suspension (NPH)
  2627. Long-Acting Insulins
  2628. ▸ extended insulin zinc suspension (Ultralente) and glargine
  2629. Fixed-Combination Insulins
  2630. Sliding-Scale Insulin Dosing
  2631. ORAL ANTIDIABETIC DRUGS
  2632. Mechanism of Action and Drug Effects
  2633. Sulfonylureas
  2634. Meglitinides
  2635. Biguanide
  2636. Table 31-8 Sulfonylurea Drugs: Qualitative Comparison of Pharmacokinetic Properties
  2637. Thiazolidinediones
  2638. α-Glucosidase Inhibitors
  2639. Indications
  2640. Contraindications
  2641. Adverse Effects
  2642. Sulfonylureas
  2643. Meglitinides
  2644. Biguanide
  2645. Thiazolidinediones
  2646. α-Glucosidase Inhibitors
  2647. Interactions
  2648. Sulfonylureas
  2649. Meglitinides
  2650. Biguanide
  2651. Thiazolidinediones
  2652. α-Glucosidase Inhibitors
  2653. Dosages
  2654. Drug Profiles
  2655. acarbose
  2656. DOSAGES
  2657. Selected Oral Antidiabetic Drugs
  2658. Pharmacokinetics
  2659. ▸ glipizide
  2660. Pharmacokinetics
  2661. ▸ glyburide
  2662. Pharmacokinetics
  2663. glimepiride
  2664. Pharmacokinetics
  2665. ▸ metformin
  2666. Pharmacokinetics
  2667. repaglinide
  2668. Pharmacokinetics
  2669. ▸ rosiglitazone
  2670. Pharmacokinetics
  2671. MISCELLANEOUS ANTIDIABETIC DRUGS
  2672. Amylin Mimetic
  2673. Incretin Mimetic
  2674. HYPOGLYCEMIA
  2675. GLUCOSE-ELEVATING DRUGS
  2676. PHARMACOKINETIC BRIDGE to Nursing Practice
  2677. ♦ NURSING PROCESS
  2678. ♦ ASSESSMENT
  2679. CASE STUDY
  2680. Diabetes Mellitus
  2681. ♦ NURSING DIAGNOSES
  2682. ♦ PLANNING
  2683. Goals
  2684. Outcome Criteria
  2685. ♦ IMPLEMENTATION
  2686. Box 31-4 Administration, Handling, and Storage of Insulin
  2687. Dosages, Storage, Handling, and Mixing
  2688. Administration
  2689. ♦ EVALUATION
  2690. EVIDENCE-BASED PRACTICE
  2691. Tight Insulin Control
  2692. Review
  2693. Type of Evidence
  2694. Results of Study
  2695. Link of Evidence to Nursing Practice
  2696. Patient Teaching Tips
  2697. Insulin Therapy
  2698. Table 31-9 Diabetes Care: Correlation of Glycosylated Hemoglobin Levels with Mean Serum Glucose Levels
  2699. Points to Remember
  2700. NCLEX Examination Review Questions
  2701. Critical Thinking Activities
  2702. CHAPTER 32 Adrenal Drugs
  2703. Objectives
  2704. e-Learning Activities
  2705. Companion CD
  2706. evolve Website (http://evolve.elsevier.com/Lilley)
  2707. Drug Profiles
  2708. Glossary
  2709. ADRENAL SYSTEM
  2710. Table 32-1 Adrenal Gland: Characteristics
  2711. Box 32-1 Adrenal Cortex Hormones: Biologic Functions
  2712. Glucocorticoids
  2713. Mineralocorticoids
  2714. ADRENAL DRUGS
  2715. Mechanism of Action and Drug Effects
  2716. Table 32-2 Available Synthetic Corticosteroids
  2717. Indications
  2718. Table 32-3 Systemic Glucocorticoids: A Comparison
  2719. Contraindications
  2720. Adverse Effects
  2721. Interactions
  2722. Table 32-4 Corticosteroids: Common Adverse Effects
  2723. Dosages
  2724. Drug Profiles
  2725. Corticosteroids
  2726. DOSAGES
  2727. Selected Antiadrenal and Corticosteroid Drugs
  2728. ▸ fludrocortisone
  2729. Pharmacokinetics
  2730. ▸ prednisone
  2731. Pharmacokinetics
  2732. Antiadrenals
  2733. ▸ aminoglutethimide
  2734. Pharmacokinetics
  2735. ♦ NURSING PROCESS
  2736. ♦ ASSESSMENT
  2737. ♦ NURSING DIAGNOSES
  2738. ♦ PLANNING
  2739. Goals
  2740. Outcome Criteria
  2741. ♦ IMPLEMENTATION
  2742. ♦ EVALUATION
  2743. Patient Teaching Tips
  2744. Points to Remember
  2745. NCLEX Examination Review Questions
  2746. Critical Thinking Activities
  2747. CHAPTER 33 Women’s Health Drugs
  2748. Objectives
  2749. e-Learning Activities
  2750. Companion CD
  2751. evolve Website (http://evolve.elsevier.com/Lilley)
  2752. Drug Profiles
  2753. Glossary
  2754. OVERVIEW OF FEMALE REPRODUCTIVE FUNCTIONS
  2755. Table 33-1 Phases of the Menstrual Cycle
  2756. FIGURE 33-1 Hormonal activity during the monthly menstrual cycle. Gonadotropin-releasing hormone (Gn-RH) from the hypothalamus stimulates the pituitary gland, causing it to secrete follicle-stimulating hormone (FSH) early in the cycle (coinciding with the menses) and later luteinizing hormone (LH). FSH stimulates the ovaries to produce estrogen (primarily estradiol). Later in the cycle the combined surges in the levels of estrogen, Gn-RH, FSH, and LH stimulate ovulation. The corpus luteum then secretes estrogen and progesterone, providing negative feedback to the hypothalamus and pituitary gland to reduce Gn-RH, FSH, and LH secretions. If the ovum (egg) is not fertilized by a spermatozoon, levels of estrogen and progesterone then fall to their monthly lows, Gn-RH and FSH rise again, and the onset of menses begins a new cycle.
  2757. FEMALE SEX HORMONES
  2758. ESTROGENS
  2759. FIGURE 33-2 Chemical structures for steroid nucleus. A, Detailed structure. B, Abbreviated structure.
  2760. Mechanism of Action and Drug Effects
  2761. Box 33-1 Diethylstilbestrol
  2762. Indications
  2763. Contraindications
  2764. Box 33-2 Indications for Estrogen Therapy
  2765. Table 33-2 Estrogens: Common Adverse Effects
  2766. Adverse Effects
  2767. Interactions
  2768. Dosages
  2769. Drug Profiles
  2770. ▸ estrogen
  2771. DOSAGES
  2772. Selected Estrogenic Drugs
  2773. CULTURAL IMPLICATIONS
  2774. Racial Disparities in Survival of Women with Endometrial Cancers
  2775. PROGESTINS
  2776. Mechanism of Action and Drug Effects
  2777. Indications
  2778. Contraindications
  2779. Adverse Effects
  2780. Interactions
  2781. Table 33-3 Progestins: Common Adverse Effects
  2782. Dosages
  2783. Drug Profiles
  2784. ▸ medroxyprogesterone
  2785. Pharmacokinetics
  2786. megestrol
  2787. Pharmacokinetics
  2788. CONTRACEPTIVE DRUGS
  2789. DOSAGES
  2790. Selected Progestational Drugs
  2791. Mechanism of Action and Drug Effects
  2792. Indications
  2793. Contraindications
  2794. Adverse Effects
  2795. Interactions
  2796. Table 33-4 Oral Contraceptives: Common Adverse Effects
  2797. Dosages
  2798. Drug Profiles
  2799. Contraceptive Drugs
  2800. DOSAGES
  2801. Selected Contraceptive Drugs
  2802. CURRENT DRUG THERAPY FOR OSTEOPOROSIS
  2803. CASE STUDY
  2804. Osteoporosis
  2805. Mechanism of Action and Drug Effects
  2806. Bisphosphonates
  2807. Selective Estrogen Receptor Modulators
  2808. Calcitonin
  2809. Teriparatide
  2810. Indications
  2811. Contraindications
  2812. Bisphosphonates
  2813. Selective Estrogen Receptor Modulators
  2814. Calcitonin
  2815. Teriparatide
  2816. Adverse Effects
  2817. Interactions
  2818. Dosages
  2819. Drug Profiles
  2820. ▸ alendronate
  2821. Pharmacokinetics
  2822. raloxifene
  2823. DOSAGES
  2824. Selected Drugs Used Specifically for Osteoporosis
  2825. Pharmacokinetics
  2826. calcitonin
  2827. Pharmacokinetics (Nasal Spray)
  2828. DRUG THERAPY RELATED TO PREGNANCY, LABOR, DELIVERY, AND THE POSTPARTUM PERIOD
  2829. FERTILITY DRUGS
  2830. Mechanism Of Action And Drug Effects
  2831. Indications
  2832. Contraindications
  2833. Adverse Effects
  2834. Table 33-5 Fertility Drugs: Most Common Adverse Effects
  2835. DOSAGES
  2836. Selected Fertility Drugs
  2837. Interactions
  2838. Dosages
  2839. Drug Profiles
  2840. choriogonadotropin alfa
  2841. Pharmacokinetics
  2842. clomiphene
  2843. Pharmacokinetics
  2844. ▸ menotropins
  2845. Pharmacokinetics
  2846. LABOR, DELIVERY, AND POSTPARTUM DRUGS: UTERINE-ACTIVE MEDICATIONS
  2847. Uterine Stimulants
  2848. Mechanism of Action and Drug Effects
  2849. Indications
  2850. Contraindications
  2851. Adverse Effects
  2852. Interactions
  2853. Table 33-6 Oxytocic Drugs: Most Common Adverse Effects
  2854. Dosages
  2855. Drug Profiles
  2856. ▸ dinoprostone
  2857. Pharmacokinetics
  2858. ▸ methylergonovine
  2859. Pharmacokinetics
  2860. mifepristone
  2861. Pharmacokinetics
  2862. ▸ oxytocin
  2863. DOSAGES
  2864. Selected Uterine Stimulants
  2865. Pharmacokinetics
  2866. Uterine Relaxants
  2867. Mechanism of Action and Drug Effects
  2868. Indications
  2869. Contraindications
  2870. Adverse Effects
  2871. Toxicity and Management of Overdose
  2872. Interactions
  2873. Table 33-7 Tocolytic Drugs: Most Common Adverse Effects
  2874. Dosages
  2875. Drug Profiles
  2876. ritodrine
  2877. Pharmacokinetics
  2878. terbutaline
  2879. Pharmacokinetics
  2880. ♦ NURSING PROCESS
  2881. ♦ ASSESSMENT
  2882. DOSAGES
  2883. Selected Uterine Relaxants
  2884. ♦ NURSING DIAGNOSES
  2885. ♦ PLANNING
  2886. Goals
  2887. Outcome Criteria
  2888. ♦ IMPLEMENTATION
  2889. ♦ EVALUATION
  2890. Patient Teaching Tips
  2891. Points to Remember
  2892. NCLEX Examination Review Questions
  2893. Critical Thinking Activities
  2894. CHAPTER 34 Men’s Health Drugs
  2895. Objectives
  2896. e-Learning Activities
  2897. Companion CD
  2898. evolve Website (http://evolve.elsevier.com/Lilley)
  2899. Drug Profiles
  2900. Glossary
  2901. MALE REPRODUCTIVE SYSTEM
  2902. ANDROGENS AND OTHER DRUGS PERTAINING TO MEN’S HEALTH
  2903. Mechanism of Action and Drug Effects
  2904. CULTURAL IMPLICATIONS
  2905. Men’s Health Concerns and Screening
  2906. Indications
  2907. Box 34-1 Currently Available Men’s Health Drugs
  2908. a1-Adrenergic Blockers
  2909. Anabolic Steroids
  2910. Other Androgens
  2911. Antiandrogens
  2912. 5α-Reductase Inhibitors
  2913. Gonadotropin-Releasing Hormone Analogues
  2914. Peripheral Vasodilator
  2915. Drugs for Erectile Dysfunction
  2916. Table 34-1 Men’s Health Drugs: Indications
  2917. Contraindications
  2918. Adverse Effects
  2919. Table 34-2 Mens’ Health Drugs: Selected Adverse Effects
  2920. Interactions
  2921. Dosages
  2922. Drug Profiles
  2923. finasteride
  2924. DOSAGES
  2925. Selected Men’s Health Drugs
  2926. Pharmacokinetics
  2927. ▸ sildenafil
  2928. Pharmacokinetics
  2929. ▸ testosterone
  2930. Pharmacokinetics
  2931. PHARMACOKINETIC BRIDGE to Nursing Practice
  2932. ♦ NURSING PROCESS
  2933. ♦ ASSESSMENT
  2934. Life Span Considerations: The Elderly Patient
  2935. Sildenafil: Use and Concerns
  2936. ♦ NURSING DIAGNOSES
  2937. ♦ PLANNING
  2938. Goals
  2939. Outcome Criteria
  2940. ♦ IMPLEMENTATION
  2941. HERBAL THERAPIES AND DIETARY SUPPLEMENTS
  2942. Saw Palmetto (Serenoa repens, Sabal serrulata)
  2943. Overview
  2944. Common Uses
  2945. Adverse Effects
  2946. Potential Drug Interactions
  2947. Contraindications
  2948. ♦ EVALUATION
  2949. Patient Teaching Tips
  2950. Points to Remember
  2951. NCLEX Examination Review Questions
  2952. Critical Thinking Activities
  2953. PART 6 Drugs Affecting the Respiratory System
  2954. Drugs Affecting the Respiratory System
  2955. STUDY SKILLS TIPS
  2956. STUDY ON THE RUN, PURR
  2957. Where Is the Time?
  2958. SOTR and Plan
  2959. SOTR and Vocabulary
  2960. Creating Vocabulary Cards with SOTR
  2961. SOTR and Vocabulary Review
  2962. SOTR and Chapter Review
  2963. CHAPTER 35 Antihistamines, Decongestants, Antitussives, and Expectorants
  2964. Objectives
  2965. e-Learning Activities
  2966. Companion CD
  2967. evolve Website (http://evolve.elsevier.com/Lilley)
  2968. Drug Profiles
  2969. Glossary
  2970. COLD MEDICATIONS
  2971. HERBAL THERAPIES AND DIETARY SUPPLEMENTS
  2972. Echinacea (Echinacea)
  2973. Overview
  2974. Common Uses
  2975. Adverse Effects
  2976. Potential Drug Interactions
  2977. Contraindications
  2978. ANTIHISTAMINES
  2979. Mechanism of Action and Drug Effects
  2980. FIGURE 35-1 Comparison of efficacy and adverse effects of selected antihistamines.
  2981. Indications
  2982. Contraindications
  2983. Table 35-1 Effects of Various Antihistamines
  2984. Table 35-2 Antihistamines: Drug Effects
  2985. Adverse Effects
  2986. Table 35-3 Antihistamines: Reported Adverse Effects
  2987. Interactions
  2988. Dosages
  2989. Drug Profiles
  2990. Nonsedating Antihistamines
  2991. ▸ loratadine
  2992. Pharmacokinetics
  2993. Traditional Antihistamines
  2994. ▸ diphenhydramine
  2995. DOSAGES
  2996. Selected Antihistamines
  2997. Pharmacokinetics
  2998. DECONGESTANTS
  2999. HERBAL THERAPIES AND DIETARY SUPPLEMENTS
  3000. Goldenseal (Hydrastis canadensis)
  3001. Overview
  3002. Common Uses
  3003. Adverse Effects
  3004. Potential Drug Interactions
  3005. Contraindications
  3006. Mechanism of Action and Drug Effects
  3007. Indications
  3008. Contraindications
  3009. Adverse Effects
  3010. Interactions
  3011. Dosages
  3012. Drug Profiles
  3013. naphazoline
  3014. DOSAGES
  3015. Selected Decongestant, Expectorant, and Antitussive Drugs
  3016. Pharmacokinetics
  3017. ANTITUSSIVES
  3018. Mechanism of Action and Drug Effects
  3019. Indications
  3020. Contraindications
  3021. Adverse Effects
  3022. Interactions
  3023. Dosages
  3024. Drug Profiles
  3025. benzonatate
  3026. Pharmacokinetics
  3027. codeine
  3028. Pharmacokinetics
  3029. ▸ dextromethorphan
  3030. Pharmacokinetics
  3031. EXPECTORANTS
  3032. Mechanism of Action and Drug Effects
  3033. Indications
  3034. Contraindications
  3035. Adverse Effects
  3036. Interactions
  3037. Dosages
  3038. Table 35-4 Expectorants: Reported Adverse Effects
  3039. Drug Profiles
  3040. ▸ guaifenesin
  3041. ♦ NURSING PROCESS
  3042. ♦ ASSESSMENT
  3043. ♦ NURSING DIAGNOSES
  3044. CASE STUDY
  3045. Decongestants
  3046. ♦ PLANNING
  3047. Goals
  3048. Outcome Criteria
  3049. ♦ IMPLEMENTATION
  3050. ♦ EVALUATION
  3051. Patient Teaching Tips
  3052. Points to Remember
  3053. NCLEX Examination Review Questions
  3054. Critical Thinking Activities
  3055. CHAPTER 36 Bronchodilators and Other Respiratory Drugs
  3056. Objectives
  3057. e-Learning Activities
  3058. Companion CD
  3059. evolve Website (http://evolve.elsevier.com/Lilley)
  3060. Drug Profiles
  3061. Glossary
  3062. DISEASES OF THE RESPIRATORY SYSTEM
  3063. ASTHMA
  3064. Box 36-1 Steps Involved in an Attack of Allergic Asthma
  3065. Box 36-2 Classifications of Drugs Used to Treat Asthma
  3066. Long-Term Control
  3067. Quick Relief
  3068. Table 36-1 Stepwise Therapy for the Management of Asthma
  3069. CHRONIC BRONCHITIS
  3070. EMPHYSEMA
  3071. TREATMENT OF DISEASES OF THE LOWER RESPIRATORY TRACT
  3072. BRONCHODILATORS
  3073. β-ADRENERGIC AGONISTS
  3074. Mechanism of Action and Drug Effects
  3075. Table 36-2 Mechanisms of Antiasthmatic Drug Action
  3076. Table 36-3 β-Agonist Bronchodilators
  3077. PREVENTING MEDICATION ERRORS
  3078. Oral Ingestion of Capsules for Inhalation Devices
  3079. Indications
  3080. Contraindications
  3081. Adverse Effects
  3082. Interactions
  3083. Dosages
  3084. Drug Profiles
  3085. ▸ albuterol
  3086. Pharmacokinetics
  3087. ANTICHOLINERGICS
  3088. Mechanism of Action and Drug Effects
  3089. DOSAGES
  3090. Bronchodilators
  3091. Indications
  3092. Contraindications
  3093. Adverse Effects
  3094. Drug Interactions
  3095. Dosages
  3096. Drug Profiles
  3097. ipratropium
  3098. Pharmacokinetics
  3099. XANTHINE DERIVATIVES
  3100. Mechanism of Action and Drug Effects
  3101. Indications
  3102. Contraindications
  3103. Adverse Effects
  3104. Interactions
  3105. Dosages
  3106. Drug Profiles
  3107. ▸ theophylline
  3108. DOSAGES
  3109. Theophylline Salts
  3110. Table 36-4 Available Theophylline Preparations
  3111. Pharmacokinetics
  3112. NONBRONCHODILATING RESPIRATORY DRUGS
  3113. ANTILEUKOTRIENE DRUGS
  3114. Mechanism of Action and Drug Effects
  3115. Indications
  3116. Contraindications
  3117. Adverse Effects
  3118. Table 36-5 Drug Interactions: Antileukotriene Drugs
  3119. Interactions
  3120. Dosages
  3121. Drug Profiles
  3122. ▸ montelukast
  3123. DOSAGES
  3124. Selected Antileukotriene Drugs
  3125. Pharmacokinetics
  3126. CORTICOSTEROIDS
  3127. Mechanism of Action and Drug Effects
  3128. Indications
  3129. Table 36-6 White Blood Cells (Leukocytes)
  3130. Contraindications
  3131. Adverse Effects
  3132. Interactions
  3133. Dosages
  3134. Drug Profiles
  3135. fluticasone
  3136. DOSAGES
  3137. Selected Corticosteroids
  3138. Pharmacokinetics
  3139. CASE STUDY
  3140. Chronic Obstructive Pulmonary Disease
  3141. methylprednisolone
  3142. Pharmacokinetics
  3143. ♦ NURSING PROCESS
  3144. ♦ ASSESSMENT
  3145. Life Span Considerations: The Elderly Patient
  3146. Xanthine Derivatives
  3147. ♦ NURSING DIAGNOSES
  3148. ♦ PLANNING
  3149. Goals
  3150. Outcome Criteria
  3151. ♦ IMPLEMENTATION
  3152. LEGAL AND ETHICAL PRINCIPLES
  3153. Chlorofluorocarbons and the Environment
  3154. ♦ EVALUATION
  3155. Patient Teaching Tips
  3156. β-Agonists
  3157. Xanthines
  3158. Anticholinergics
  3159. Corticosteroids/Glucocorticoids
  3160. Leukotriene Antagonists
  3161. Points to Remember
  3162. NCLEX Examination Review Questions
  3163. Critical Thinking Activities
  3164. PART 7 Antiinfective and Antiinflammatory Drugs
  3165. Antiinfective and Antiinflammatory Drugs
  3166. STUDY SKILLS TIPS
  3167. NURSING PROCESS
  3168. ASSESSMENT
  3169. NURSING DIAGNOSES
  3170. EVALUATION
  3171. CHAPTER 37 Antibiotics Part 1
  3172. Objectives
  3173. e-Learning Activities
  3174. Companion CD
  3175. evolve Website (http://evolve.elsevier.com/Lilley)
  3176. Drug Profiles
  3177. Glossary
  3178. MICROBIAL INFECTION
  3179. FIGURE 37-1 General morphology of bacteria. (From Murray PR et al: Medical microbiology, St Louis, 2002, Mosby.)
  3180. FIGURE 37-2 A dividing bacterial cell with a single flagellum, four sex pili, numerous common fibrae, a cell wall, a cytoplasmic membrane, two nuclear bodies, three mesosomes, and numerous ribosomes. (From Greenwood D et al: Medical microbiology, ed 16, Edinburgh, 2002, Elsevier Science.)
  3181. FIGURE 37-3 Gram-stain differentiation of bacteria. The crystal violet of Gram stain is precipitated by Gram iodine and is trapped in the thick peptidoglycan layer in gram-positive bacteria. The decolorizer disperses the gram-negative outer membrane and washes the crystal violet from the thin layer of peptidoglycan. Gram-negative bacteria are visualized by the red counterstain. (From Murray PR et al: Medical microbiology, St Louis, 2002, Mosby.)
  3182. FIGURE 37-4 Gram-positive and gram-negative bacteria. A gram-positive bacterium has a thick layer of peptidoglycan (left). A gram-negative bacterium has a thin peptidoglycan layer and an outer membrane (right). Structures in parentheses are not found in all bacteria. (From Murray PR et al: Medical microbiology, St Louis, 2002, Mosby.)
  3183. FIGURE 37-5 Molecules on the surface of gram-negative and gram-positive bacteria involved in pathogenesis. Not shown is the type 3 secretory apparatus of gram-negative bacteria. (From Cotran RS, Kumar V, Collins T: Robbins pathologic basis of disease, ed 6, Philadelphia, 1999, Saunders.)
  3184. GENERAL PRINCIPLES OF ANTIBIOTIC THERAPY
  3185. ANTIBIOTICS
  3186. FIGURE 37-6 Basic sites of antibiotic activity. DNA, Deoxyribonucleic acid; mRNA, messenger ribonucleic acid; RNA, ribonucleic acid. (From Murray PR et al: Medical microbiology, St Louis, 2002, Mosby.)
  3187. SULFONAMIDES
  3188. Mechanism of Action and Drug Effects
  3189. Indications
  3190. Contraindications
  3191. Adverse Effects
  3192. Interactions
  3193. Table 37-1 Sulfonamides: Reported Adverse Effects
  3194. Dosages
  3195. Drug Profiles
  3196. sulfamethoxazole-trimethoprim (co-trimoxazole)
  3197. Pharmacokinetics
  3198. β-LACTAM ANTIBIOTICS
  3199. DOSAGES
  3200. Selected Sulfonamides and Combination Drug Products
  3201. FIGURE 37-7 Chemical structure of penicillins showing the β-lactam ring. R, Variable portion of drug chemical structure.
  3202. PENICILLINS
  3203. Mechanism of Action and Drug Effects
  3204. Table 37-2 Classification of Penicillins
  3205. Indications
  3206. Contraindications
  3207. Adverse Effects
  3208. Table 37-3 Penicillins: Reported Adverse Effects
  3209. Interactions
  3210. Table 37-4 Penicillins: Drug Interactions
  3211. Dosages
  3212. Drug Profiles
  3213. Natural Penicillins
  3214. ▸ penicillin G and penicillin V potassium
  3215. Pharmacokinetics
  3216. Penicillinase-Resistant Penicillins
  3217. nafcillin
  3218. Pharmacokinetics
  3219. Aminopenicillins
  3220. ▸ amoxicillin
  3221. Pharmacokinetics
  3222. ampicillin
  3223. DOSAGES
  3224. Selected Penicillins
  3225. Pharmacokinetics
  3226. Extended-Spectrum Penicillins
  3227. Pharmacokinetics
  3228. Half-Life of Intravenously Administered Ampicillin
  3229. CEPHALOSPORINS
  3230. Table 37-5 Cephalosporins: Parenteral and Oral Preparations
  3231. Table 37-6 Cephalosporins: Drug Interactions
  3232. Dosages
  3233. DOSAGES
  3234. Selected Cephalosporins
  3235. Drug Profiles
  3236. First-Generation Cephalosporins
  3237. ▸ cefazolin
  3238. Pharmacokinetics
  3239. ▸ cephalexin
  3240. Pharmacokinetics
  3241. Second-Generation Cephalosporins
  3242. ▸ cefoxitin
  3243. Pharmacokinetics
  3244. cefuroxime
  3245. Pharmacokinetics
  3246. Third-Generation Cephalosporins
  3247. ▸ ceftriaxone
  3248. Pharmacokinetics
  3249. ceftazidime
  3250. Pharmacokinetics
  3251. Fourth-Generation Cephalosporins
  3252. cefepime
  3253. Pharmacokinetics
  3254. CARBAPENEMS
  3255. Drug Profiles
  3256. ▸ imipenem-cilastatin
  3257. DOSAGES
  3258. Carbapenems and Monobactams
  3259. Pharmacokinetics
  3260. MONOBACTAMS
  3261. Drug Profiles
  3262. aztreonam
  3263. Pharmacokinetics
  3264. MACROLIDES AND KETOLIDES
  3265. Mechanism of Action and Drug Effects
  3266. Table 37-7 Erythromycin Formulations
  3267. Indications
  3268. Table 37-8 Macrolides: Reported Adverse Effects
  3269. Contraindications
  3270. Adverse Effects
  3271. Interactions
  3272. Dosages
  3273. Drug Profiles
  3274. ▸ erythromycin
  3275. ▸ azithromycin and clarithromycin
  3276. DOSAGES
  3277. Selected Macrolides and Ketolides
  3278. Table 37-9 Erythromycin Dosage Forms and Product Names
  3279. Pharmacokinetics
  3280. telithromycin
  3281. Pharmacokinetics
  3282. TETRACYCLINES
  3283. Table 37-10 Available Tetracycline Antibiotics
  3284. Mechanism of Action and Drug Effects
  3285. Indications
  3286. Contraindications
  3287. Adverse Effects
  3288. Interactions
  3289. Dosages
  3290. Drug Profiles
  3291. DOSAGES
  3292. Selected Tetracyclines
  3293. demeclocycline
  3294. Pharmacokinetics
  3295. ▸ doxycycline
  3296. Pharmacokinetics
  3297. ♦ NURSING PROCESS
  3298. ♦ ASSESSMENT
  3299. ♦ NURSING DIAGNOSES
  3300. ♦ PLANNING
  3301. Goals
  3302. Outcome Criteria
  3303. ♦ IMPLEMENTATION
  3304. CASE STUDY
  3305. Antibiotic Therapy
  3306. ♦ EVALUATION
  3307. Patient Teaching Tips
  3308. Points to Remember
  3309. NCLEX Examination Review Questions
  3310. Critical Thinking Activities
  3311. CHAPTER 38 Antibiotics Part 2
  3312. Objectives
  3313. e-Learning Activities
  3314. Companion CD
  3315. evolve Website (http://evolve.elsevier.com/Lilley)
  3316. Drug Profiles
  3317. Glossary
  3318. AMINOGLYCOSIDES
  3319. Table 38-1 Availability of Aminoglycoside Antibiotics
  3320. Mechanism of Action and Drug Effects
  3321. Indications
  3322. Contraindications
  3323. Adverse Effects
  3324. Table 38-2 Aminoglycosides: Comparative Spectra of Antimicrobial Activity
  3325. Interactions
  3326. Dosages
  3327. Drug Profiles
  3328. amikacin
  3329. Pharmacokinetics
  3330. ▸ gentamicin
  3331. Pharmacokinetics
  3332. DOSAGES
  3333. Selected Aminoglycosides
  3334. tobramycin
  3335. Pharmacokinetics
  3336. neomycin
  3337. Pharmacokinetics
  3338. FLUOROQUINOLONES
  3339. Mechanism of Action and Drug Effects
  3340. Indications
  3341. Box 38-1 Overview of Quinolone-Susceptible Microbial Spectra
  3342. Table 38-3 Quinolones: Common Indications for Specific Drugs
  3343. Contraindications
  3344. Adverse Effects
  3345. Interactions
  3346. Dosages
  3347. Table 38-4 Quinolones: Reported Adverse Effects
  3348. Drug Profiles
  3349. Quinolones
  3350. ▸ ciprofloxacin
  3351. Pharmacokinetics
  3352. levofloxacin
  3353. Pharmacokinetics
  3354. Miscellaneous Antibiotics
  3355. ▸ clindamycin
  3356. DOSAGES
  3357. Selected Fluoroquinolones (“Quinolones”)
  3358. DOSAGES
  3359. Selected Miscellaneous Antibiotics
  3360. Pharmacokinetics
  3361. dapsone
  3362. Pharmacokinetics
  3363. linezolid
  3364. Pharmacokinetics
  3365. ▸ metronidazole
  3366. Pharmacokinetics
  3367. nitrofurantoin
  3368. Pharmacokinetics
  3369. quinupristin and dalfopristin
  3370. Pharmacokinetics
  3371. ▸ vancomycin
  3372. Pharmacokinetics
  3373. daptomycin
  3374. Pharmacokinetics
  3375. ♦ NURSING PROCESS
  3376. ♦ ASSESSMENT
  3377. ♦ NURSING DIAGNOSES
  3378. ♦ PLANNING
  3379. Goals
  3380. Outcome Criteria
  3381. ♦ IMPLEMENTATION
  3382. EVALUATION
  3383. Patient Teaching Tips
  3384. Aminoglycosides
  3385. Fluoroquinolones
  3386. Clindamycin
  3387. Vancomycin
  3388. Dapsone
  3389. Linezolid
  3390. Metronidazole Hydrochloride
  3391. Nitrofurantoin
  3392. Points to Remember
  3393. NCLEX Examination Review Questions
  3394. Critical Thinking Activities
  3395. CHAPTER 39 Antiviral Drugs
  3396. Objectives
  3397. e-Learning Activities
  3398. Companion CD
  3399. evolve Website (http://evolve.elsevier.com/Lilley)
  3400. Drug Profiles
  3401. Glossary
  3402. GENERAL PRINCIPLES OF VIROLOGY
  3403. FIGURE 39-1 Virus replication. Some viruses integrate into host chromosome with development of latency. (Modified from Brody TM, Larner J, Minneman KP: Human pharmacology: molecular to clinical, ed 3, St Louis, 1998, Mosby.)
  3404. OVERVIEW OF VIRAL ILLNESSES AND THEIR TREATMENT
  3405. Table 39-1 Examples of Nucleoside Analog Antiviral Drugs
  3406. Table 39-2 Examples of Non-Nucleoside Analog Antiviral Drugs
  3407. OVERVIEW OF HERPES SIMPLEX VIRUSES AND VARICELLA-ZOSTER VIRUS INFECTION
  3408. Herpes Simplex Viruses
  3409. Table 39-3 Antiviral Drugs: Viral Spectra, Indications, and Therapeutic Effects
  3410. Table 39-4 Selected Antiviral Drugs: Adverse Effects
  3411. Box 39-1 Selected Antiviral Drugs: Interactions
  3412. Acyclovir with the Following
  3413. Amantadine with the Following
  3414. Didanosine with the Following
  3415. Ganciclovir with the Following
  3416. Indinavir with the Following
  3417. Nevirapine with the Following
  3418. Zalcitabine with the Following
  3419. Zidovudine with the Following
  3420. Varicella Zoster Virus
  3421. ANTIVIRAL DRUGS (NONRETROVIRAL)
  3422. Mechanism of Action and Drug Effects
  3423. Indications
  3424. Contraindications
  3425. PPREVENTING MEDICATION ERRORS
  3426. Look-Alike Drugs: Zostrix and Zovirax
  3427. Adverse Effects
  3428. Interactions
  3429. Dosages
  3430. Drug Profiles
  3431. Nonretroviral Antiviral Drugs
  3432. amantadine and rimantadine
  3433. Pharmacokinetics
  3434. ▸ acyclovir
  3435. Pharmacokinetics
  3436. ▸ ganciclovir
  3437. DOSAGES
  3438. Antiviral Drugs (Nonretroviral)
  3439. Pharmacokinetics
  3440. oseltamivir and zanamivir
  3441. Pharmacokinetics (zanamivir)
  3442. Pharmacokinetics (oseltamivir)
  3443. ribavirin
  3444. Pharmacokinetics
  3445. OVERVIEW OF HIV INFECTION AND THE AIDS PANDEMIC
  3446. FIGURE 39-2 Human immunodeficiency virus (HIV). Within the core capsid, the diploid, single-stranded, positive-sense RNA is complexed to nucleoprotein. (From Dorland’s illustrated medical dictionary, ed 30, Philadelphia, 2003, Saunders.)
  3447. FIGURE 39-3 Life cycle of the HIV virus. The extracellular envelope protein gp120 binds to CD4 on the surface of T lymphocytes or mononuclear phagocytes, while the transmembrane protein gp41 mediates the fusion of the viral envelope with the cell membrane. gp, Glycoprotein. (From Dorland’s illustrated medical dictionary, ed 30, Philadelphia, 2003, Saunders.)
  3448. Box 39-2 Epidemiology of HIV Infection
  3449. Disease Viral Factors
  3450. Transmission
  3451. Who Is At Risk?
  3452. Geographic Factors
  3453. Modes of Control
  3454. Box 39-3 Indicator Diseases of AIDS
  3455. Opportunistic Infections
  3456. Protozoal
  3457. Fungal
  3458. Viral
  3459. Bacterial
  3460. Opportunistic Neoplasias
  3461. Others
  3462. FIGURE 39-4 Natural history of HIV infection in the absence of therapy in a hypothetical patient. (From Fauci AS, Pantaleo G, Stanley S, Weissman D: Immunopathogenic mechanisms of HIV infection. Ann Intern Med 1996; 124:654-663. In Mandell GL, Bennett JE, Dolin R: Principles and practice of infectious diseases, ed 6, Philadelphia, 2005, Churchill Livingstone.)
  3463. ANTIRETROVIRAL DRUGS
  3464. Mechanism of Action and Drug Effects
  3465. Table 39-5 Recommendations for Occupational HIV Exposure Chemoprophylaxis
  3466. Indications
  3467. Contraindications
  3468. Adverse Effects
  3469. Interactions
  3470. Dosages
  3471. Drug Profiles
  3472. enfuvirtide
  3473. Pharmacokinetics
  3474. ▸ indinavir
  3475. Pharmacokinetics
  3476. ▸ nevirapine
  3477. Pharmacokinetics
  3478. tenofovir
  3479. Pharmacokinetics
  3480. ▸ zidovudine
  3481. Pharmacokinetics
  3482. DOSAGES
  3483. Antiretroviral Drugs
  3484. OTHER SIGNIFICANT VIRAL ILLNESSES OF RECENT CONCERN
  3485. NURSING PROCESS
  3486. ♦ ASSESSMENT
  3487. ♦ NURSING DIAGNOSES
  3488. ♦ PLANNING
  3489. Goals
  3490. Outcome Criteria
  3491. ♦ IMPLEMENTATION
  3492. ♦ EVALUATION
  3493. CASE STUDY
  3494. Antiviral Therapy
  3495. Patient Teaching Tips
  3496. Points to Remember
  3497. NCLEX Examination Review Questions
  3498. Critical Thinking Activities
  3499. CHAPTER 40 Antitubercular Drugs
  3500. Objectives
  3501. e-Learning Activities
  3502. Companion CD
  3503. evolve Website (http://evolve.elsevier.com/Lilley)
  3504. Drug Profiles
  3505. Glossary
  3506. TUBERCULOSIS
  3507. ANTITUBERCULAR DRUGS
  3508. Box 40-1 First- and Second-Line Antitubercular Drugs
  3509. First-Line Drugs
  3510. Second-Line Drugs
  3511. Box 40-2 Miscellaneous TB-related Injections
  3512. Table 40-1 Antitubercular Drugs: Mechanisms of Action
  3513. Mechanism of Action and Drug Effects
  3514. Indications
  3515. Contraindications
  3516. Table 40-2 Antitubercular Drugs: Indications
  3517. Adverse Effects
  3518. Interactions
  3519. Table 40-3 Antitubercular Drugs: Common Adverse Effects
  3520. Table 40-4 Antitubercular Drugs: Drug Interactions
  3521. Dosages
  3522. Drug Profiles
  3523. ethambutol
  3524. Pharmacokinetics
  3525. ▸ isoniazid
  3526. DOSAGES
  3527. Selected Antitubercular Drugs
  3528. Pharmacokinetics
  3529. pyrazinamide
  3530. Pharmacokinetics
  3531. rifabutin
  3532. Pharmacokinetics
  3533. rifampin
  3534. Pharmacokinetics
  3535. rifapentine
  3536. Pharmacokinetics
  3537. streptomycin
  3538. Pharmacokinetics
  3539. ♦ NURSING PROCESS
  3540. ♦ ASSESSMENT
  3541. ♦ NURSING DIAGNOSES
  3542. ♦ PLANNING
  3543. Goals
  3544. Outcome Criteria
  3545. ♦ IMPLEMENTATION
  3546. ♦ EVALUATION
  3547. CASE STUDY Tuberculosis
  3548. Patient Teaching Tips
  3549. Points to Remember
  3550. NCLEX Examination Review Questions
  3551. Critical Thinking Activities
  3552. CHAPTER 41 Antifungal Drugs
  3553. Objectives
  3554. e-Learning Activities
  3555. Companion CD
  3556. Evolve Website (http://evolve.elsevier.com/Lilley)
  3557. Drug Profiles
  3558. Glossary
  3559. FUNGAL INFECTIONS
  3560. Table 41-1 Mycotic Infections
  3561. ANTIFUNGAL DRUGS
  3562. Mechanism of Action and Drug Effects
  3563. Indications
  3564. Box 41-1 Fungal Species That Are Susceptible to Current Antifungal Drugs
  3565. Cutaneous and Subcutaneous Mycoses
  3566. Systemic Mycoses
  3567. Contraindications
  3568. Adverse Effects
  3569. Interactions
  3570. Dosages
  3571. Drug Profiles
  3572. ▸ amphotericin B
  3573. Pharmacokinetics*
  3574. caspofungin
  3575. Pharmacokinetics
  3576. ▸ fluconazole
  3577. Pharmacokinetics
  3578. nystatin
  3579. Pharmacokinetics
  3580. terbinafine
  3581. Table 41-2 Selected Antifungal Drugs: Common Adverse Effects and Cautions
  3582. Table 41-3 Antifungal Drugs: Drug Interactions
  3583. DOSAGES
  3584. Selected Antifungal Drugs
  3585. Pharmacokinetics
  3586. voriconazole
  3587. Pharmacokinetics
  3588. ♦ NURSING PROCESS
  3589. ♦ ASSESSMENT
  3590. ♦ NURSING DIAGNOSES
  3591. ♦ PLANNING
  3592. Goals
  3593. Outcome Criteria
  3594. ♦ IMPLEMENTATION
  3595. ♦ EVALUATION
  3596. Patient Teaching Tips
  3597. Points to Remember
  3598. NCLEX Examination Review Questions
  3599. Critical Thinking Activities
  3600. CHAPTER 42 Antimalarial, Antiprotozoal, and Anthelmintic Drugs
  3601. Objectives
  3602. e-Learning Activities
  3603. Companion CD
  3604. Evolve Website (http://evolve.elsevier.com/Lilley)
  3605. Drug Profiles
  3606. Glossary
  3607. MALARIA
  3608. FIGURE 42-1 Life cycle of the malarial parasite. (From McKenry LM, Salerno E: Mosby’s pharmacology in nursing—revised and updated, ed 21, St Louis, 2003, Mosby.)
  3609. ANTIMALARIAL DRUGS
  3610. Mechanism of Action and Drug Effects
  3611. Indications
  3612. Contraindications
  3613. Adverse Effects
  3614. Interactions
  3615. Dosages
  3616. Table 42-1 Antimalarial Drugs: Common Adverse Effects
  3617. Table 42-2 Antimalarial Drugs: Drug Interactions
  3618. Drug Profiles
  3619. ▸ chloroquine and hydroxychloroquine
  3620. Pharmacokinetics
  3621. mefloquine
  3622. Pharmacokinetics
  3623. ▸ primaquine
  3624. DOSAGES
  3625. Selected Antimalarial Drugs
  3626. Table 42-3 Types of Protozoal Infections and Common Drug Therapy
  3627. Pharmacokinetics
  3628. pyrimethamine
  3629. Pharmacokinetics
  3630. OTHER PROTOZOAL INFECTIONS
  3631. ANTIPROTOZOAL DRUGS
  3632. Mechanism of Action and Drug Effects
  3633. Table 42-4 Selected Antiprotozoal Drugs: Mechanisms of Action
  3634. Indications
  3635. Contraindications
  3636. Table 42-5 Indications for Selected Antiprotozoal Drugs
  3637. Adverse Effects
  3638. Interactions
  3639. Dosages
  3640. Drug Profiles
  3641. atovaquone
  3642. Pharmacokinetics
  3643. iodoquinol
  3644. Table 42-6 Adverse Effects for Selected Antiprotozoal Drugs
  3645. Table 42-7 Antiprotozoal Drugs: Drug and Laboratory Test Interactions
  3646. DOSAGES
  3647. Selected Antiprotozoal Drugs
  3648. Pharmacokinetics
  3649. ▸ metronidazole
  3650. Pharmacokinetics
  3651. paromomycin
  3652. Pharmacokinetics
  3653. pentamidine
  3654. Pharmacokinetics
  3655. HELMINTHIC INFECTIONS
  3656. Table 42-8 Helminthic Infections
  3657. Table 42-9 Anthelmintics: Class of Worms Killed
  3658. ANTHELMINTIC DRUGS
  3659. Mechanism of Action and Drug Effects
  3660. Indications
  3661. Contraindications
  3662. Adverse Effects
  3663. Interactions
  3664. Dosages
  3665. Drug Profiles
  3666. diethylcarbamazine
  3667. Pharmacokinetics
  3668. Table 42-10 Anthelmintics: Mechanisms of Action
  3669. Table 42-11 Anthelmintics: Indications
  3670. Table 42-12 Anthelmintics: Common Adverse Effects
  3671. ▸ mebendazole
  3672. Pharmacokinetics
  3673. praziquantel
  3674. Pharmacokinetics
  3675. pyrantel
  3676. Pharmacokinetics
  3677. DOSAGES
  3678. Selected Anthelmintic Drugs
  3679. ♦ NURSING PROCESS
  3680. ♦ ASSESSMENT
  3681. ♦ NURSING DIAGNOSES
  3682. ♦ PLANNING
  3683. Goals
  3684. Outcome Criteria
  3685. ♦ IMPLEMENTATION
  3686. ♦ EVALUATION
  3687. Patient Teaching Tips
  3688. Points to Remember
  3689. NCLEX Examination Review Questions
  3690. Critical Thinking Activities
  3691. CHAPTER 43 Antiseptic and Disinfectant Agents
  3692. Objectives
  3693. e-Learning Activities
  3694. Companion CD
  3695. Evolve Website (http://evolve.elsevier.com/Lilley)
  3696. Drug Profiles
  3697. Glossary
  3698. COMMUNITY-ACQUIRED AND NOSOCOMIAL INFECTIONS
  3699. Table 43-1 Changing Prevalence of Nosocomial Pathogens
  3700. TOPICAL ANTIMICROBIALS
  3701. Mechanism of Action and Effects of Antiseptics and Disinfectants
  3702. Table 43-2 Antiseptics Versus Disinfectants
  3703. Table 43-3 Disinfectants and Antiseptics: Chemical Categories
  3704. Table 43-4 Antiseptics and Disinfectants: Mechanisms of Action
  3705. Table 43-5 Antiseptics and Disinfectants: Therapeutic Effects
  3706. Indications
  3707. Table 43-6 Antiseptic and Disinfectant Agents: Adverse Effects
  3708. Contraindications
  3709. Adverse Effects
  3710. Interactions
  3711. Dosages
  3712. Drug Profiles
  3713. Acid Agents
  3714. Alcohol Agents
  3715. Aldehyde Agents
  3716. Biguanide Agents
  3717. Dyes
  3718. Chlorine Compounds
  3719. DOSAGES
  3720. Selected Antiseptic and Disinfectant Agents
  3721. Mercurial Agents
  3722. Iodine Compounds
  3723. Oxidizing Agents
  3724. Phenolic Compounds
  3725. Surface-Active Agents
  3726. Table 43-7 Iodine Formulations
  3727. ♦ NURSING PROCESS
  3728. ♦ ASSESSMENT
  3729. ♦ NURSING DIAGNOSES
  3730. ♦ PLANNING
  3731. Goals
  3732. Outcome Criteria
  3733. ♦ IMPLEMENTATION
  3734. ♦ EVALUATION
  3735. Patient Teaching Tips
  3736. Points to Remember
  3737. NCLEX Examination Review Questions
  3738. Critical Thinking Activities
  3739. CHAPTER 44 Antiinflammatory, Antirheumatic, and Related Drugs
  3740. Objectives
  3741. e-Learning Activities
  3742. Companion CD
  3743. Evolve Website (http://evolve.elsevier.com/Lilley)
  3744. Drug Profiles
  3745. Glossary
  3746. CASE STUDY
  3747. Postoperative Pain
  3748. ARACHIDONIC ACID PATHWAY
  3749. NONSTEROIDAL ANTIINFLAMMATORY DRUGS
  3750. Mechanism of Action and Drug Effects
  3751. FIGURE 44-1 Arachidonic acid pathway.
  3752. Box 44-1 Chemical Categories of NSAIDs
  3753. Acetic Acids
  3754. Carboxylic Acids
  3755. Acetylated
  3756. Nonacetylated
  3757. COX-2 Inhibitors
  3758. Fenamic Acids
  3759. Napthylalkanones (Nonacidic)
  3760. Oxicams
  3761. Propionic Acids
  3762. Box 44-2 NSAIDs: FDA-Approved Indications
  3763. Indications
  3764. Table 44-1 Suggested NSAIDs for Patients with Various Medical Conditions
  3765. Contraindications
  3766. Adverse Effects
  3767. Table 44-2 NSAIDs: Adverse Effects
  3768. Toxicity and Management of Overdose
  3769. Table 44-3 Acute or Chronic Salicylate Intoxication: Signs and Symptoms
  3770. Table 44-4 Acute Salicylate Intoxication: Treatment
  3771. Table 44-5 Acute Salicylate Intoxication: Treatment Goals
  3772. Table 44-6 Salicylates and Other NSAIDs: Drug Interactions
  3773. Interactions
  3774. DOSAGES
  3775. Most Commonly Used NSAIDs
  3776. Dosages
  3777. Drug Profiles
  3778. Nonsteroidal Antiinflammatory Drugs
  3779. Acetic Acids
  3780. ▸ aspirin
  3781. Pharmacokinetics
  3782. ▸ indomethacin
  3783. Pharmacokinetics
  3784. Propionic Acids
  3785. ▸ ibuprofen
  3786. Pharmacokinetics
  3787. Pyrrolizine Carboxylic Acids
  3788. ▸ ketorolac
  3789. Pharmacokinetics
  3790. COX-2 Inhibitors
  3791. ▸ celecoxib
  3792. Pharmacokinetics
  3793. ENOLIC ACIDS, FENAMIC ACIDS, AND NONACIDIC COMPOUNDS
  3794. ANTIRHEUMATIC DRUGS
  3795. FIGURE 44-2 Uric acid production. XO, Xanthine oxidase.
  3796. Drug Profiles
  3797. Antigout Drugs
  3798. ▸ allopurinol
  3799. colchicine
  3800. probenecid and sulfinpyrazone
  3801. Antirheumatoid Arthritis Drugs
  3802. auranofin
  3803. aurothioglucose and gold sodium thiomalate
  3804. leflunomide
  3805. ♦ NURSING PROCESS
  3806. ♦ ASSESSMENT
  3807. Herbal Therapies and Dietary Supplements
  3808. Glucosamine and Chondroitin
  3809. Overview
  3810. Common Uses
  3811. Adverse Effects
  3812. Potential Drug Interactions
  3813. Contraindications
  3814. ♦ NURSING DIAGNOSES
  3815. ♦ PLANNING
  3816. Goals
  3817. Outcome Criteria
  3818. ♦ IMPLEMENTATION
  3819. Lifespan Considerations: The Pediatric Patient
  3820. Reye’s Syndrome
  3821. Signs and Symptoms
  3822. Medical Management
  3823. Nursing Management
  3824. ♦ EVALUATION
  3825. Patient Teaching Tips
  3826. Points to Remember
  3827. NCLEX Examination Review Questions
  3828. Critical Thinking Activities
  3829. PART 8 Immune and Biologic Modifiers and Chemotherapeutic Drugs
  3830. Immune and Biologic Modifiers and Chemotherapeutic Drugs
  3831. STUDY SKILLS TIPS
  3832. TIME MANAGEMENT
  3833. EVALUATE PRIOR PERFORMANCE
  3834. What Type of Errors Did I Make?
  3835. Did I Have Trouble with Questions That Required Mastery of Terminology?
  3836. Did I Miss Concept Questions?
  3837. Did I Make Errors Because I Did not Know the Material?
  3838. ANTICIPATE THE TEST
  3839. PLAN FOR DISTRIBUTED STUDY
  3840. CHAPTER 45 Immunosuppressant Drugs
  3841. Objectives
  3842. e-Learning Activities
  3843. Companion CD
  3844. evolve Website (http://evolve.elsevier.com/Lilley)
  3845. Drug Profiles
  3846. Glossary
  3847. IMMUNOSUPPRESSANT DRUGS
  3848. Mechanism of Action and Drug Effects
  3849. Indications
  3850. Table 45-1 Classification, Mechanisms of Action, and Indications for Available Immunosuppressant Drugs
  3851. Contraindications
  3852. Adverse Effects
  3853. Table 45-2 Selected Immunosuppressant Drugs: Common Adverse Effects
  3854. Interactions
  3855. Dosages
  3856. DOSAGES
  3857. Selected Immunosuppressant Drugs
  3858. Drug Profiles
  3859. ▸ azathioprine and mycophenolate mofetil
  3860. Pharmacokinetics (azathioprine)
  3861. Pharmacokinetics (mycophenolate mofetil)
  3862. basiliximab and daclizumab
  3863. Pharmacokinetics(basiliximab)
  3864. Pharmacokinetics(daclizumab)
  3865. ▸ cyclosporine
  3866. Pharmacokinetics*
  3867. glatiramer acetate
  3868. ▸ muromonab-CD3
  3869. Pharmacokinetics
  3870. sirolimus and tacrolimus
  3871. Pharmacokinetics(sirolimus)
  3872. Pharmacokinetics(sirolimus)
  3873. ♦ NURSING PROCESS
  3874. ♦ ASSESSMENT
  3875. ♦ NURSING DIAGNOSES
  3876. ♦ PLANNING
  3877. Goals
  3878. Outcome Criteria
  3879. ♦ IMPLEMENTATION
  3880. ♦ EVALUATION
  3881. Patient Teaching Tips
  3882. Points to Remember
  3883. NCLEX Examination Review Questions
  3884. Critical Thinking Activities
  3885. CHAPTER 46 Immunizing Drugs and Biochemical Terrorism
  3886. Objectives
  3887. e-Learning Activities
  3888. Companion CD
  3889. Evolve Website (http://evolve.elsevier.com/Lilley)
  3890. Drug Profiles
  3891. Glossary
  3892. IMMUNITY AND IMMUNIZATION
  3893. Table 46-1 Active Versus Passive Immunization
  3894. ACTIVE IMMUNIZATION
  3895. Toxoids
  3896. Vaccines
  3897. PASSIVE IMMUNIZATION
  3898. Box 46-1 Available Immunizing Drugs
  3899. Passively Immunizing Drugs
  3900. Actively Immunizing Drugs
  3901. FIGURE 46-1 Recommended childhood immunization schedule. ACIP, Advisory Committee on Immunization Practices; DTP, diphtheria, tetanus, and pertussis vaccine; HBsAG, hepatitis B surface antigen; Tdap, tetanus and diphtheria toxoids and acellular pertussis vaccine. (From Centers for Disease Control and Prevention, National Immunization Program: Recommended childhood and adolescent immunization schedule: United States: 2006. Available at www.cdc.gov/nip/recs/child-schedule-color-print.pdf.)
  3902. IMMUNIZING DRUGS
  3903. Mechanism of Action and Drug Effects
  3904. Indications
  3905. Contraindications
  3906. Adverse Effects
  3907. Table 46-2 Immunizing Drugs: Minor and Severe Adverse Effects
  3908. Interactions
  3909. Table 46-3 Vaccine Injury Table
  3910. Dosages
  3911. Drug Profiles
  3912. Active Immunizing Drugs
  3913. diphtheria and tetanus toxoids, and acellular pertussis vaccine (adsorbed)
  3914. Haemophilus Influenzae Type b conjugate vaccine
  3915. ▸ hepatitis B virus vaccine (inactivated)
  3916. ▸ influenza virus vaccine
  3917. DOSAGES
  3918. Selected Immunizing Drugs
  3919. ▸ measles, mumps, and rubella virus vaccine (live)
  3920. ▸ pneumococcal vaccine, polyvalent and seven-valent
  3921. ▸ poliovirus vaccine (inactivated)
  3922. rabies virus vaccine
  3923. ▸ varicella virus vaccine
  3924. Passive Immunizing Drugs
  3925. ▸ hepatitis B immunoglobulin
  3926. ▸ immunoglobulin
  3927. Box 46-2 Current FDA-Approved Uses of Immunoglobulins*
  3928. Rh0(D) immunoglobulin
  3929. rabies immunoglobulin
  3930. tetanus immunoglobulin
  3931. varicella-zoster immunoglobulin
  3932. BIOLOGIC AND CHEMICAL TERRORISM
  3933. ANTHRAX
  3934. Table 46-4 Illnesses Caused by CDC Category “A” Possible Bioterrorism Agents*
  3935. Table 46-5 Possible Chemical Terrorism Agents
  3936. ♦ NURSING PROCESS
  3937. ♦ ASSESSMENT
  3938. ♦ NURSING DIAGNOSES
  3939. ♦ PLANNING
  3940. Goals
  3941. Outcome Criteria
  3942. ♦ IMPLEMENTATION
  3943. ♦ EVALUATION
  3944. Patient Teaching Tips
  3945. Points to Remember
  3946. NCLEX Examination Review Questions
  3947. Critical Thinking Activities
  3948. CHAPTER 47 Antineoplastic Drugs Part 1: Cancer Overview and Cell Cycle–Specific Drugs
  3949. Objectives
  3950. e-Learning Activities
  3951. Companion CD
  3952. evolve Website (http://evolve.elsevier.com/Lilley)
  3953. Drug Profiles
  3954. Glossary
  3955. FIGURE 47-1 Schematic model of multistep carcinogenesis. Genetic change refers to events such as the activation of protooncogenes or drug-resistance genes or the inactivation of tumor suppressor genes, antimetastasis genes, or apoptosis (normal cell death). Genetic change may be relatively minimal, as with the translocations seen in various leukemias, or it may involve multiple sequential genetic alterations, as exemplified by the development of colon cancer. (From Haskell CM: Cancer treatment, ed 5, Philadelphia, 2001, Saunders.)
  3956. Table 47-1 Tumor Characteristics: Benign and Malignant
  3957. Table 47-2 Tumor Classification Based on Specific Tissue of Origin
  3958. Table 47-3 Paraneoplastic Syndromes Associated with Some Cancers
  3959. ETIOLOGY OF CANCER
  3960. AGE- AND SEX-RELATED DIFFERENCES
  3961. Table 47-4 Cancer: Proposed Etiologic Factors
  3962. GENETIC AND ETHNIC FACTORS
  3963. ONCOGENIC VIRUSES
  3964. OCCUPATIONAL AND ENVIRONMENTAL CARCINOGENS
  3965. RADIATION
  3966. IMMUNOLOGIC FACTORS
  3967. Table 47-5 Common Names for Selected Cell Cycle–Specific Antineoplastic Drugs
  3968. CANCER DRUG NOMENCLATURE
  3969. CELL GROWTH CYCLE
  3970. Table 47-6 Cell Cycle Phases
  3971. FIGURE 47-2 General phase of the cell cycle in which the various cell cycle–specific chemotherapeutic drugs have their greatest proportionate kill of cancer cells.
  3972. DRUG THERAPY
  3973. FIGURE 47-3 Gompertzian tumor growth curve showing the relationship between tumor size and clinical status. (From Lehne RA: Pharmacology for nursing care, ed 6, St Louis, 2007, Saunders.)
  3974. FIGURE 47-4 Relationship of tumor burden to treatment strategies and outcome with systemic chemotherapy. Human tumors grow in accordance with the Gompertz curve (dashed line), with a decreasing doubling time as tumor burden increases. Treatment interventions relate to tumor type and extent of disease. A, Surgery followed by pulse courses of adjuvant chemotherapy. Combined modality has curative potential with the addition of chemotherapy after surgery. B, Systemic chemotherapy for stage III Hodgkin’s disease. Cure is possible with prolonged administration of combination chemotherapy. C, Palliative chemotherapy for advanced non–small cell cancer. The patient’s tumor burden is too great, and the potency of the drugs for this specific form of cancer too inadequate because of the development of drug resistance, to allow cure. (Modified from Salmon SE, Sartorelli AC: Cancer chemotherapy. In Katzung BG, editor: Basic and clinical pharmacology, ed 4, Norwalk, Conn, 1989, Appleton & Lange, p. 685.)
  3975. Box 47-1 Relative Emetic Potential of Selected Antineoplastic Drugs*
  3976. Low (Less Than 10% to 30%)
  3977. Moderate (30% to 60%)
  3978. High (60% to More Than 90%)
  3979. CELL CYCLE–SPECIFIC ANTINEOPLASTIC DRUGS
  3980. ANTIMETABOLITES
  3981. Mechanism of Action and Drug Effects
  3982. Folic Acid Antagonism
  3983. Purine Antagonism
  3984. Pyrimidine Antagonism
  3985. Indications
  3986. Adverse Effects
  3987. Table 47-7 Common Manifestations of Antineoplastic Toxicity
  3988. Table 47-8 Selected Antimetabolites: Common Drug-Specific Adverse Effects
  3989. Table 47-9 Selected Antimetabolites: Common Drug Interactions
  3990. Interactions
  3991. Dosages
  3992. Drug Profiles
  3993. Folate Antagonists
  3994. ▸ methotrexate
  3995. Purine Antagonists
  3996. cladribine
  3997. fludarabine
  3998. Pyrimidine Antagonists
  3999. capecitabine
  4000. DOSAGES
  4001. Selected Antimetabolites
  4002. ▸ cytarabine
  4003. fluorouracil
  4004. gemcitabine
  4005. MITOTIC INHIBITORS
  4006. Mechanism of Action and Drug Effects
  4007. Indications
  4008. Adverse Effects
  4009. Table 47-10 Selected Mitotic Inhibitors: Adverse Effects
  4010. Toxicity: Management of Extravasation
  4011. Interactions
  4012. Dosages
  4013. Drug Profiles
  4014. ▸ etoposide
  4015. ▸ paclitaxel
  4016. Table 47-11 Mitotic Inhibitor Extravasation: Listed Specific Antidotes
  4017. Table 47-12 Selected Mitotic Inhibitors: Common Drug Interactions
  4018. DOSAGES
  4019. Selected Mitotic Inhibitors
  4020. ▸ vincristine
  4021. TOPOISOMERASE I INHIBITORS
  4022. Mechanism of Action and Drug Effects
  4023. Indications
  4024. Adverse Effects
  4025. Table 47-13 Irinotecan: Common Drug Interactions
  4026. Interactions
  4027. Dosages
  4028. Drug Profiles
  4029. irinotecan
  4030. topotecan
  4031. ANTINEOPLASTIC ENZYMES
  4032. DOSAGES
  4033. Selected Topoisomerase I Inhibitors
  4034. Indications
  4035. Adverse Effects
  4036. Table 47-14 Selected Antineoplastic Enzymes: Common Drug Interactions
  4037. Interactions
  4038. Dosages
  4039. Drug Profiles
  4040. ▸ asparaginase
  4041. pegaspargase
  4042. DOSAGES
  4043. Selected Antineoplastic Enzymes
  4044. ♦ NURSING PROCESS
  4045. ♦ ASSESSMENT
  4046. LABORATORY VALUES RELATED TO DRUG THERAPY
  4047. Antineoplastic Therapy: Rationales for Assessment and Monitoring of Blood Cell Counts
  4048. Box 47-2 Effects of Antineoplastic Drugs on Normal Cells and Related Adverse Effects
  4049. ♦ NURSING DIAGNOSES
  4050. ♦ PLANNING
  4051. Goals
  4052. Outcome Criteria
  4053. ♦ IMPLEMENTATION
  4054. CASE STUDY
  4055. Facing Chemotherapy
  4056. ♦ EVALUATION
  4057. Patient Teaching Tips
  4058. Points to Remember
  4059. NCLEX Examination Review Questions
  4060. Critical Thinking Activities
  4061. CHAPTER 48 Antineoplastic Drugs Part 2: Cell Cycle–Nonspecific and Miscellaneous Drugs
  4062. Objectives
  4063. e-Learning Activities
  4064. Companion CD
  4065. Evolve Website (http://evolve.elsevier.com/Lilley)
  4066. Drug Profiles
  4067. Glossary
  4068. Table 48-1 Common Names for Selected Antineoplastic Drugs
  4069. CELL CYCLE–NONSPECIFIC ANTINEOPLASTIC DRUGS
  4070. ALKYLATING DRUGS
  4071. Mechanism of Action and Drug Effects
  4072. Indications
  4073. Adverse Effects
  4074. Interactions
  4075. FIGURE 48-1 Deoxyribonucleic acid (DNA) double helix. A, Diagrammatic model of the helical structure, showing its dimensions, the major and minor grooves, the periodicity of the bases, and the antiparallel orientation of the backbone chains (represented by ribbons). The base pairs (represented by rods) are perpendicular to the axis and lie stacked one on another. B, The chemical structure of the backbone and bases of DNA, showing the sugar-phosphate linkages of the backbone and the hydrogen bonding between the base pairs. There are two hydrogen bonds between adenine and thymine, and three between cytosine and guanine. (From Dorland’s illustrated medical dictionary, ed 30, Philadelphia, 2003, Saunders.)
  4076. FIGURE 48-2 Organization of deoxyribonucleic acid (DNA) and site of action of alkylating drugs.
  4077. Table 48-2 Commonly Used Alkylating Drugs: Severe Adverse Effects
  4078. Box 48-1 Extravasation of Antineoplastics
  4079. Table 48-3 Alkylating Drug Extravasation: Specific Antidotes
  4080. Dosages
  4081. Drug Profiles
  4082. ▸ cisplatin
  4083. ▸ cyclophosphamide
  4084. DOSAGES
  4085. Selected Alkylating Drugs
  4086. ▸ mechlorethamine
  4087. CYTOTOXIC ANTIBIOTICS
  4088. Preventing Medication Errors
  4089. Sound-Alike Drugs: “Rubicins”
  4090. Mechanism of Action and Drug Effects
  4091. Table 48-4 Cytotoxic Antibiotics: Severe Adverse Effects
  4092. Box 48-2 Treatment of Doxorubicin Extravasation
  4093. Indications
  4094. Adverse Effects
  4095. Toxicity and Management of Overdose
  4096. Interactions
  4097. Dosages
  4098. DOSAGES
  4099. Selected Cytotoxic Antibiotics
  4100. Drug Profiles
  4101. ▸ doxorubicin
  4102. mitoxantrone
  4103. MISCELLANEOUS ANTINEOPLASTICS
  4104. Drug Profiles
  4105. bevacizumab
  4106. hydroxyurea
  4107. imatinib
  4108. mitotane
  4109. octreotide
  4110. HORMONAL ANTINEOPLASTICS
  4111. RADIOPHARMACEUTICALS AND RELATED ANTINEOPLASTICS
  4112. CYTOPROTECTIVE DRUGS AND MISCELLANEOUS TOXICITY INHIBITORS
  4113. Box 48-3 Concerns in the Handling and Administration of Vesicant Antineoplastic Drugs
  4114. ♦ NURSING PROCESS
  4115. ♦ ASSESSMENT
  4116. LABORATORY VALUES RELATED TO DRUG THERAPY
  4117. Antineoplastics
  4118. ♦ NURSING DIAGNOSES
  4119. ♦ PLANNING
  4120. Goals
  4121. Outcome Criteria
  4122. ♦ IMPLEMENTATION
  4123. ♦ EVALUATION
  4124. Box 48-4 Indications of an Oncologic Emergency
  4125. Patient Teaching Tips
  4126. Points to Remember
  4127. NCLEX Examination Review Questions
  4128. Critical Thinking Activities
  4129. CHAPTER 49 Biologic Response–Modifying Drugs
  4130. Objectives
  4131. e-Learning Activities
  4132. Companion CD
  4133. evolve Website (http://evolve.elsevier.com/Lilley)
  4134. Drug Profiles
  4135. Glossary
  4136. OVERVIEW OF IMMUNOMODULATORS
  4137. IMMUNE SYSTEM
  4138. Humoral Immune System
  4139. Cell-Mediated Immune System
  4140. FIGURE 49-1 Cells of the humoral (antibody-mediated) immune system. Ab, Antibody; Ag, antigen; Ig, immunoglobulin.
  4141. FIGURE 49-2 Cells of the cellular immune system.
  4142. Box 49-1 Biologic Response Modifiers
  4143. Hematopoietic Drugs
  4144. Colony-Stimulating Factors
  4145. Other
  4146. Immunomodulating Drugs
  4147. Interferons
  4148. Monoclonal Antibodies
  4149. Interleukin Receptor Agonists and Antagonists
  4150. Miscellaneous Immunomodulators
  4151. HEMATOPOIETIC DRUGS
  4152. Mechanism of Action and Drug Effects
  4153. Indications
  4154. Contraindications
  4155. Table 49-1 Hematopoietic Drugs: Common Adverse Effects
  4156. Adverse Effects
  4157. Interactions
  4158. Dosages
  4159. Drug Profiles
  4160. ▸ epoetin alfa
  4161. DOSAGES
  4162. Hematopoietic Drugs
  4163. Pharmacokinetics
  4164. ▸ filgrastim
  4165. Pharmacokinetics
  4166. ▸ sargramostim
  4167. Pharmacokinetics
  4168. ▸ oprelvekin
  4169. Pharmacokinetics
  4170. INTERFERONS
  4171. Mechanism of Action and Drug Effects
  4172. Indications
  4173. Contraindications
  4174. Adverse Effects
  4175. Interactions
  4176. Table 49-2 Interferons: Adverse Effects
  4177. Dosages
  4178. Drug Profiles
  4179. Interferon Alfa Products
  4180. ▸ interferon alfa-2a, interferon alfa-2b, interferon alfa-n3, interferon alfacon-1, peginterferon alfa-2a, peginterferon alfa-2b
  4181. DOSAGES
  4182. Interferons
  4183. Interferon Beta Products
  4184. ▸ interferon beta-1a
  4185. Interferon Gamma Products
  4186. interferon gamma-1b
  4187. MONOCLONAL ANTIBODIES
  4188. Mechanism of Action, Drug Effects, and Indications
  4189. Contraindications
  4190. Table 49-3 Common Adverse Effects Associated with Specific Immunomodulating Drugs
  4191. Adverse Effects
  4192. Interactions
  4193. Dosages
  4194. Drug Profiles
  4195. adalimumab
  4196. DOSAGES
  4197. Monoclonal Antibodies
  4198. alemtuzumab
  4199. bevacizumab
  4200. cetuximab
  4201. gemtuzumab ozogamicin
  4202. ibritumomab tiuxetan
  4203. infliximab
  4204. natalizumab
  4205. ▸ rituximab
  4206. tositumomab and iodine I 131 tositumomab
  4207. trastuzumab
  4208. INTERLEUKINS AND RELATED DRUGS
  4209. Mechanism of Action and Drug Effects
  4210. Box 49-2 Interleukin-2: Drug Effects
  4211. Modulating Effects
  4212. Enhancing Effects
  4213. Indications
  4214. Contraindications
  4215. Adverse Effects
  4216. Interactions
  4217. DOSAGES
  4218. Interleukins and Related Drugs
  4219. Dosages
  4220. Drug Profiles
  4221. ▸ aldesleukin
  4222. denileukin diftitox
  4223. anakinra
  4224. MISCELLANEOUS IMMUNOMODULATING DRUGS
  4225. ♦ NURSING PROCESS
  4226. ♦ ASSESSMENT
  4227. Table 49-4 Miscellaneous Immunomodulating Drugs
  4228. ♦ NURSING DIAGNOSES
  4229. PLANNING
  4230. Goals
  4231. LEGAL AND ETHICAL PRINCIPLES
  4232. The Nurse and Patient Care
  4233. Outcome Criteria
  4234. ♦ IMPLEMENTATION
  4235. ♦ EVALUATION
  4236. Patient Teaching Tips
  4237. Points to Remember
  4238. NCLEX Examination Review Questions
  4239. Critical Thinking Activities
  4240. CHAPTER 50 Gene Therapy and Pharmacogenomics
  4241. Objectives
  4242. e-Learning Activities
  4243. Companion CD
  4244. evolve Website (http://evolve.elsevier.com/Lilley)
  4245. Glossary
  4246. INTRODUCTION
  4247. BASIC PRINCIPLES OF GENETIC INHERITANCE
  4248. DISCOVERY, STRUCTURE, AND FUNCTION OF DNA
  4249. Protein Synthesis
  4250. The Human Genome Project
  4251. GENE THERAPY
  4252. Regulatory and Ethical Issues Regarding Gene Therapy
  4253. FIGURE 50-1 Gene therapy for adenosine deaminase (ADA) deficiency attempts to correct this immunodeficiency state. The viral vector containing the therapeutic gene is inserted into the patient’s lymphocytes. These cells can then make the ADA enzyme. (From Lewis SM, Heitkemper MM, Dirksen SR: Medical-surgical nursing: assessment and management of clinical problems, ed 6, St Louis, 2004, Mosby.)
  4254. PHARMACOGENOMICS
  4255. Table 50-1 Clinical Applications of Pharmacogenomics
  4256. SUMMARY
  4257. Box 50-1 Application of Genetics, Genomics, and Pharmacogenomics in Nursing and Health Care
  4258. Points to Remember
  4259. NCLEX Examination Review Questions
  4260. Critical Thinking Activities
  4261. PART 9 Drugs Affecting the Gastrointestinal System and Nutrition
  4262. Drugs Affecting the Gastrointestinal System and Nutrition
  4263. STUDY SKILLS TIPS
  4264. ACTIVE QUESTIONING
  4265. WHAT ARE THE RIGHT QUESTIONS?
  4266. KINDS OF QUESTIONS
  4267. Literal Questions
  4268. Interpretive Questions
  4269. QUESTIONING APPLICATION
  4270. CHAPTER 51 Acid-Controlling Drugs
  4271. Objectives
  4272. e-Learning Activities
  4273. Companion CD
  4274. evolve Website (http://evolve.elsevier.com/Lilley)
  4275. Drug Profiles
  4276. Glossary
  4277. ACID-RELATED PATHOPHYSIOLOGY
  4278. FIGURE 51-1 The three zones of the stomach and the associated glands.
  4279. FIGURE 51-2 Parietal cell stimulation and secretion. ADP, Adenosine diphosphate; ATP, adenosine triphosphate; ATPase, adenosine triphosphatase; cAMP, cyclic adenosine monophosphate.
  4280. Table 51-1 Current FDA-Approved Regimens for Eradication of Helicobacter pylori
  4281. ANTACIDS
  4282. Mechanism of Action and Drug Effects
  4283. Indications
  4284. Contraindications
  4285. Adverse Effects
  4286. Interactions
  4287. Box 51-1 Nursing Concerns for Patients Taking Antacids
  4288. Dosages
  4289. Drug Profiles
  4290. Antacids, general
  4291. DOSAGES
  4292. Selected Antacid Drugs*
  4293. Box 51-2 Antacids
  4294. Antacids: Salt Content
  4295. Commonly Available Antacid Products
  4296. Magnesium-Containing Antacids
  4297. Aluminum-Containing Antacids
  4298. Calcium-Containing Antacids
  4299. Sodium-Containing Antacids
  4300. H2 ANTAGONISTS
  4301. Mechanism of Action and Drug Effects
  4302. Indications
  4303. Contraindications
  4304. Adverse Effects
  4305. Interactions
  4306. Table 51-2 H2 Antagonists: Adverse Effects
  4307. Dosages
  4308. Drug Profiles
  4309. ▸ cimetidine
  4310. DOSAGES
  4311. Selected H2 Antagonists
  4312. Pharmacokinetics
  4313. PROTON PUMP INHIBITORS
  4314. Mechanism of Action and Drug Effects
  4315. Indications
  4316. Contraindications
  4317. Adverse Effects
  4318. Interactions
  4319. Dosages
  4320. DOSAGES
  4321. Selected Proton Pump Inhibitors
  4322. Drug Profiles
  4323. ▸ omeprazole
  4324. Pharmacokinetics
  4325. MISCELLANEOUS ACID-CONTROLLING DRUGS
  4326. Drug Profiles
  4327. ▸ sucralfate
  4328. Pharmacokinetics
  4329. misoprostol
  4330. Pharmacokinetics
  4331. simethicone
  4332. ♦ NURSING PROCESS
  4333. ♦ ASSESSMENT
  4334. ♦ NURSING DIAGNOSES
  4335. ♦ PLANNING
  4336. Goals
  4337. Outcome Criteria
  4338. ♦ IMPLEMENTATION
  4339. CASE STUDY
  4340. Gastroesophageal Reflux Disease
  4341. ♦ EVALUATION
  4342. Patient Teaching Tips
  4343. Points to Remember
  4344. NCLEX Examination Review Questions
  4345. Critical Thinking Activities
  4346. CHAPTER 52 Antidiarrheals and Laxatives
  4347. Objectives
  4348. e-Learning Activities
  4349. Companion CD
  4350. evolve Website (http://evolve.elsevier.com/Lilley)
  4351. Drug Profiles
  4352. Glossary
  4353. ANTIDIARRHEALS
  4354. Mechanism of Action and Drug Effects
  4355. Table 52-1 Antidiarrheals: Drug Categories and Selected Drugs
  4356. Indications
  4357. Contraindications
  4358. Adverse Effects
  4359. Interactions
  4360. Table 52-2 Selected Antidiarrheals: Adverse Effects
  4361. Life Span Considerations: The Pediatric Patient
  4362. Antidiarrheal Preparations
  4363. Dosages
  4364. Drug Profiles
  4365. Adsorbents
  4366. bismuth subsalicylate
  4367. Pharmacokinetics
  4368. Anticholinergics
  4369. belladonna alkaloid combinations
  4370. DOSAGES
  4371. Selected Antidiarrheal Drugs
  4372. Pharmacokinetics
  4373. Opiates
  4374. ▸ diphenoxylate with atropine
  4375. Pharmacokinetics*
  4376. ▸ loperamide
  4377. Pharmacokinetics
  4378. Intestinal Flora Modifiers
  4379. Lactobacillus acidophilus
  4380. LAXATIVES
  4381. Table 52-3 Causes of Constipation
  4382. Mechanism of Action and Drug Effects
  4383. Table 52-4 Laxatives: Drug Categories and Selected Drugs
  4384. Table 52-5 Laxatives: Drug Effects
  4385. Indications
  4386. Table 52-6 Laxatives: Indications
  4387. Contraindications
  4388. Adverse Effects
  4389. Interactions
  4390. Table 52-7 Laxatives: Adverse Effects
  4391. Dosages
  4392. Drug Profiles
  4393. Bulk-Forming Laxatives
  4394. methylcellulose
  4395. Pharmacokinetics
  4396. ▸ psyllium
  4397. Pharmacokinetics
  4398. Emollient Laxatives
  4399. ▸ docusate salts
  4400. Pharmacokinetics
  4401. mineral oil
  4402. Pharmacokinetics
  4403. Hyperosmotic Laxatives
  4404. ▸ glycerin
  4405. Pharmacokinetics
  4406. DOSAGES
  4407. Selected Laxatives
  4408. ▸ lactulose
  4409. Pharmacokinetics
  4410. polyethylene glycol 3350
  4411. Pharmacokinetics
  4412. Box 52-1 Saline Laxatives
  4413. Magnesium Laxatives
  4414. Sulfate
  4415. Hydroxide
  4416. Citrate
  4417. Sodium Laxatives
  4418. Saline Laxatives
  4419. magnesium salts
  4420. Pharmacokinetics
  4421. Stimulant Laxatives
  4422. ▸ senna
  4423. Pharmacokinetics
  4424. Drugs for Irritable Bowel Syndrome
  4425. DOSAGES
  4426. Drugs for Irritable Bowel Syndrome
  4427. ♦ NURSING PROCESS
  4428. ♦ ASSESSMENT
  4429. CASE STUDY
  4430. Constipation
  4431. ♦ NURSING DIAGNOSES
  4432. ♦ PLANNING
  4433. Goals
  4434. Outcome Criteria
  4435. ♦ IMPLEMENTATION
  4436. ♦ EVALUATION
  4437. Patient Teaching Tips
  4438. Points to Remember
  4439. NCLEX Examination Review Questions
  4440. Critical Thinking Activities
  4441. CHAPTER 53 Antiemetic and Antinausea Drugs
  4442. Objectives
  4443. e-Learning Activities
  4444. Companion CD
  4445. evolve Website (http://evolve.elsevier.com/Lilley)
  4446. Drug Profiles
  4447. Glossary
  4448. NAUSEA AND VOMITING
  4449. ANTIEMETIC DRUGS
  4450. Life Span Considerations: The Pediatric Patient
  4451. Syrup of Ipecac
  4452. Mechanism of Action and Drug Effects
  4453. Table 53-1 Neurotransmitters Involved in Nausea and Vomiting
  4454. FIGURE 53-1 The various pathways and areas in the body sending signals to the vomiting center.
  4455. Table 53-2 Antiemetic Drugs: Common Drug Categories
  4456. Indications
  4457. Contraindications
  4458. Adverse Effects
  4459. Interactions
  4460. Dosages
  4461. Drug Profiles
  4462. FIGURE 53-2 Sites of action of selected antinausea drugs. THC, Tetrahydrocannabinol.
  4463. Table 53-3 Antiemetic Drugs: Mechanisms of Action
  4464. Anticholinergics
  4465. scopolamine
  4466. Table 53-4 Antiemetic Drugs: Indications
  4467. Pharmacokinetics
  4468. Table 53-5 Antinausea Drugs: Adverse Effects
  4469. Antihistamines
  4470. ▸ meclizine
  4471. Pharmacokinetics
  4472. Neuroleptics
  4473. ▸ prochlorperazine
  4474. Pharmacokinetics
  4475. Prokinetics
  4476. ▸ metoclopramide
  4477. Pharmacokinetics
  4478. Serotonin Blockers
  4479. ▸ ondansetron
  4480. Pharmacokinetics
  4481. Tetrahydrocannabinoids
  4482. dronabinol
  4483. DOSAGES
  4484. Selected Antitubercular Drugs
  4485. Pharmacokinetics
  4486. Miscellaneous Antinausea Drugs
  4487. phosphorated carbohydrate solution
  4488. aprepitant
  4489. CASE STUDY
  4490. Nausea and Chemotherapy
  4491. ♦ NURSING PROCESS
  4492. ♦ ASSESSMENT
  4493. HERBAL THERAPIES AND DIETARY SUPPLEMENTS
  4494. Ginger (Zingiber officinale)
  4495. Overview
  4496. Common Uses
  4497. Adverse Effects
  4498. Potential Drug Interactions
  4499. Contraindications
  4500. ♦ NURSING DIAGNOSES
  4501. ♦ PLANNING
  4502. Goals
  4503. Outcome Criteria
  4504. ♦ IMPLEMENTATION
  4505. EVALUATION
  4506. Patient Teaching Tips
  4507. Points to Remember
  4508. NCLEX Examination Review Questions
  4509. Critical Thinking Activities
  4510. CHAPTER 54 Vitamins and Minerals
  4511. Objectives
  4512. e-Learning Activities
  4513. Companion CD
  4514. evolve Website (http://evolve.elsevier.com/Lilley)
  4515. Drug Profiles
  4516. Glossary
  4517. VITAMINS
  4518. Table 54-1 Fat- and Water-Soluble Vitamins
  4519. FAT-SOLUBLE VITAMINS
  4520. VITAMIN A
  4521. Mechanism of Action and Drug Effects
  4522. Table 54-2 Food Sources for Selected Nutrients
  4523. Table 54-3 Vitamin A: Adverse Effects
  4524. Indications
  4525. Contraindications
  4526. Adverse Effects
  4527. Toxicity and Management of Overdose
  4528. Interactions
  4529. Dosages
  4530. Drug Profiles
  4531. vitamin A
  4532. Pharmacokinetics
  4533. VITAMIN D
  4534. Mechanism of Action and Drug Effects
  4535. Indications
  4536. Contraindications
  4537. Adverse Effects
  4538. DOSAGES
  4539. Selected Vitamins
  4540. Table 54-4 Vitamin D: Adverse Effects
  4541. Toxicity and Management of Overdose
  4542. Interactions
  4543. Dosages
  4544. Drug Profiles
  4545. calcifediol
  4546. Pharmacokinetics
  4547. calcitriol
  4548. Pharmacokinetics
  4549. dihydrotachysterol
  4550. Pharmacokinetics
  4551. ergocalciferol
  4552. Pharmacokinetics
  4553. VITAMIN E
  4554. Mechanism of Action and Drug Effects
  4555. Indications
  4556. Table 54-5 Vitamin E: Adverse Effects
  4557. Contraindications
  4558. Adverse Effects
  4559. Dosages
  4560. Drug Profiles
  4561. vitamin E
  4562. Pharmacokinetics
  4563. VITAMIN K
  4564. Mechanism of Action and Drug Effects
  4565. Indications
  4566. Contraindications
  4567. Adverse Effects
  4568. Toxicity and Management of Overdose
  4569. Table 54-6 Vitamin K: Adverse Effects
  4570. Dosages
  4571. Drug Profiles
  4572. vitamin K1
  4573. Pharmacokinetics
  4574. WATER-SOLUBLE VITAMINS
  4575. Box 54-1 Water-Soluble Vitamins: Alternate Names
  4576. VITAMIN B1
  4577. Mechanism of Action and Drug Effects
  4578. Indications
  4579. Contraindications
  4580. Adverse Effects
  4581. Interactions
  4582. Dosages
  4583. Drug Profiles
  4584. thiamine
  4585. Pharmacokinetics
  4586. VITAMIN B2
  4587. Mechanism of Action and Drug Effects
  4588. Indications
  4589. Contraindications
  4590. Adverse Effects
  4591. Dosages
  4592. Drug Profiles
  4593. riboflavin
  4594. Pharmacokinetics
  4595. VITAMIN B3
  4596. Mechanism of Action and Drug Effects
  4597. FIGURE 54-1 Niacin, once in the body, is converted to nicotinamide adenosine dinucleotide (NAD) and nicotinamide adenosine dinucleotide (NADP), which are coenzymes needed for many metabolic processes.
  4598. Indications
  4599. Contraindications
  4600. Adverse Effects
  4601. Dosages
  4602. Table 54-7 Niacin: Adverse Effects
  4603. Drug Profiles
  4604. niacin
  4605. Pharmacokinetics
  4606. VITAMIN B6
  4607. Mechanism of Action and Drug Effects
  4608. Indications
  4609. Contraindications
  4610. Table 54-8 Pyridoxine: Adverse Effects
  4611. Adverse Effects
  4612. Interactions
  4613. Dosages
  4614. Drug Profiles
  4615. pyridoxine
  4616. Pharmacokinetics
  4617. VITAMIN B12
  4618. FIGURE 54-2 Cyanocobalamin is a required coenzyme for many body processes.
  4619. FIGURE 54-3 The oral absorption of cyanocobalamin requires the presence of the intrinsic factor secreted by gastric parietal cells.
  4620. Mechanism of Action and Drug Effects
  4621. Indications
  4622. Table 54-9 Cyanocobalamin: Adverse Effects
  4623. Contraindications
  4624. Adverse Effects
  4625. Interactions
  4626. Dosages
  4627. Drug Profiles
  4628. cyanocobalamin
  4629. Pharmacokinetics
  4630. VITAMIN C
  4631. Mechanism of Action and Drug Effects
  4632. Indications
  4633. Contraindications
  4634. Adverse Effects
  4635. Interactions
  4636. Dosages
  4637. Drug Profiles
  4638. ascorbic acid
  4639. Pharmacokinetics
  4640. MINERALS
  4641. FIGURE 54-4 When mineral compounds are dissolved in water, they separate into positively charged metabolic cations or negatively charged nonmetallic anions and electrolytes.
  4642. Table 54-10 Mineral Elements
  4643. CALCIUM
  4644. Table 54-11 Calcium Deficiency: Causes and Disorders
  4645. Mechanism of Action and Drug Effects
  4646. Indications
  4647. Table 54-12 Calcium Salts: Calcium Content
  4648. Table 54-13 Calcium Salts: Adverse Effects
  4649. Contraindications
  4650. Adverse Effects
  4651. Toxicity and Management of Overdose
  4652. Interactions
  4653. Drug Profiles
  4654. calcium
  4655. MAGNESIUM
  4656. Mechanism of Action and Drug Effects
  4657. Indications
  4658. Contraindications
  4659. Adverse Effects
  4660. Toxicity and Management of Overdose
  4661. Interactions
  4662. Drug Profiles
  4663. magnesium
  4664. PHOSPHORUS
  4665. Mechanism of Action and Drug Effects
  4666. Indications
  4667. Contraindications
  4668. Adverse Effects
  4669. Toxicity and Management of Overdose
  4670. Interactions
  4671. Drug Profiles
  4672. phosphorus
  4673. ZINC
  4674. ♦ NURSING PROCESS
  4675. ♦ ASSESSMENT
  4676. ♦ NURSING DIAGNOSES
  4677. ♦ PLANNING
  4678. Goals
  4679. Outcome Criteria
  4680. ♦ IMPLEMENTATION
  4681. CASE STUDY
  4682. Magnesium Sulfate Therapy
  4683. ♦ EVALUATION
  4684. Patient Teaching Tips
  4685. Points to Remember
  4686. NCLEX Examination Review Questions
  4687. Critical Thinking Activities
  4688. CHAPTER 55 Nutrition Supplements
  4689. Objectives
  4690. e-Learning Activities
  4691. Companion CD
  4692. evolve Website (http://evolve.elsevier.com/Lilley)
  4693. Drug Profiles
  4694. Glossary
  4695. ENTERAL NUTRITION
  4696. Mechanism of Action and Drug Effects
  4697. Indications
  4698. Contraindications
  4699. FIGURE 55-1 Tube feeding routes. (From Beare PG, Myers JL: Adult health nursing, ed 3, St Louis, 1998, Mosby.)
  4700. Table 55-1 Routes of Enteral Nutrition Delivery
  4701. Adverse Effects
  4702. Interactions
  4703. Box 55-1 Enteral Formulations
  4704. Box 55-2 Enteral Nutrition Supplements: Indications
  4705. Complete Nutrition Formulations (i.e., for General Nutrition Deficiencies)
  4706. Incomplete Nutrition Formulations (i.e., for Specific Nutrition Deficiencies)
  4707. Infant Nutrition Formulations
  4708. Dosages
  4709. Drug Profiles
  4710. Elemental Formulations
  4711. Polymeric Formulations
  4712. Modular Formulations
  4713. carbohydrate formulation
  4714. fat formulation
  4715. protein formulation
  4716. Altered Amino Acid Formulations
  4717. PARENTERAL NUTRITION
  4718. Table 55-2 Peripheral and Central Parenteral Nutrition: Characteristics
  4719. PERIPHERAL TOTAL PARENTERAL NUTRITION
  4720. Mechanism of Action and Drug Effects
  4721. Indications
  4722. Contraindications
  4723. Table 55-3 Amino Acids: Recommended Daily Dosage Guidelines
  4724. Adverse Effects
  4725. Dosages
  4726. Drug Profiles
  4727. Amino Acids
  4728. amino acids
  4729. Box 55-3 Enteral Formulations
  4730. Essential
  4731. Nonessential
  4732. Semiessential
  4733. FIGURE 55-2 One gram of dextrose, fat, or protein will provide varying amounts of energy as calories.
  4734. carbohydrates
  4735. fat
  4736. FIGURE 55-3 Lipid emulsions supply essential fatty acids and energy.
  4737. lipid emulsions
  4738. TRACE ELEMENTS
  4739. CENTRAL TOTAL PARENTERAL NUTRITION
  4740. Mechanism of Action and Drug Effects
  4741. Indications
  4742. Contraindications
  4743. Adverse Effects
  4744. Dosages
  4745. Drug Profiles
  4746. NURSING PROCESS
  4747. ♦ ASSESSMENT
  4748. ♦ NURSING DIAGNOSES
  4749. ♦ PLANNING
  4750. Goals
  4751. Outcome Criteria
  4752. ♦ IMPLEMENTATION
  4753. ♦ EVALUATION
  4754. Patient Teaching Tips
  4755. Points to Remember
  4756. NCLEX Examination Review Questions
  4757. Critical Thinking Activities
  4758. PART 10 Miscellaneous Therapeutics: Hematologic, Dermatologic, Ophthalmic, and Otic Drugs
  4759. Miscellaneous Therapeutics: Hematologic, Dermatologic, Ophthalmic, and Otic Drugs
  4760. STUDY SKILLS TIPS
  4761. TIME MANAGEMENT
  4762. Goal Statements
  4763. Action Planning
  4764. Action Steps Example
  4765. PURR
  4766. Prepare Example
  4767. Outline Example
  4768. REPEAT THE STEPS
  4769. CHAPTER 56 Blood-Forming Drugs
  4770. Objectives
  4771. e-Learning Activities
  4772. Companion CD
  4773. evolve Website (http://evolve.elsevier.com/Lilley)
  4774. Drug Profiles
  4775. Glossary
  4776. ERYTHROPOIESIS
  4777. FIGURE 56-1 Schematic structure of a hemoglobin molecule.
  4778. FIGURE 56-2 Underlying causes of anemia are RBC maturation defects and factors secondary to excessive RBC destruction. RBC, Red blood cell.
  4779. FIGURE 56-3 Schematic showing common causes and results of RBC cytoplasmic maturation defects.
  4780. TYPES OF ANEMIA
  4781. FIGURE 56-4 Schematic showing common causes and results of RBC nuclear maturation defects.
  4782. FIGURE 56-5 Increased red blood cell destruction occurs as a result of intrinsic and extrinsic factors. DIC, Disseminated intravascular coagulation; G6PD, glucose-6-phosphate dehydrogenase; RBC, red blood cell.
  4783. IRON
  4784. Mechanism of Action and Drug Effects
  4785. Table 56-1 Ferrous Salts: Iron Content
  4786. Indications
  4787. Contraindications
  4788. Adverse Effects
  4789. Toxicity and Management of Overdose
  4790. Table 56-2 Iron Preparations: Adverse Effects
  4791. Interactions
  4792. Dosages
  4793. Drug Profiles
  4794. ▸ ferrous fumarate
  4795. Pharmacokinetics
  4796. Pharmacokinetics
  4797. FOLIC ACID
  4798. Mechanism of Action and Drug Effects
  4799. DOSAGES
  4800. Selected Iron Preparations and Folic Acid
  4801. Indications
  4802. Contraindications
  4803. Adverse Effects
  4804. Interactions
  4805. Dosages
  4806. Drug Profiles
  4807. ▸ folic acid
  4808. Pharmacokinetics
  4809. OTHER BLOOD-FORMING DRUGS
  4810. ♦ NURSING PROCESS
  4811. ♦ ASSESSMENT
  4812. ♦ NURSING DIAGNOSES
  4813. ♦ PLANNING
  4814. Goals
  4815. Outcome Criteria
  4816. ♦ IMPLEMENTATION
  4817. Life Span Considerations: The Elderly Patient
  4818. Iron Products
  4819. ♦ EVALUATION
  4820. Patient Teaching Tips
  4821. Points to Remember
  4822. NCLEX Examination Review Questions
  4823. Critical Thinking Activities
  4824. CHAPTER 57 Dermatologic Drugs
  4825. Objectives
  4826. e-Learning Activities
  4827. Companion CD
  4828. evolve Website (http://evolve.elsevier.com/Lilley)
  4829. Drug Profiles
  4830. Glossary
  4831. FIGURE 57-1 A microscopic view of the skin. The epidermis, shown in longitudinal section, is raised at one corner to reveal the ridges in the dermis. (Modified from Thibodeau GA, Patton KT: Anatomy and physiology, ed 5, St. Louis, 2003, Mosby.)
  4832. SKIN ANATOMY AND PHYSIOLOGY
  4833. Table 57-1 Epidermal Layers
  4834. Table 57-2 Exocrine Glands of the Skin
  4835. TOPICAL DERMATOLOGIC DRUGS
  4836. ANTIMICROBIALS
  4837. Drug Profiles
  4838. General Antibacterial Drugs
  4839. Table 57-3 Dermatologic Formulations: Characteristics and Examples
  4840. ▸ bacitracin
  4841. neomycin and polymyxin B
  4842. mupirocin
  4843. ▸ silver sulfadiazine
  4844. EVIDENCE-BASED PRACTICE
  4845. Antiseptics and Wound Care
  4846. Review
  4847. Type of Evidence and Research
  4848. Results of Study
  4849. Link of Evidence to Nursing Practice
  4850. Anti-Acne Drugs
  4851. ▸ benzoyl peroxide
  4852. clindamycin
  4853. ▸ isotretinoin
  4854. tretinoin
  4855. Antifungal Drugs
  4856. ▸ clotrimazole
  4857. miconazole
  4858. Table 57-4 Topical Antifungal Drugs
  4859. Antiviral Drugs
  4860. ANESTHETIC, ANTIPRURITIC, AND ANTIINFLAMMATORY DRUGS
  4861. TOPICAL ANESTHETICS
  4862. TOPICAL ANTIPRURITICS
  4863. Table 57-5 Commonly Used Topical Corticosteroids (in Order of Decreasing Potency)
  4864. ANTIPSORIATIC DRUGS
  4865. Drug Profiles
  4866. tazarotene
  4867. tar-containing products
  4868. anthralin
  4869. calcipotriene
  4870. MISCELLANEOUS DERMATOLOGIC DRUGS
  4871. Drug Profiles
  4872. Ectoparasiticidal Drugs
  4873. Herbal Therapies and Dietary Supplements
  4874. Aloe (Aloe vera L.)
  4875. Overview
  4876. Common Uses
  4877. Adverse Effects
  4878. Potential Drug Interactions
  4879. Contraindications
  4880. ▸ lindane
  4881. Hair Growth Drugs
  4882. minoxidil
  4883. Sunscreens
  4884. Antineoplastic Drugs
  4885. fluorouracil
  4886. Immunomodulators
  4887. ▸ pimecrolimus
  4888. imiquimod
  4889. WOUND CARE DRUGS
  4890. ♦ NURSING PROCESS
  4891. ♦ ASSESSMENT
  4892. Table 57-6 Selected Wound-Care Products
  4893. ♦ NURSING DIAGNOSES
  4894. ♦ PLANNING
  4895. Goals
  4896. Outcome Criteria
  4897. ♦ IMPLEMENTATION
  4898. ♦ EVALUATION
  4899. Patient Teaching Tips
  4900. Points to Remember
  4901. NCLEX Examination Review Questions
  4902. Critical Thinking Activities
  4903. CHAPTER 58 Ophthalmic Drugs
  4904. Objectives
  4905. e-Learning Activities
  4906. Companion CD
  4907. evolve Website (http://evolve.elsevier.com/Lilley)
  4908. Drug Profiles
  4909. Glossary
  4910. OCULAR ANATOMY AND PHYSIOLOGY
  4911. FIGURE 58-1 A horizontal section through the left eyeball, looking from the top down. (Modified from Thibodeau GA, Patton KT: Anatomy and physiology, ed 5, St Louis, 2003, Mosby.)
  4912. FIGURE 58-2 Extrinsic muscles of the right eye. Lateral view. (Modified from Thibodeau GA, Patton KT: Anatomy and physiology, ed 5, St Louis, 2003, Mosby.)
  4913. LACRIMAL GLANDS
  4914. LAYERS OF THE EYE
  4915. FIGURE 58-3 Different nervous systems control pupil size.
  4916. FIGURE 58-4 Drug classes and their effects on pupil size.
  4917. FIGURE 58-5 Function of rods and cones in relation to color vision.
  4918. FIGURE 58-6 Main structures of the eye and an enlargement of the canal of Schlemm showing an aqueous flow. A, Normal eye. B, In angle-closure glaucoma, the closure of the anterior angle prevents aqueous humor from exiting through the canal of Schlemm, leading to increased intraocular pressure. C, In open-angle glaucoma, the anterior angle remains open, but the canal of Schlemm is obstructed by tissue abnormalities. (Modified from McKenry LM, Salerno E: Mosby’s pharmacology in nursing—revised and updated, ed 21, St Louis, 2003, Mosby.)
  4919. OCULAR DRUGS
  4920. ANTIGLAUCOMA DRUGS
  4921. Table 58-1 Glaucoma: Types and Characteristics
  4922. FIGURE 58-7 How increased aqueous humor can result in impaired vision. IOP, Intraocular pressure.
  4923. Table 58-2 Antiglaucoma Drug Effects on Aqueous Humor
  4924. CHOLINERGIC DRUGS
  4925. Mechanism of Action and Drug Effects
  4926. FIGURE 58-8 The therapeutic effects of direct- and indirect-acting parasympathomimetics on glaucoma. IOP, Intraocular pressure.
  4927. FIGURE 58-9 Cholinergic response of miosis to parasympathomimetics. ACh, Acetylcholine; AChE, acetylcholinesterase; PSNS, parasympathetic nervous system.
  4928. FIGURE 58-10 Metabolism of acetylcholine by endogenous enzymes.
  4929. Indications
  4930. Contraindications
  4931. Adverse Effects
  4932. Table 58-3 Miotics: Indications
  4933. Toxicity and Management of Overdose
  4934. Interactions
  4935. Dosages
  4936. Table 58-4 Miotics: Adverse Effects
  4937. Drug Profiles
  4938. Direct-Acting Miotics
  4939. acetylcholine
  4940. Pharmacokinetics
  4941. ▸ pilocarpine
  4942. Pharmacokinetics (Immediate-Release Formulation)
  4943. Indirect-Acting Miotics
  4944. ▸ echothiophate and demecarium
  4945. Pharmacokinetics
  4946. DOSAGES
  4947. Selected Miotics
  4948. SYMPATHOMIMETICS
  4949. Mechanism of Action and Drug Effects
  4950. Indications
  4951. Contraindications
  4952. FIGURE 58-11 Mechanism of mydriasis.
  4953. FIGURE 58-12 Ocular effects of alpha (a) and beta (b) stimulation. IOP, Intraocular pressure.
  4954. Adverse Effects
  4955. Toxicity and Management of Overdose
  4956. Interactions
  4957. Dosages
  4958. Drug Profiles
  4959. apraclonidine
  4960. DOSAGES
  4961. Selected Ocular Sympathomimetics
  4962. Pharmacokinetics
  4963. ▸ dipivefrin
  4964. Pharmacokinetics
  4965. β-ADRENERGIC BLOCKERS
  4966. Mechanism of Action and Drug Effects
  4967. Indications
  4968. Contraindications
  4969. Adverse Effects
  4970. Toxicity and Management of Overdose
  4971. Interactions
  4972. Dosages
  4973. Drug Profiles
  4974. ▸ betaxolol
  4975. DOSAGES
  4976. Selected Ocular β-Blockers
  4977. Pharmacokinetics
  4978. ▸ timolol
  4979. Pharmacokinetics
  4980. CARBONIC ANHYDRASE INHIBITORS
  4981. Mechanism of Action and Drug Effects
  4982. Indications
  4983. Contraindications
  4984. Table 58-5 Carbonic Anhydrase Inhibitors: Adverse Effects
  4985. Adverse Effects
  4986. Toxicity and Management of Overdose
  4987. Interactions
  4988. Dosages
  4989. DOSAGES
  4990. Ocular Carbonic Anhydrase Inhibitors
  4991. Drug Profiles
  4992. ▸ dorzolamide
  4993. Pharmacokinetics
  4994. OSMOTIC DIURETICS
  4995. Mechanism of Action and Drug Effects
  4996. Indications
  4997. Contraindications
  4998. Adverse Effects
  4999. Interactions
  5000. Toxicity and Management of Overdose
  5001. Dosages
  5002. Drug Profiles
  5003. glycerin
  5004. Pharmacokinetics
  5005. mannitol
  5006. FIGURE 58-13 Mechanism and ocular effects of osmotic diuretics. IOP, Intraocular pressure.
  5007. Table 58-6 Osmotic Diuretics: Adverse Effects
  5008. DOSAGES
  5009. Osmotic Diuretics
  5010. Pharmacokinetics
  5011. PROSTAGLANDIN AGONISTS
  5012. Mechanism of Action and Drug Effects
  5013. Indications
  5014. Contraindications
  5015. Adverse Effects
  5016. Interactions
  5017. Dosages
  5018. Drug Profiles
  5019. ▸ latanoprost
  5020. DOSAGES
  5021. Prostaglandin Agonists
  5022. Pharmacokinetics
  5023. ANTIMICROBIAL DRUGS
  5024. Mechanism of Action and Drug Effects
  5025. Indications
  5026. Contraindications
  5027. Table 58-7 Common Ocular Infections
  5028. Adverse Effects
  5029. Interactions
  5030. Dosages
  5031. DOSAGES
  5032. Selected Ocular Antimicrobials
  5033. Drug Profiles
  5034. ANTIBACTERIAL DRUGS
  5035. Aminoglycosides
  5036. ▸ gentamicin
  5037. Pharmacokinetics
  5038. Macrolides
  5039. ▸ erythromycin
  5040. Pharmacokinetics
  5041. Polypeptides
  5042. ▸ bacitracin
  5043. Pharmacokinetics
  5044. Quinolones
  5045. ▸ ciprofloxacin
  5046. Pharmacokinetics
  5047. Sulfonamides
  5048. ▸ sulfacetamide
  5049. Pharmacokinetics
  5050. Antifungal Drugs
  5051. natamycin
  5052. Pharmacokinetics
  5053. ANTIVIRALS
  5054. ganciclovir and fomivirsen
  5055. trifluridine
  5056. ANTIINFLAMMATORY DRUGS
  5057. Box 58-1 Ophthalmic Antiinflammatory Drugs
  5058. NSAIDs
  5059. Corticosteroids
  5060. Mechanism of Action and Drug Effects
  5061. FIGURE 58-14 Antiinflammatory action of corticosteroids and nonsteroidal antiinflammatory drugs (NSAIDs).
  5062. Indications
  5063. Contraindications
  5064. Adverse Effects
  5065. Drug Profiles
  5066. Corticosteroids
  5067. ▸ dexamethasone
  5068. Pharmacokinetics
  5069. Nonsteroidal Antiinflammatory Drugs (NSAIDs)
  5070. flurbiprofen
  5071. Pharmacokinetics
  5072. ketorolac
  5073. Pharmacokinetics
  5074. TOPICAL ANESTHETICS
  5075. Mechanism of Action and Drug Effects
  5076. Indications
  5077. Contraindications
  5078. Adverse Effects
  5079. Interactions
  5080. Drug Profiles
  5081. tetracaine
  5082. Pharmacokinetics
  5083. DIAGNOSTIC DRUGS
  5084. Drug Profiles
  5085. Cycloplegic Mydriatics
  5086. ▸ atropine sulfate
  5087. cyclopentolate
  5088. Mydriatic-Reversal Drug
  5089. dapiprazole
  5090. Ophthalmic Dye
  5091. fluorescein
  5092. ANTIALLERGIC DRUGS
  5093. Antihistamines
  5094. azelastine
  5095. Mast Cell Stabilizers
  5096. cromolyn
  5097. Decongestants
  5098. tetrahydrozoline
  5099. Lubricants and Moisturizers
  5100. ▸ artificial tears
  5101. ♦ NURSING PROCESS
  5102. ♦ ASSESSMENT
  5103. DOSAGES
  5104. Ocular Antiallergics
  5105. ♦ NURSING DIAGNOSES
  5106. ♦ PLANNING
  5107. Goals
  5108. Outcome Criteria
  5109. ♦ IMPLEMENTATION
  5110. Case Study
  5111. Eye Trauma
  5112. ♦ EVALUATION
  5113. Patient Teaching Tips
  5114. Points to Remember
  5115. NCLEX Examination Review Questions
  5116. Critical Thinking Activities
  5117. CHAPTER 59 Otic Drugs
  5118. Objectives
  5119. e-Learning Activities
  5120. Companion CD
  5121. evolve Website (http://evolve.elsevier.com/Lilley)
  5122. Drug Profiles
  5123. Glossary
  5124. OVERVIEW OF EAR ANATOMY AND PATHOLOGY
  5125. FIGURE 59-1 Structure of the ear.
  5126. TREATMENT OF EAR DISORDERS
  5127. ANTIBACTERIAL AND ANTIFUNGAL OTIC DRUGS
  5128. Drug Profiles
  5129. Antibacterial Products
  5130. Cortisporin Otic, Ciprodex, Cipro HC Otic, Floxin Otic
  5131. Table 59-1 Common Antibacterial Otic Products
  5132. Table 59-2 Common Antifungal Otic Products
  5133. Antifungal Products
  5134. Cortic, Acetasol HC
  5135. Earwax Emsulfiers
  5136. ▸ carbamide peroxide
  5137. ♦ NURSING PROCESS
  5138. ♦ ASSESSMENT
  5139. ♦ NURSING DIAGNOSES
  5140. PLANNING
  5141. Goals
  5142. Outcome Criteria
  5143. ♦ IMPLEMENTATION
  5144. ♦ EVALUATION
  5145. Patient Teaching Tips
  5146. Points to Remember
  5147. NCLEX Examination Review Questions
  5148. Critical Thinking Activities
  5149. Appendix
  5150. APPENDIX Pharmaceutical Abbreviations
  5151. Bibliography
  5152. General
  5153. Chapter 1
  5154. Chapter 3
  5155. Chapter 4
  5156. Chapter 5
  5157. Chapter 6
  5158. Chapter 7
  5159. Chapter 8
  5160. Chapter 9
  5161. Chapter 10
  5162. Chapter 11
  5163. Chapter 12
  5164. Chapter 13
  5165. Chapter 14
  5166. Chapter 15
  5167. Chapter 16
  5168. Chapter 18
  5169. Chapter 20
  5170. Chapter 21
  5171. Chapter 22
  5172. Chapter 23
  5173. Chapter 24
  5174. Chapter 25
  5175. Chapter 27
  5176. Chapter 28
  5177. Chapter 29
  5178. Chapter 30
  5179. Chapter 31
  5180. Chapter 33
  5181. Chapter 34
  5182. Chapter 35
  5183. Chapter 36
  5184. Chapter 37
  5185. Chapter 38
  5186. Chapter 39
  5187. Chapter 40
  5188. Chapter 41
  5189. Chapter 42
  5190. Chapter 44
  5191. Chapter 46
  5192. Chapters 47 and 48
  5193. Chapter 49
  5194. Chapter 50
  5195. Chapter 51
  5196. Chapter 53
  5197. Chapter 54
  5198. Chapter 57
  5199. Chapter 58